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Abstract 
Skin cancer is the most commonly diagnosed human malignancy. Even though melanoma only 
accounts for 1% of all skin cancer cases, it causes the vast majority of skin cancer deaths. There is 
currently no conventional treatment available that is able to cure metastatic melanoma patients. 
However, recent advances in the understanding of immunology have led to the development of an 
entirely novel treatment modality: cancer immunotherapy. Cancer immunotherapy approaches are 
designed to raise potent, tumor-specific T cell responses that are able to recognize and eliminate 
cancerous cells. Despite the fact that for the first time in history some metastatic melanoma patients 
can be cured, it is currently unclear why a large fraction of patients does not respond to 
immunotherapy. Thus, the overarching goal of this thesis was to gain a better understanding of the 
molecular mechanisms dictating the outcome to immunotherapy.  
Pre-existing inflammation within the tumor microenvironment is associated with good clinical 
prognosis following immunotherapy. Because our lab has previously shown that tumor associated 
lymphatic vessels can modulate tumor inflammation, we hypothesized that the lymphatic system 
might be involved in modulating the outcome of cancer immunotherapy. To explore this hypothesis, 
we characterized two mouse models that recapitulate primary human lymphangiogenic melanoma. 
Using these models, we found that the secretion of CCL21 chemokine is a novel mechanism by which 
tumor associated lymphatics can actively attract naïve T cells into the tumor microenvironment. 
Interestingly, we found that immunogenic cell death following tumor antigen-specific immunotherapy 
induced activation of these naïve T cell infiltrates, which not only resulted in eradication of the primary 
melanoma tumors, but also conferred the mice with long-term protection against tumor re-challenge. 
We thus demonstrate that lymphatics actively increase the quantity and quality of tumor inflammation, 
thereby establishing a microenvironment that is able to potentiate antigen-specific immunotherapy.  
We then engineered an injectable hydrogel system based on fibrin and functionalized 
polyethylene glycol, and show that controlled release of VEGFC from these hydrogels leads to 
lymphangiogenesis in the mouse dermis. Similar to what we found in lymphangiogenic tumors, 
engineered lymphangiogenic skin sites displayed increased expression of CCL21, and increased 
infiltrations of CD4+ and CD8+ T cells. Delivery of the model antigen ovalbumin into lymphangiogenic 
sites led to enhanced release of the effector cytokine interferon-γ upon antigen-restimulation, 
suggesting that engineered lymphangiogenic sites could be exploited for therapeutic 
immunomodulation.  
Finally, to better understand mechanisms underlying successful cancer immunotherapy, we 
established a tool for the observation of anti-tumor immune responses in the context of the native 
tumor microenvironment. By combining existing methods in a novel way, we developed an intravital 
microscopy method based on immunofluorescence that allows simultaneous, high resolution and 
dynamic visualization of the tumor microenvironment including immune cells and extracellular matrix 
proteins.  
In conclusion, this thesis demonstrates that lymphatic endothelial cells orchestrate immune 
cell recruitment into peripheral tissues by secretion of CCL21 chemokine, both in steady-state and 
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disease. Our findings add more evidence to the hypothesis that LECs might play an underappreciated 
role in driving the formation of peripheral sites of immunomodulation. Our findings have translational 
potential, as immune cell infiltrates attracted by local lymphangiogenesis can be exploited for 
therapeutic immune regulation, such as to improving the efficacy of cancer immunotherapy.  
 
Keywords: cancer, melanoma, immunotherapy, lymphangiogenesis, VEGFC, tumor infiltrating 
lymphocytes, tumor microenvironment, bioengineering, hydrogels, intravital microscopy 
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Sommario 
Il cancro della pelle è il tumore maligno più comunemente diagnosticato umana. Anche se il 
melanoma rappresenta solo l' 1% di tutti i casi di cancro della pelle, che provoca la stragrande 
maggioranza dei decessi per cancro della pelle. Non vi è attualmente alcun trattamento 
convenzionale disponibile che è in grado di curare pazienti con melanoma metastatico. Tuttavia, 
recenti progressi nella comprensione dell'immunologia hanno portato allo sviluppo di una 
completamente nuova modalità di trattamento: immunoterapia del cancro. Questi approcci, cosiddetti 
metodi immunoterapici per il cancro, sono progettati per sollevare una potente risposta immunitaria 
da parte delle cellule T specifiche per il tumore, le quali sono in grado di riconoscere ed eliminare le 
cellule cancerogene. Utilizzando gli approcci immunoterapici, alcuni pazienti con melanoma 
metastatico sono stati completamente curati, per la prima volta nella storia. Ad oggi, la terapia 
cellulare adottiva con cellule T (ACT) e il blocco dei checkpoint rappresentano le immunoterapie più 
efficaci nel trattamento del melanoma metastatico. La terapia ACT, l'infusione di cellule T che sono 
istruiti e/o attrezzati a riconoscere e uccidere le cellule tumorali, di solito guarisce circa il 20% dei 
pazienti. Il blocco dei checkpoint, consistente nell’uso di anticorpi per bloccare le vie molecolari 
essenziali per la soppressione delle cellule T, ha dimostrato di avere un potenziale terapeutico simile. 
Nonostante questi risultati incoraggianti, non è ancora chiaro il motivo per cui una larga parte di 
pazienti non risponde alle immunoterapie. Pertanto, l'obiettivo di questa tesi è lo studio e l’analisi dei 
meccanismi molecolari che dettano il risultato di immunoterapia. 
Uno stato infiammatorio preesistente all'interno del microambiente tumorale è associato ad 
un buon risultato clinico dopo l'immunoterapia. Poiché il nostro laboratorio ha già dimostrato che i vasi 
linfatici presenti nella massa tumorale possono modulare tale infiammazione, abbiamo ipotizzato che 
il sistema linfatico possa avere un ruolo importante nel modulare l'immunoterapia del cancro. Per 
esplorare questa ipotesi, abbiamo caratterizzato due modelli murini che ricapitolano il melanoma 
primario linfangiogenico umano: il B16 con sovraespressione di VEGFC (B16-OVA/VC) e il melanoma 
mutante iBIP2 guidato dal BRAF. Usando questi modelli, abbiamo evidenziato per la prima volta 
come la secrezione della chemochina CCL21 sia un meccanismo attraverso il quale i linfatici associati 
al tumore possono aumentare attivamente la presenza di cellule T naive nel tumore primario. 
Abbiamo scoperto che la morte cellulare immunogenica seguente all’immunoterapia induce 
l’attivazione di tali cellule immunitarie, le quali non solo provocano l'eliminazione del melanoma 
primario, ma conferisce ai topi anche una protezione a lungo termine contro ula ricrescita tumorale. In 
conclusione, abbiamo dimostrato che i vai linfatici aumentano la quantità e la qualità di infiammazione 
tumorale, promuovendo così un microambiente che favorisce e intensifica l’effetto dell’immunoterapia 
antigene-specifica.  
Per decifrare ulteriormente il ruolo delle cellule endoteliali linfatiche nello sviluppo della 
risposta immunitaria nei tessuti periferici, abbiamo voluto creare una piattaforma che consente 
l'induzione di linfangiogenesi in un ambiente più controllato rispetto al tumore. Abbiamo quindi 
ingegnerizzato un sistema basato su un idrogelo iniettabile, composto da fibrina e poly(etylene glycol) 
(PEG), mostrando che il rilascio controllato del fattore di crescita linfatica VEGFC a partire da questo 
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idrogelo induce linfoangiogenesi nei tessuti periferici. Analogamente a quanto abbiamo trovato nei 
tumori linfangiogenici, i tratti di pelle ingegnerizzati per indurre linfangiogenesi presentano un 
incremento nell’espressione di CCL21, e una maggiore infiltrazione di cellule CD4+ e CD8+. La 
presentazione simultanea del modello di antigene ovoalbumina nei siti linfangiogenici ha comportato 
un aumento del rilascio della citochina interferone-γ a seguito della ri-stimolazione con lo stesso 
antigene, suggerendo che i siti con linfangiogenesi ingegnerizzata possono essere sfruttati per 
l'immunomodulazione terapeutica. 
Infine, per meglio comprendere il meccanismo alla base dell’immunoterapia del cancro, 
abbiamo voluto sviluppare uno strumento che consenta l'osservazione di risposte antitumorali 
immunitarie nel contesto del microambiente tumorale nativo. Combinando metodi esistenti in un modo 
nuovo, abbiamo sviluppato un nuovo metodo di microscopia intravitale basato 
sull’immunofluorescenza, la quale permette allo stesso tempo una alta risoluzione ed una 
visualizzazione dinamica delle diverse componenti del microambiente tumorale. Utilizzando questa 
modalità di imaging, siamo stati in grado di osservare i processi dinamici nel microambiente tumorale, 
come l’uccisione delle cellule tumorali mediata dai linfciti. 
Nel suo insieme, questa tesi di ricerca dimostra che le cellule endoteliali linfatiche 
orchestrano il reclutamento delle cellule immunitarie nei tessuti periferici attraverso la secrezione 
della chemochina CCL21, sia in omeostasi che in condizioni patologiche. I nostri risultati aggiungono 
ulteriori elementi di prova a sostegno dell'ipotesi formulata in precedenza, secondo la quale le LECs 
potrebbero avere un ruolo, finora sottovalutato, nel guidare la formazione di siti periferici di 
immunomodulazione, i cosìddetti organi linfoidi terziari. Infine, abbiamo dimostrato come sia possibile 
ingegnerizzare uno stato immunitario localizzato basato sulla linfangiogenesi, e susseguentemente 
sfruttarlo per regolazione terapeutica della risposta immunitaria, in modo da migliorare l'efficacia 
dell'immunoterapia del cancro. 
 
Parole chiave: cancro, melanoma, immunoterapia, linfangiogenesi, VEGFC, linfociti infiltranti il 
tumore, microambiente tumorale, idrogeli, rilascio controllato, microscopia intravitale. 
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Résumé 
Cancer de la peau est le cancer le plus fréquemment diagnostiqué humaine. Même si le mélanome 
ne représente que 1 % de tous les cas de cancer de la peau, il provoque la grande majorité des 
décès dus au cancer de la peau . Il n'y a actuellement aucun traitement conventionnel disponible qui 
est capable de guérir les patients atteints de mélanome métastatique . Cependant, les avancées 
récentes dans la compréhension de l'immunologie ont conduit à l'élaboration d'un mode de traitement 
entièrement nouvelle : immunothérapie du cancer. Les immunothérapies contre le cancer servent à 
induire une réponse de type lymphocyte T, puissante et spécifique à la tumeur, qui est capable de 
reconnaître et éliminer les cellules cancéreuses. Grâce aux immunothérapies, certains patients 
atteints de mélanomes avancés ont été entièrement guéris. A ce jour, le transfert adoptif de cellules 
(ACT) et le “blocage de checkpoints” sont les thérapies les plus efficaces dans le traitement du 
mélanome. L’infusion de lymphocytes T manipulés afin de reconnaître et de tuer la tumeur (aussi 
appelé ACT) peut soigner jusqu’à 20% des patients. Le blocage de molécules inhibitrices de 
lymphocytes T par des anticorps monoclonaux (blocage de checkpoints) est aussi efficace que l’ACT. 
En dépit de ces résultats encourageants, on ne comprend pas encore pourquoi la plupart des patients 
de répondent pas à ces modalités immunothérapeutiques. Par conséquent, le but principal de cette 
thèse était de comprendre et décrire certains des mécanismes moléculaires impliqués dans la 
réponse aux immunothérapies. 
L’inflammation pré-existante dans le microenvironnement de la tumeur est associé à des 
résultats positifs d’immunothérapie. Comme notre laboratoire a auparavant montré que les vaisseaux 
lymphatiques associés aux tumeurs peuvent moduler l’inflammation tumorale, nous avons émis 
l’hypothèse que le système lymphatique pourrait jouer un rôle encore méconnu dans la modulation de 
l’immunothérapie du cancer. Afin d’explorer cette hypothèse, nous avons étudié deux modèles murins 
qui récapitulent le mélanome lymphangiogénique humain, notamment le mélanome B16 qui 
surexprime VEGFC (B16-OVA/VC) et le mélanome iBIP2 dû à une mutation de BRAF. Grâce à ces 
modèles, nous avons trouvé que la sécrétion de la chimiokine CCL21 est un nouveau mécanisme par 
lequel les vaisseaux lymphatiques associés à la tumeur peuvent attirer des lymphocytes T naïfs dans 
la tumeur. Nous avons trouvé que la mort immunogénique des cellules tumorales suite à une 
immunothérapie spécifique aux antigènes de la tumeur induit l’activation des lymphocytes infiltrés 
dans la tumeur, ce qui non seulement mène à l’éradication des tumeurs, mais aussi confère une 
protection à long terme contre un re-challenge avec des cellules tumorales. En conclusion, nous 
démontrons que les vaisseaux lymphatiques augmentent la quantité et la qualité de l’inflammation 
tumorale et ainsi établissent un microenvironnement favorable aux immunothérapies spécifiques aux 
antigènes de la tumeur. Contre toute attente, même si la densité des vaisseaux lymphatiques et 
CCL21 constituent tous deux un pronostic négatif, les deux pourraient servir de biomarqueurs pour 
des résultats positifs suite à une immunothérapie spécifique à la tumeur. 
Afin d’étudier plus en profondeur le rôle des cellules endothéliales lymphatiques (LECs) dans 
la modulation des réponses immunitaires dans les organes lymphoïdes périphériques, nous avons 
généré une plateforme qui permet l’induction de lymphangiogénèse d’une manière plus contrôlée que 
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dans une tumeur. Nous avons mis au point un système d’hydrogel injectable composé de fibrine et de 
poly(éthylène glycol) fonctionnalisé et avons montré que la libération contrôlée du facteur de 
croissance lymphatique VEGFC de ces gels mène à la lymphangiogénèse dans les tissus 
lymphatiques périphériques. Comme dans les tumeurs lymphangiogéniques, les sites cutanés 
injectés de gels lymphangiogéniques affichaient une expression élevée de CCL21 et une infiltration 
importante de lymphocytes T CD4+ et CD8+. La livraison simultanée de l’antigène type ovalbumine 
dans les sites lymphangiogéniques mena à une sécrétion plus forte de la cytokine IFN-γ après 
restimulation avec l’antigène, suggérant ainsi que les sites lymphangiogéniques mis au point 
pourraient être utilisés à des fins d’immunomodulation thérapeutique. 
Finalement, afin de mieux comprendre les mécanismes régulant les immunothérapies 
fructueuses contre le cancer, nous avons essayé d’établir un outil qui permettrait d’observer les 
réponses immunitaires anti-tumorales dans le contexte du microenvironnement natif de la tumeur. En 
combinant des méthodes existantes d’une manière innovante, nous avons développé une nouvelle 
méthode de microscopie intravitale basée sur l’immunofluorescence qui permet une visualisation 
simultanée, dynamique et à haute résolution des différents composants du microenvironnement de la 
tumeur, notamment des cellules immunitaires et des protéines de la matrice extracellulaire. Grâce à 
cette méthode d’imagerie, nous avons pu observer des procédés dynamiques dans la tumeur tels que 
l’attaque des lymphocytes sur les cellules cancéreuses et leur mort ensuivante. 
Dans l’ensemble, cette thèse démontre que les cellules endothéliales lymphatiques 
orchestrent le recrutement des cellules immunitaires dans les organes lymphoïdes périphériques en 
sécrétant la chimiokine CCL21, dans l’homéostasie et dans la maladie. Nos découvertes s’ajoutent à 
l’hypothèse que les LECs peuvent jouer un rôle encore sous-estimé dans la formation de sites 
lymphoïdes périphériques d’immunomodulation, aussi appelés organes tertiaires lymphoïdes. 
Finalement, nous montrons que le milieu local immunitaire formé par lymphangiogénèse peut être 
manipulé et exploité à des fins de régulations immunitaires thérapeutiques, comme pour améliorer 
l’efficacité des immunothérapies contre le cancer. 
 
Mots-clefs: cancer, mélanome, immunothérapie, lymphangiogénèse, VEGF-C, lymphocytes infiltrant 
la tumeur, microenvironnement tumoral, hydrogels, libération contrôlée, microscopie intravitale. 
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1.1 Motivation 
Cancer is one of the major global health threats. It represents a collection of hundreds of types of 
diseases that all have one characteristic in common: the uncontrolled proliferation of cells that can 
eventually lead to organ failure and death. Facing the devastating consequences that these diseases 
have already had on our societies, former US president Richard Nixon even declared a “war on 
cancer” in 1971. This doctoral thesis can be considered as a small contribution to the global efforts 
that have ever since been devoted to winning this war.  
A battle can be won in three steps: 1) Identify the most dangerous opponent, 2) try to 
understand how he operates, and 3) focus all the efforts on targeting his weaknesses. In case of this 
thesis, the opponent of choice was melanoma, a rare but deadly form of skin cancer. Even though 
melanoma only accounts for 1% of all skin cancer cases, it causes the vast majority of skin cancer 
deaths (Simões et al., 2015). Patients can only be cured by surgical resection of the tumor mass if 
they are diagnosed before the cancer was able to spread to distant organs. However, once melanoma 
cells colonize other organs such as lymph nodes, the lung, liver, or brain, the survival rate drops 
dramatically. Radio- and chemotherapy, the conventional approaches for cancer therapy, are 
unfortunately not able to cure metastatic patients. The quest for alternative therapeutic approaches 
led to the development of targeted therapies, small molecular drugs that inhibit proteins of cellular 
pathways essential for tumor growth (Flaherty, 2012). Introducing these drugs into clinics has doubled 
the 12-month overall survival of metastatic melanoma patients from about 36% using conventional 
therapy to about 72% (Eroglu and Ribas, 2016). However, because melanoma cells constantly mutate 
their genome, they evolve to survive in an ever-changing environment. This constant evolution 
ensures that the cells find alternative growth pathways that are not inhibited by targeted therapies, 
allowing them to develop so called resistance. Essentially all metastatic melanoma patients eventually 
develop resistance to targeted therapy and succumb to disease (Fedorenko et al., 2015; Holohan et 
al., 2013). 
The recent introduction of a novel treatment modality, immunotherapy, has led to a paradigm 
shift in the fight against metastatic melanoma. Immunotherapy approaches are designed to raise a 
potent, tumor-specific immune response that is able to recognize and eliminate cancerous cells 
(Drake et al., 2013). Using immunotherapy, metastatic melanoma patients have been completely 
cured for the first time in the history. There are three main reasons why it the immune system seems 
to be so efficient for anti-tumor therapy: Firstly, immune cells have evolved to specifically recognize 
their target cells, allowing them to kill cancer cells without damaging any normal tissues. Secondly, 
immune responses tackle cancer cells from multiple sides at the same time, thus making it more 
difficult for them to evolve resistance mechanism and escape therapy. Thirdly, the immune system 
develops memory, allowing it to recognize and eliminate cancer cells even more efficiently in case the 
tumor recurs at a later stage of life. Amongst the different immunotherapy approaches, adoptive T cell 
therapy (ACT) and checkpoint blockade have proven especially promising in human clinical trials. 
ACT, the infusion of autologous, ex vivo stimulated lymphocytes, has shown clinical response rates of 
up to 50%, with around 20% of patients being cured (Hinrichs and Rosenberg, 2014; Restifo et al., 
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2012). Similarly, antibody-mediated blocking of pathways essential to T cell suppression, called 
checkpoint blockade, has resulted in complete response rates of up to 22% in human clinical trials 
(Larkin et al., 2015; Postow et al., 2015). Despite these encouraging results, about 80% of patients do 
not respond to immunotherapy. It is currently unclear, why only certain patient populations can benefit 
from immunotherapy. A better understanding of the molecular mechanisms dictating the clinical 
response to immunotherapy will allow the development of rational approaches to increase the number 
of metastatic melanoma patients who can be cured. 
Until today, no clear-cut biomarkers have been described that are able to distinguish whether 
metastatic melanoma patients will or will not respond to immunotherapy (Patel and Kurzrock, 2015; 
Schumacher et al., 2015). However, recent research has highlighted that pre-existing inflammation 
within the tumor microenvironment is associated with good clinical outcome following these types of 
therapies (Ji et al., 2011; Spranger et al., 2015; Tumeh et al., 2014). Interestingly, our lab has 
established several connections between the lymphatic system and tumor-associated inflammation 
over the past few years. For example, we have shown that CCL21, a chemokine that can be secreted 
by lymphatic endothelial cells (LECs), can promote inflammation in the tumor microenvironment 
(Shields et al., 2010). Furthermore, we found that lymphatic endothelial cells in the draining lymph 
node can actively regulate anti-tumor immune responses (Lund et al., 2012), and that the presence of 
tumor draining lymphatics is essential for the generation of a T cell inflamed microenvironment in 
mouse and human melanoma (Lund et al., under review). These findings have been strengthening 
the broader notion that the lymphatic system is not only a passive transport system, but actively 
involved in immune cell education and trafficking both in steady-state and disease (Card et al., 2014; 
Hirosue and Dubrot, 2015; Hirosue et al., 2014; Lund et al., 2016; Tewalt et al., 2012). However, it 
has never been explored whether and how peri-and intratumoral lymphatic vessels actively participate 
in the regulation of tumor inflammation. Because intratumoral lymphatic vessels (LVs) have previously 
been shown to be non-functional in terms of drainage (Padera et al., 2002), their relevance in tumor 
progression has always been questioned. Nevertheless, considering that secretion of bioactive factors 
and engagement in cell-cell interactions by LECs does not specifically require LVs to have a lumen, 
we hypothesized that both peri- and intratumoral LECs might be actively involved in the regulation of 
tumor inflammation. Furthermore, we speculated that if indeed this was the case, tumor-associated 
lymphatics might be critical in guiding the outcome of cancer immunotherapy. Not only could LECs be 
a biomarker to stratify patients eligible for immunotherapy, but inducing them locally might also 
improve response rates of patients with non-inflamed primary melanomas. The overall motivation 
behind this thesis research was thus to create knowledge and tools that could potentially have a 
translational impact on improving immunotherapy in metastatic melanoma patients. 
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1.2 Aims 
The overall aim of this thesis was to determine whether and how peri- and intratumoral LECs are 
actively involved in the regulation of tumor inflammation, and if so, whether this could be 
therapeutically exploited. We wanted to approach our overall hypothesis from three different angles. 
First, we utilized two lymphangiogenic mouse melanoma models to study how peri- and intratumoral 
LEC density regulates the presence and/or phenotype of tumor infiltrating lymphocytes. Once 
characterized, we used these models to assess whether the extent of primary tumor 
lymphangiogenesis affects the outcome of different immunotherapy approaches. Second, we wanted 
to determine whether mechanistic findings from the tumor studies could be recapitulated and/or 
expanded by studying the same biology in a more controlled setting. We thus aimed at creating non-
inflammatory lymphangiogenesis by engineering controlled release of VEGFC from intradermally 
injectable hydrogels. Third, we wanted to develop a novel intravital imaging method to study how anti-
tumor immune responses unfold in the native tumor microenvironment. 
 
The specific aims addressed in this thesis are: 
1) Identify and characterize two mouse melanoma models that show similar peri- and 
intratumoral lymphatic density as human melanomas. 
2) Using antibody-mediated anti-VEGFR3 blocking, determine whether peri- and intratumoral 
lymphatic density influences intratumoral cytokine levels in these models in vivo. 
3) Similarly to 2), determine whether peri- and intratumoral lymphatic density influences the 
number and phenotype of tumor infiltrating lymphocytes in vivo. 
4) Based on the insights gathered in 2) and 3), determine the mechanism of LEC-mediated 
immunoregulation in primary melanomas in vivo. 
5) Assess whether and how the presence of peri- and intratumoral lymphatics influences the 
outcome of cancer immunotherapy in vivo. 
6) Engineer a hydrogel-based system for controlled in vivo release of VEGFC to induce non-
inflammatory lymphangiogenesis in mouse dermis.  
7) Similarly to 2) an 3), assess whether engineered lymphangiogenesis induces changes in the 
local chemokine and/or immune cell milieu. 
8) Determine whether engineered lymphangiogenic sites can be exploited for therapeutic 
immunoregulation. 
9) Establish an intravital imaging method based on immunofluorescence that is suitable for the 
visualization with two-photon microscopy.  
10) Using the intravital imaging method established in 9), study how anti-tumor immune 
responses unfold in the native tumor microenvironment, especially in the context of fibrillar 
and non-fibrillar extracellular matrix.  
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1.3 Thesis overview and accomplishments  
The chapters of this thesis are summarized below to put their content in the context of the motivation 
and the overall goals. 
 
Chapter 2 provides a general overview of relevant literature, focusing on the state-of-the-art in cancer 
immunotherapy and lymphatic immunomodulation.  
 
Chapter 3 presents our studies on lymphangiogenic melanoma. Specifically, the aim of this chapter 
was to determine whether chemokine-mediated recruitment of tumor infiltrating lymphocytes (TILs) is 
dependent on lymphatic density within primary melanoma tumors, and if so, whether this could be 
therapeutically exploited. Using two lymphangiogenic mouse models, we found that the secretion of 
CCL21 chemokine is a novel mechanism by which tumor associated lymphatics can actively increase 
the recruitment of naïve CCR7+ T cells into the primary tumor. To evaluate whether these findings are 
relevant in human, we mined a gene expression data set and show that the expression of VEGFC, 
CCL21 and CCR7 indeed correlate in human melanoma. Finally, we establish that naïve T cell 
infiltrates in lymphangiogenic tumors can be locally activated in response to immunotherapy, leading 
to antigen spreading and long lasting protection from tumor re-challenge. We conclude that peri- and 
intratumoral LECs secrete CCL21 to actively increase tumor inflammation, thereby establishing a 
microenvironment that is more sensitive to antigen-specific immunotherapy. 
 
Chapter 4 builds upon the insights gained in chapter 3, and asks whether the observed mechanisms 
of LEC-mediated immunoregulation are specific to the tumor environment, or whether they are more 
broadly valid in settings of lymphangiogenesis. Specifically, we asked whether engineered 
lymphangiogenesis induces chemokine mediated immune cell recruitment into the steady-state 
dermis and if so, whether this could be therapeutically exploited. We first establish an injectable 
hydrogel system for the sustained and localized delivery of the lymphatic growth factor VEGFC, and 
show that this system is able to induce dermal lymphangiogenesis with minimal bystander 
inflammation. These lymphangiogenic sites resemble tertiary lymphoid organs (TLOs) as they present 
an altered immune milieu with high levels of CCL21 and T cells infiltrates, similar to what we observed 
in the lymphangiogenic melanomas in chapter 3. Delivering the model antigen ovalbumin (OVA) into 
engineered lymphangiogenic sites increased the numbers of IFNγ secreting cells upon ex vivo antigen 
re-stimulation, indicating that engineered lymphangiogenic sites can potentially be exploited to steer 
therapeutic immune responses.  
 
Chapter 5 describes a novel intravital imaging method that we established to study anti-tumor immune 
responses in the context of the native tumor microenvironment. The aim was to overcome certain 
shortcomings of existing intravital imaging methods, such as a limited variety of structures and cells 
that can be visualized, and photobleaching of fluorescent probes. We thus further optimized an 
existing protocol that is based on staining the exposed mouse ear dermis with primary and secondary 
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antibodies, so called intravital immunofluorescence (IF). Intravital IF allows simultaneous, high 
resolution and dynamic visualization of different components of the tumor microenvironment, including 
immune cells and fibrillar as well as mesh-like matrix proteins. The protocol includes all the 
procedures from tumor inoculation in the thin dorsal ear skin, to immunolabeling components of the 
tumor microenvironment with primary and secondary antibodies, to live imaging of the exposed tissue 
using fluorescence stereomicroscopy and two-photon microscopy. We show that intravital IF is 
suitable for the prolonged observation of interactions between tumor cells and their microenvironment, 
without inducing noticeable immunotoxicity or photobleaching. We thus propose that this novel 
method allows investigating dynamic processes within the tumor microenvironment, and might as 
such be used to better understand LEC-mediated immune regulation during cancer immunotherapy. 
 
Chapter 6 summarizes the major conclusions that came out of this thesis research and proposes a 
novel model by which lymphatic vessels influence immunity by regulating immune cell trafficking into 
peripheral tissues. We discuss the implications that our results might have for the clinics, especially 
considering cancer immunotherapy, and suggest some of the most exciting directions that future 
research in this field could take.   
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Chapter 2 
Background and state-of-the-art 
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2.1 Cancer immunotherapy 
2.1.1 The tumor microenvironment suppresses the Cancer-Immunity Cycle 
Genomic instability is the most prominent characteristic shared amongst cancer cells. Together with 
tumor-promoting inflammation, genetic alterations represent the so-called enabling characteristics that 
drive the eight hallmarks of cancer: sustained proliferative signaling, evading growth suppressors, 
avoiding immune destruction, enabling replicative immortality, activating invasion and metastasis, 
inducing angiogenesis, resisting cell death, and deregulating cellular energetics (Figure 2.1) 
(Hanahan and Weinberg, 2011). Even tough random mutations are essential for tumor initiation and 
progression, they also render cancer cells vulnerable to immune cell destruction. This is because 
mutations can lead to the aberrant expression of tumor antigens including neoantigens, differentiation 
antigens, and cancer testis antigens, which are then presented by cancer cells on major 
histocompatibility class I and II (MHCI and MHCII) molecules (Chen and Mellman, 2013). Recognition 
of these cancer-specific peptide-MHC complexes by cognate T cells can initiate spontaneous anti-
tumor immune responses, occasionally leading to tumor regression (Halliday et al., 1995; Heemskerk  
 
Figure 2.1 The Hallmarks of Cancer. There are ten capabilities necessary for tumor growth and
progression. Genome instability and tumor promoting inflammation are the enabling characteristics
that drive the eight hallmarks of cancer: sustained proliferative signaling, evading growth suppressors, 
enabling replicative immortality, activating invasion and metastasis, inducing angiogenesis, resisting
cell death, avoiding immune destruction, and deregulating cellular energetics. The two latter ones
have only recently been added to this list, and are thus called emerging hallmarks. Drugs targeting
each one of these characteristic have been developed (shown in the most outer circle), some of which
are used in clinics today. Illustration taken from Hanahan and Weinberg, 2011. 
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Figure 2.2 The Cancer-Immunity Cycle. The immune system is highly efficient in recognizing and 
killing tumor cells. However, the induction of anti-tumor immune responses requires a series of
stepwise events to take place. (1) Tumor-associated antigens are released by dying cancer cells and
captured by dendritic cells (DCs). (2) DCs process the antigens, migrate to the draining lymph node,
and present them on MHC class I and II molecules to the naïve T cell repertoire. (3) If a T cell
recognizes its cognate antigen, priming and activation ensues, leading to an effector T cell response
against the tumor antigen. (4) Effector T cells egress into the circulation to home to and (5)
extravasate into the tumor tissue. (6) In the tumor tissue, the interaction between the T cell receptor
(TCR) and its cognate antigen presented by MHC-I on the cancer cell surface leads to the release of
mediators such as IFNγ and perforins that (7) induce tumor cell death. The Cancer-Immunity Cycle
represents a positive feedback loop that is able to increases the breadth and depth of an ongoing
anti-tumor immune response. However, in order to escape immune-mediated destruction, tumors 
evolve immunosuppressive mechanisms to inhibit one or multiple steps of the Cancer-Immunity
Cycle. Illustration taken from Chen and Mellman, 2013. 
et al., 2013). However, tumors have several strategies to escape immune-mediated destruction. One 
such strategy, immunoediting, has been described by Dunn and colleagues (Dunn et al., 2002; 2004). 
During immunoediting, cancer cells that express T cell targets are eliminated, while cells that have 
evolved genetic and epigenetic changes conferring them with resistance to immune detection and/or 
elimination will be selected for. Another set of evasion strategies, collectively called 
immunosuppressive mechanisms of the tumor microenvironment, actively dampen anti-tumor immune 
responses in lymphoid organs and in the tumor microenvironment itself (Rabinovich et al., 2007). 
These mechanisms can interfere at any step of the Cancer-Immunity Cycle, a stepwise process 
needed to initiate effective anti-tumor immune responses (Figure 2.2) (Chen and Mellman, 2013).  
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Briefly, the cycle is divided into seven major steps, starting with the release of antigens from dying 
cancer cells, to antigen-presentation by dendritic cells in the draining lymph node, to trafficking of  
tumor-specific effector T cells into the tumor and the killing of individual cancer cells. Interestingly, 
once the Cancer-Immunity Cycle is underway, it represents a self-propelling machinery that increases  
the breadth and depth of an ongoing anti-tumor immune response. However, in most patients, one or 
multiple immunosuppressive mechanisms are active to inhibit the optimal performance of the Cancer-
Immunity Cycle (Motz and Coukos, 2013). 
2.1.2 Immunotherapy aims at boosting the Cancer-Immunity Cycle 
Cancer immunotherapy aims at initiating and reinforcing the Cancer-Immunity Cycle, thereby creating 
an environment that enables a potent anti-tumor immune response to develop. Many different 
approaches of cancer immunotherapy have been evaluated, either potentiating anti-tumor, or 
inhibiting pro-tumor immunity (Figure 2.3) (Butt and Mills, 2014). Even though a major part of pre-
clinical research has focused on designing therapeutic cancer vaccines, unfortunately no clinical 
success stories have come out from these efforts (Melief et al., 2015). In contrast, adoptive T cell 
therapy (ACT) and checkpoint blockade have recently introduced a paradigm shift in the fight against 
cancer, curing patients for which there was no therapy available before (Restifo et al., 2016). During 
ACT, either autologous, ex vivo stimulated tumor-reactive T cells, or host cells that have been 
genetically engineered are infused into patients (Rosenberg and Restifo, 2015).  ACT using 
autologous T cells has shown clinical response rates of up to 50%, with around 20% of patients 
having complete and long-lasting regression in solid tumors, including metastatic melanoma (Hinrichs 
and Rosenberg, 2014; Restifo et al., 2012). Alternatively to using autologous T cells, host cells can be 
 
Figure 2.3 The targets of cancer immunotherapy. Cancer immunotherapy aims at initiating or 
potentiating the Cancer-Immunity Cycle. Many different approaches have been evaluated, and they
can be divided on whether they potentiate anti-tumor or inhibit pro-tumor mechanisms of
immunoregulation. In all cases, the ultimate goal is to induce a potent anti-tumor immune response
that kills cancer cells. So far, adoptive T cell therapy and checkpoint blockade (antibodies against
CTLA-4, PD-1, PDL-1) have shown most efficacy in clinics. DC, dendritic cell; TLR, Toll-like receptor;
aGalCer, alpha-galactosylceramide; M1 Mθ, type I macrophage; NK, Natural killer; Th1, IFNγ-
secreting CD4 T cell; CTL, cytotoxic T lymphocyte; MDSC, myeloid-derived suppressor cell; Treg cell,
regulatory T cell; RA, retinoic acid; Ab, antibody; i, inhibitor; Cy, cyclophosphoamide; Pi3Ki,
Phosphatidylinositol 3-kinase inhibitor; p38i, p38 MAP kinase inhibitor; RARi, retinoic acid receptor-
alpha inhibitor. Illustration taken from Butt and Mills, 2014. 
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genetically engineered to carry either tumor-specific T cell receptors (TCRs) or chimeric antigen 
receptors (CARs) that are designed to target a tumor-specific antigen (Gill and June, 2015). CAR 
modified T cells targeting CD19 have been especially successful in the treatment of leukemia 
patients, with complete response rates of up to 60% depending on the exact patient population (Lee 
et al., 2015; Porter et al., 2015). The main hurdle to broadly implement these promising therapies in 
clinics might be the fact that performing ACT is expensive, resource intensive, and require specialized 
GMP facilities (Tey et al., 2006). Checkpoint therapy, antibody-mediated blocking of pathways 
essential to T cell suppression, would certainly be easier to implement in clinics. Similarly to ACT, 
combined checkpoint therapy of the immunosuppressive molecules CTLA-4 and PD-1 has resulted in 
complete response rates of up to 22% in human clinical trials (Larkin et al., 2015; Postow et al., 
2015). Because every tumor may rely on different immunosuppressive mechanisms to interfere with 
the Cancer-Immunity Cycle, personalized immunotherapy combining multiple approaches are 
believed to lead to even better response rates in the future (Mahoney et al., 2015; Rosenberg and 
Restifo, 2015). 
2.1.3 Biomarkers in cancer immunotherapy 
Despite the encouraging results from clinics, it is currently unclear why only a fraction of patients 
responds to immunotherapy (Sharma and Allison, 2015). Thus, the identification of biomarkers that 
allow patient stratification based upon whether they can benefit from immunotherapy or not is urgently 
needed (Patel and Kurzrock, 2015; Schumacher et al., 2015). Intuitively, tumor cell expression of the 
PD-1 ligand PD-L1 should be a positive prognostic marker for checkpoint inhibition using antibodies 
targeting the PD-1/PDL-1 pathway. However, while some studies found a correlation between tumor 
PDL-1 expression and patient outcome (Topalian et al., 2012), others did not (Hamid et al., 2013). 
Citing James Allison, one of the founding fathers of checkpoint inhibition: “Because of the very nature 
of immune checkpoint therapy, the development of pharmacodynamics, predictive, or prognostic 
biomarkers faces unique challenges” (Sharma and Allison, 2015). Interfering with tumor immunity 
creates dynamic and complex changes in the microenvironment, and it is unlikely that a single 
parameter will be able to serve as a biomarker. For example, the secretion of the effector cytokine 
interferon-γ by tumor infiltrating CD8+ T cells induces adaptive resistance mechanisms of the tumor 
microenvironment, including the upregulation of IDO, PD-L1 and the influx of regulatory T cells 
(Spranger et al., 2013). However, recent research has highlighted two readouts that might serve as 
predictive biomarkers for checkpoint therapy. First, pre-existing inflammation within the tumor 
microenvironment has been shown to correlate with good clinical outcome following immunotherapy 
(Ji et al., 2011; Spranger et al., 2015; Tumeh et al., 2014). It has been suggested that means to 
inducing T cell infiltration into “cold tumors”, tumors that do not present pre-existing T cell 
inflammation, prior to immunotherapy might therefore improve therapy outcome (Gajewski, 2015). 
Second, is has been shown that the mutational load of the tumor and the number of generated 
neoantigens correlate with immunotherapy outcome (Snyder et al., 2014; Van Allen et al., 2015). It 
has been proposed that due to the lack of central tolerance, much more potent immune responses 
can be raised against neoantigens as compared to self-antigens (Gilboa, 1999). Because different 
tumor types have very different mutational loads (Figure 2.4), this indicates that immunotherapy might  
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Figure 2.4 Mutational load across cancer types. The number of antigens that are created
correlates with the mutational load of cancer cells. Neoantigens are critical for the induction of potent
anti-tumor immunotherapy. The graph shows individual tumor samples (dots) and the median number 
of mutation per cancer type (red bars). The y-axis indicates the number of mutations per megabase
(log scale). Most melanomas have more than 10 somatic mutations per megabase of coding DNA,
which corresponds to roughly 150 nonsynonymous mutations within expressed genes. All of these
can potentially lead to the generation of neoantigens. The tumor types are categorized according to 
the likelihood of neoantigen formation. Illustration taken from Schumacher et al., 2015. 
not be equally suitable for all indications. Patients with tumors at the high end of the mutational 
spectrum, such as metastatic melanoma patients, are more likely to benefit from immunotherapy 
(Alexandrov et al., 2013; Schumacher et al., 2015). Taken together, even though cancer 
immunotherapy is revolutionizing the way cancer patients can be treated, the field is still in its infancy. 
A better understanding of the molecular mechanisms dictating the clinical response to immunotherapy 
is needed and will increase the number of cancer patients who can be cured. 
2.2 The lymphatic system 
2.2.1 The lymphatic system as a transport route 
Hippocrates has observed components of what today are considered the blood and lymphatic 
networks, the two major circulatory systems of the human body, more than two thousand years ago. 
Even though the two systems have a lot in common in terms of function (transport of liquid, cells, and 
solutes), structure (networks of vessels), and anatomic distribution (they mostly run in parallel), the 
extent to which they have been studied has varied greatly. While the blood vascular system has been 
object to vast investigation ever since, the lymphatic system has largely been neglected by the 
scientific community (Choi et al., 2012; Swartz, 2001). It was a series of landmark discoveries in the 
late 1990s, which sparked a new area of lymphatic research. First, the major signaling pathways for 
lymphatic vessel growth, VEGFC and VEGFD mediated stimulation of the VEGFR2 and VEGFR3  
tyrosine kinases, were described (Achen et al., 1998; Jeltsch et al., 1997; Joukov et al., 1996; 
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Kaipainen et al., 1995; Kukk et al., 1996; Lee et al., 1996; Oh et al., 1997). A few years later, the 
lymphatic markers Lyve1, podoplanin, and Prox1 were discovered almost simultaneously (Banerji et 
al., 1999; Breiteneder-Geleff et al., 1999; Wigle and Oliver, 1999).  
The high pressure in the blood circulation forces plasma fluid and proteins continuously out of 
the capillaries into the interstitial space. About 90% of this filtrate gets reabsorbed at the venous side. 
However, because of osmotic forces resulting from extravasated protein, there is a net fluid flux of 
about 10% out of the vasculature into the interstitium. One of the main functions of the lymphatic 
system is to return this excess fluid back into the blood circulation (Tammela and Alitalo, 2010). By 
forming a one-way drainage system consisting of a hierarchical network of open-ended initial 
lymphatics that lead into pre-collecting, then collecting vessels and finally empty into the subclavian 
veins, the lymphatic network is perfectly built to perform this function. Initial lymphatics are blind-
ended sacs that have minimal basement membrane coverage and are attached to the extracellular 
matrix (ECM) with anchoring filaments. This allows them to adapt their permeability to the interstitial 
fluid pressure (IFP), such that when the ECM is stretched under elevated IFP, the initial capillaries are 
dilated to allow enhanced fluid flows and cellular trafficking. In contrast, collecting vessels are 
equipped to ensure optimal downstream drainage of the lymph fluid. They are characterized by a 
continuous basement membrane, pericyte coverage that allows active pumping of lymph fluid, and a 
system of valves that prevents retrograde fluid flow (Figure 2.5) (Kerjaschki, 2014; Stacker et al., 
2014).  
2.2.2 Lymphangiogenesis  
Remodeling of the lymphatic vessel structure and morphology can be achieved either by lymphatic 
vessel enlargement or lymphangiogenesis (Stacker et al., 2014). Lymphangiogenesis is the process 
of new lymphatic vessel formation by sprouting from pre-existing vessels, even though some studies 
suggest that macrophages may also contribute to lymphangiogenesis by transdifferentiating into 
lymphatic endothelium (Kerjaschki, 2014). Physiologic lymphangiogenesis in the adult only occurs 
during the development of the corpus luteum and wound healing (Tammela and Alitalo, 2010). 
However, lymphangiogenesis is also be induced in a variety of pathological conditions, including 
cancer, inflammation, and transplant rejection. In most cases, it remains unclear whether 
lymphangiogenesis is contributing to pathology by driving inflammation or whether it is an active 
attempt to resolve inflammation. Recent research suggests that there might indeed not be a black and 
white answer that is valid for all situations, but rather, that the consequences of lymphangiogenesis 
on the host might be highly context dependent (Lund et al., 2016). However, in the context of tumors, 
it is well established that tumor-associated lymphangiogenesis correlates with poor prognosis (Dadras 
et al., 2010; Pasquali et al., 2013; Shayan et al., 2012). The main hypothesis has been that newly 
generated lymphatic vessels offer routes for metastatic spread to the draining lymph nodes and 
distant organs (Karaman and Detmar, 2014; Stacker et al., 2014; Tammela and Alitalo, 2010). More 
recently, it has been appreciated that tumor-associated lymphatic vessels might also influence tumor 
progression by actively shaping anti-tumor immunity, a concept which we will further introduce in 
chapter 2 of this thesis (Lund et al., 2016; Swartz, 2014).  
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Figure 2.5 The structure of the lymphatic network. (A) The illustration shows the structural
differences between initial (open-ended, minimal basal membrane (BM), no pericyte coverage), pre-
collecting (occasional valves and discontinuous BM), and collecting (frequent valves, active pumping 
thanks to pericyte coverage) lymphatic vessels. (B) Lymphatic endothelial cells connect with each
other via button-like tight junctions. Fluid and cells can easily traffic across the vessel wall by crossing
the interendothelial gaps between the tight junctions. (C) Cross-section of an initial lymphatic and a
blood capillary. While blood capillaries are covered by pericytes, initial lymphatics are not. In addition,
LECs are anchored to the extracellular matrix via elastic fibers. This ensured that under conditions
when the interstitial pressure increases, the gaps between the vessels are enlarged to allow 
increased fluid drainage. Illustration adapted from Stacker et al., 2014 
Lymphangiogenesis is mediated by a variety of growth factors and receptors (Figure 2.6).
However, as mentioned previously, the receptor tyrosine kinase VEGFR3 seems to be the major 
receptor mediating lymphangiogenesis and was one of the first LEC markers to be described 
(Kaipainen et al., 1995). VEGFR3 has two known ligands, VEGFC and VEGFD, both from the VEGF
family of growth factors. VEGFC and VEGFD are matured by proteolytic processing, allowing them to 
A 
B 
C 
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bind to VEGFR3 homo- and VEGFR3/VEGFR2 heterodimers (Joukov et al., 1997; Olsson et al., 
2006; Tammela and Alitalo, 2010). Both VEGFC and VEGFR3 can interact with the co-receptor 
neuropilin-2, which increases VEGFR3 downstream signaling (Karpanen, 2006). Other growth factors 
that stimulate lymphangiogenesis in various contexts have been described, including fibroblast growth 
factor 2 (FGF-2) (Chang et al., 2004), insulin-like growth factor 1 (IGF-1) and IGF-2 (Björndahl et al., 
2005), hepatocyte growth factor (HGF) (Cao et al., 2006; Kajiya et al., 2005), endothelin-1 (ET-1) 
(Spinella et al., 2009), and platelet-derived growth factor B (PDGF-B) (Cao et al., 2004). However, it is 
unclear what the direct contribution of these factors to lymphangiogenesis is, as some of them might 
induce VEGFC and VEGFD secretion by immune cells and fibroblasts (Tammela and Alitalo, 2010). 
Lymphangiogenic signaling pathways converge on the induction of the transcription factors Prox1 and 
FoxC2/NFATct, both of which regulate genes essential that induce proliferation, migration, and 
survival of lymphatic endothelial cells (Tammela and Alitalo, 2010). Finally, it is worth noting that there 
is considerable overlap in angiogenic and lymphangiogenic signaling, mainly via VEGFR2 signaling 
 
Figure 2.6 Molecular pathways of lymphangiogenesis. A multitude of signaling pathways exist that 
can induce or influence lymphangiogenesis. Most prominently are the growth factors VEGFC and
VEGFD, which mainly signal through VEGFR3 homo- or VEGFR2/VEGFR3 heterodimers. Neuropilin-
2 (NP-2) can acts as co-receptor to increase signaling sensitivity. Lymphangiogenic signaling
pathways converge on the regulation of Prox1 and FoxC2/NFATct, transcription factors that regulate
genes essential to the lymphatic endothelial cell phenotype. It is interesting to note that there is
considerable overlap in angiogenic and lymphangiogenic signaling, mainly via involvement of
VEGFR2. The cytokines TGF-β and IFNγ both inhibit lymphangiogenesis. Illustration taken from
Tammela et al., 2010 
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(Olsson et al., 2006), and that the cytokines TGFβ, IFNγ, IL4 and IL13 have been suggested to act as 
inhibitors of lymphangiogenesis (Oka et al., 2008; Savetsky et al., 2015; Shao and Liu, 2006). 
2.2.3 The lymphatic system as an active immunomodulator  
The lymphatic network acts as a messenger for the immune system. While draining cells, 
macromolecules, ions, and interstitial fluid from peripheral tissues back to the blood circulation, lymph 
passes through to secondary lymphoid organs (SLOs), the control centers of adaptive immune 
responses (Ruddle and Akirav, 2009). The information that lymphatics deliver to SLOs contains 
important cues essential to regulating adaptive immunity including soluble antigens (Clement et al., 
2011), antigen-loaded dendritic cells (Randolph et al., 2005), danger signals and cytokines (Card et 
al., 2014). Depending on the tissue context such as homeostasis, inflammation, cancer, or infection, 
these cues lead to either tolerogenic adaptive immune mechanisms that maintain tolerance to self-
antigens, or to the induction or resolution of effector mechanisms that try to battle tumor cells and 
invading pathogens (Lund et al., 2016). The role of lymphatic vessels in shaping immunity as passive 
conduits, or simple messengers, has been well established. However, more recently, it has become 
appreciated that LVs are also actively involved in regulating immunity, both by taking an active role in 
immune cell education as well as trafficking (Card et al., 2014). 
Antigen-presenting cells (APCs) are key mediators of adaptive immune responses. The 
function of APCs is to present “self” and “foreign” antigens loaded on major histococompatibility 
complex (MHC) class I and II molecules to CD4+ and CD8+ T cells. If a T cells recognizes a cognate 
peptide-MHC complex to its T cell receptor (TCR), an immune response is elicited. In case of “self” 
antigen, this classically leads to a tolerogenic, or non-productive immune response to protect the host 
tissue, while “foreign” antigen such as from a virus or bacteria will induce an effector T cell response 
against the invading pathogen. Professional antigen-presenting cells include B cells, macrophages 
and dendritic cells (DCs). Because they possess many unique features of antigen processing and 
presentation, such as cross-presentation of exogenous antigen on MHC class I, DCs are often 
considered to be the most critical induced of adaptive immunity (Vyas et al., 2008). However, recent 
research suggests that lymph node stromal cells (LNSCs), namely fibroblastic reticular cells (FRCs), 
lymphatic endothelial cells (LECs) and extrathymic Aire-expressing cells (eTACs), can act as antigen 
presenting cells in SLOs (Fletcher et al., 2011; Hirosue and Dubrot, 2015; Link et al., 2007). While the 
rare eTAC subpopulation expresses peripheral tissue antigens (PTAs) dependent on the autoimmune 
regulator Aire gene (similar to mTECs in the thymus), FRCs and LECs do so partially independent of 
Aire (Cohen et al., 2010). Presentation of PTAs on MHC class I molecules on the surface of stromal 
cells leads to deletional CD8+ T cell tolerance (Cohen et al., 2010; Fletcher et al., 2010; Gardner et 
al., 2008). Indeed, LECs do not express costimulatory molecules needed to induce effector immune 
responses, and instead express the T cell inhibitory ligand of PD-1, PDL-1 (Tewalt et al., 2012). 
Interestingly, data from the same study suggests that blocking of inhibitory signals or enhancing of 
costimulatory signals bypasses LEC-mediated tolerance. In these settings, LECs have the potential to 
induce fully differentiated effector CD8+ T cells capable of causing autoimmune disease. Besides 
presenting endogenous PTAs, our lab has demonstrated that LECs are capable of up taking, process- 
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Figure 2.7 Mechanisms of immunoregulation by lymphatic endothelial cells. (A) LECs can inhibit
dendritic cell maturation by binding ICAM-1 to MAC-1, thereby dampening the ability of DCs to
activate T cells. (B) When stimulated with pro-inflammatory cytokines such as IFNγ and TNFα, LECs 
can secret immunosuppressive mediators including nitric oxide (NO), indoleamine 2,3-dioxygenase
(IDO), and TGFβ. (C) LECs can present endogenous and exogenous antigen on MHCI and MHCII
complexes to guide T cell activation. However, because LECs lack co-stimulatory molecules such as
CD80 and CD86 but express the T cell inhibitor PDL-1, these interactions lead to tolerogenic rather
than effector immune responses. Illustration adapted from Card et al., 2014. 
ing, and cross-presenting exogenous antigen on MHC-I in a transport associated with antigen 
processing 1 (TAP1)-dependent manner (Hirosue et al., 2014; Lund et al., 2012). CD8+ T cell 
responses elicited this way are characterized by hallmarks of immune tolerance, including reduced 
IFNγ secretion, high levels of PD-1 expression, and increased apoptosis (Hirosue et al., 2014; Lund et 
al., 2012). A novel role of LEC-mediated immunoregulation via capturing and archiving of viral 
antigens has recently been introduced (Tamburini et al., 2014). Archiving of antigen over prolonged 
periods of time increased the protective immunity provided by circulating antigen-specific CD8+
memory T cells. Because LECs can only induce tolerogenic responses, the authors speculated that 
LECs might transfer antigen to dendritic cells, which are then able to induce productive antigen-
specific immune responses (Tamburini et al., 2014). 
The role of LNSCs in presenting antigen in the context of MHC class II complexes has remained 
more elusive. LECs express low levels of MHC-II in steady-state, and upregulate its expression upon 
exposure to the pro-inflammatory cytokine IFNγ (Dubrot et al., 2014; Nörder et al., 2012). Even though 
LECs do express the non-conventional T cell co-stimulatory molecules CD54 and CD58, they failed to 
induce effector CD4+ T cell responses in vitro (Nörder et al., 2012). Interestingly, peptide-MHC-II 
complexes can be transferred from DCs to LECs via exosomes, explaining the low basal presence of 
MHC-II on LECs under non-inflammatory conditions (Dubrot et al., 2014). Similarly to archiving viral 
antigens, it has been suggested that LECs act as antigen reservoirs for CD4+ tolerance by 
transferring PTAs to dendritic cells, which subsequently present it on MHC-II to induce CD4 T-cell 
anergy (Rouhani et al., 2015).  
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Apart from shaping T cell activation, FRCs and LECs can have a suppressive influence on 
already activated T cells (Lukacs-Kornek et al., 2011). These LNSC subsets can upregulate nitric 
oxide synthase 2 (NOS2) in response to three synergistic signals IFNγ, TNFα, and direct contact with 
activated T cells. Expression of NOS2 leads to inhibition of activated T cell proliferation, suggesting 
that FRCs and LECs could be important not only in controlling the naïve T cell pool, but also in fine-
tuning the magnitude of ongoing T cell responses. Finally, apart from directly interacting with T cells, 
LNSCs inhibit immune responses indirectly by manipulating DCs in their proximity. It has been shown 
that inflamed TNFα activated dermal LECs suppress the maturation of DCs via cell-cell signaling 
(Podgrabinska et al., 2009). Interaction of ICAM-1 expressed on LECs and Mac-1 on DCs resulted in 
decreased expression of the costimulatory molecule CD86 on DCs, leading to decreased T cell 
activation. In summary, it is now evident that lymph node stromal cells actively participate in educating 
immune responses towards both exogenous and endogenous antigens in steady-state and disease. 
To influence immunity, they employ mechanisms both mediated by engaging in cell-cell contacts, as 
well as through secretion of soluble mediators influencing neighboring cells (Figure 2.7). 
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3.1 Abstract 
Tumor-associated lymphangiogenesis, the formation of new lymphatic vessels, correlates with poor 
prognosis in melanoma patients. However, while lymphatic vessels might offer a physical escape 
route for metastatic cells, it has been elusive whether this is the predominant reason for the observed 
correlation in clinics. Recent research has highlighted that the cells lining lymphatic vessels, lymphatic 
endothelial cells (LECs), can actively and passively modulate immune responses. This has raised the 
possibility that tumor-associated lymphangiogenesis might influence tumor progression by regulating 
anti-tumor immune responses. In the context of melanoma, we have previously shown that 
lymphangiogenic B16 melanomas establish an immunosuppressive microenvironment in the draining 
lymph nodes, inhibiting the activation of tumor-specific CD8+ T cells. We thus hypothesized that 
blocking the formation of intra- and peritumoral lymphatic vessels might similarly decrease 
immunosuppression in the primary tumor microenvironment itself, thereby increasing the efficacy of 
therapeutic immunotherapy. Strikingly, we found that the opposite was the case. Mice inoculated with 
B16 melanomas overexpressing the lymphatic growth factor VEGFC and the model antigen 
ovalbumin (B16-OVA/VC) were more sensitive to systemic antigen-specific immunotherapy 
approaches as compared to mice with non-lymphangiogenic B16 melanomas. Intriguingly, both B16-
OVA/VC as well as naturally lymphangiogenic, mutant BRAF-driven iBIP2 melanomas recruited 
CCR7+ tumor infiltrating lymphocytes (TILs) by VEGFR3-dependent secretion of CCL21 chemokine. 
Accordingly, VEGFC correlated with CCL21 and CCR7 in a human melanoma gene expression data 
set, and CCL21 co-localized with LECs in sections of primary human melanoma. We further 
demonstrate that naïve TILs enhanced the efficacy of antigen-specific immunotherapy against B16-
OVA/VC tumors, as they were locally activated in response to tumor cell death, leading to antigen 
spreading and long lasting protection to re-challenge with lung metastasis. We conclude that 
secretion of CCL21 is a novel pathway by which tumor-associated LECs actively increase tumor 
inflammation, thereby establishing a microenvironment that is able to potentiate antigen-specific 
immunotherapy. We propose that lymphangiogenesis and CCL21, both biomarkers indicative of poor 
primary disease outcome, might serve as biomarkers predicting favorable response to antigen-
specific immunotherapy.  
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3.2 Introduction 
De novo formation of lymphatic vessels during tumor progression, so called lymphangiogenesis, 
correlates with poor prognosis in melanoma patients (Dadras et al., 2010; Pasquali et al., 2013; 
Shayan et al., 2012). Apart from offering physical routes for metastatic spread (Karaman and Detmar, 
2014; Stacker et al., 2014; Tammela and Alitalo, 2010), tumor-associated lymphatic vessels (LVs) are 
passively and actively involved in shaping anti-tumor immunity (Lund et al., 2016; Swartz, 2014). They 
passively drain antigens, cytokines, and danger signal from the tumor to the sentinel lymph nodes 
(LNs), which is essential for the generation of a T cell-inflamed microenvironment in mouse and 
human melanoma (Lund et al., under review). Moreover, lymphatic endothelial cells (LECs) actively 
impact immune cell function by releasing immunomodulatory cytokines and by presenting 
endogenous and exogenous antigens on MHCI and MHCII molecules (Card et al., 2014). In this 
context, we have previously shown that LECs in the draining LNs of lymphangiogenic B16 melanoma 
tumors can directly suppress the activation of tumor-specific CD8+ T cell responses by tolerogenic 
cross-presentation of tumor-derived antigen (Lund et al., 2012). Considering that secretion of 
bioactive factors and engagement in cell-cell interactions by LECs does not specifically require LVs to 
have a lumen, we anticipated that both peri- and intratumoral LVs might be actively involved in the 
regulation of anti-tumor immunity. Thus, while intratumoral lymphatic vessels have previously been 
reported to be non-functional in terms of drainage (Padera et al., 2002), we here wanted to determine 
the role of tumor-associated lymphangiogenesis in regulating immune responses within the primary 
tumor itself. A better understanding of LEC-mediated immunoregulation within primary melanomas 
would inform rational approaches to modify this aspect of the tumor microenvironment, with the 
ultimate goal of increasing the number of metastatic melanoma patients who can benefit from 
immunotherapy. 
Tumor-associated CCL21, a chemokine classically expressed by lymph node stromal cells to 
guide immune cell subsets into the lymph node parenchyma (Förster et al., 2008), recruits CCR7+ 
immune cells into primary mouse melanomas and induces the formation of a lymphoid-like stroma 
with hallmarks of immunosuppression (Peske et al., 2015; Shields et al., 2010). Even though CCL21 
can be expressed by lymphatic endothelial cells (Förster et al., 2008; Gunn et al., 1998; Kuroshima et 
al., 2004; Shields et al., 2007), it is not known whether there is a link between the presence of intra- 
and peritumoral LECs, local CCL21 levels, and CCL21 mediated immunoregulation in primary 
melanomas. Thus, the purpose of this study was to determine whether CCL21 induced 
chemoattraction of tumor infiltrating lymphocytes (TILs) depends on lymphatic density within primary 
melanoma tumors, and if so, whether this can be exploited to increase the efficacy of therapeutic 
immunotherapy. Given the previous associations of both draining lymph node lymphangiogenesis and 
CCL21 with immunosuppression, we hypothesized that blocking the formation of intra- and 
peritumoral LVs might decrease CCL21-induced immunosuppression in the tumor microenvironment, 
and thus increase the efficacy of systemic immunotherapies. 
We characterized the injectable B16F10 and the inducible BRAFV600E-driven iBIP2 mouse 
models of melanoma in terms of their lymphatic density, CCL21 expression, immune infiltrates, and 
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response to various antigen-specific and antigen-non-specific immunotherapy approaches. Tumor-
associated lymphangiogenesis was manipulated through overexpression of the lymphatic growth 
factor VEGFC and/or through antibody mediated blocking of the VEGFC receptor VEGFR3. To 
assess how lymphangiogenesis would affect cancer immunotherapy, we inoculated mice with B16F10 
cell lines that express VEGFC as well as chicken ovalbumin (B16-OVA/VC), a model antigen for 
which multiple antigen-specific immunotherapy approaches exist. Opposite to what we hypothesized, 
we found that lymphangiogenic B16-OVA/VC melanomas respond much more profoundly to systemic 
antigen-specific immunotherapy including adoptive T cell transfer, dendritic cell vaccination and 
protein vaccination as compared to control tumors, a phenomenon we call lymphangiogenic 
potentiation. In contrast, the lymphangiogenic status of neither B16 nor iBIP2 tumors influenced the 
outcome of non-antigen-specific immunotherapy, such as checkpoint inhibition using anti-PD1 and 
anti-CTLA4 antibodies. To understand why lymphangiogenic melanomas are more permissive to 
antigen-specific immunotherapy, we analyzed the immune cell and cytokine environment of primary 
tumors prior to immunotherapy. In agreement with our previous publications, lymphangiogenic 
melanomas had increased levels of regulatory CD4+ T cells, a hallmark of an immunosuppressed 
microenvironment.  In addition, however, we found that VEGFR3 signaling was also driving increased 
infiltration of naïve T cells into lymphangiogenic B16 and central memory T cells into iBIP2 
melanomas. Considering that regulatory, naïve, and central memory T cells are known to rely on 
CCL21 chemokine gradients for CCR7 chemokine receptor mediated tissue homing, we analyzed this 
signaling axis within lymphangiogenic melanomas. Indeed, we found that lymphangiogenic mouse 
melanomas express high levels of CCL21, and that B16-OVA/VC tumors contained higher densities 
of T cells expressing CCR7. Furthermore, VEGFC but not VEGFA and VEGFD correlated with CCL21 
and CCR7 in a gene expression data set from 469 melanoma patients retrieved from The Cancer 
Genome Atlas (TCGA), suggesting that our findings could be relevant for human pathology.  Finally, 
by blocking lymphocyte egress from secondary lymphoid organs using the small molecule FTY720, 
we demonstrate that local activation and expansion of naïve T cell infiltrates was responsible for 
lymphangiogenic potentiation of antigen-specific immunotherapy in B16-OVA/VC tumors. The locally 
activated T cells with specificities for endogenous antigens ensured antigen-spreading of the anti-
tumor immune response, protecting mice from re-challenge with non-ovalbumin expressing wildtype 
B16 melanoma in a model of lung metastasis. Taken together, our findings reveal that naïve 
endogenous T cells recruited into lymphangiogenic tumors via the CCL21/CCR7 axis are locally 
primed and activated following antigen-specific immunotherapy-induced tumor cell death, leading to 
antigen-spreading and long lasting protection against tumor re-challenge. These results attribute a 
completely novel role to tumor-associated lymphangiogenesis. While they have been indicative of 
poor prognosis because it supports metastatic spread (Karaman and Detmar, 2014; Stacker et al., 
2014) and inhibits anti-tumor immune responses in the draining lymph node (Lund et al., 2012), it 
might serve as a biomarker to stratify metastatic melanoma patients that can benefit from systemic, 
antigen-specific immunotherapies. 
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3.3 Materials and methods 
3.3.1 Mice  
Female wild-type mice (Harlan), OT-I RAG-1−/− (Jackson Labs), and CD45.1 (Harlan), all on the 
C57BL/6 background, were used between 8-12 weeks of age. iBIP2 mice were on the FVB/N 
background and bred in house. iBIP2 mice were generated by crossing the previously published iBIP 
mice (Kwong et al., 2015) into a FVB/N line with floxed Cdnk2a alleles. iBIP2 mice have a Tet-
inducible human BRAFV600E transgene, floxed alleles of Cdkn2a and Pten, and inducible Cre 
expression under melanocyte-specific control. All experiments were performed with approval from the 
Veterinary Authority of the Canton de Vaud, Switzerland, and IACUC of University of Chicago, 
#72414. 
3.3.2 Tumor cell lines 
B16-F10 melanoma cells (ATCC) were maintained in high glucose DMEM (E15-843; GE Healthcare) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (GIBCO Invitrogen). B16-F10 
ovalbumin (OVA) expressing cells (gift of B. Huard) were engineered to overexpress VEGFC as 
described previously (Lund et al., 2012). All cell lines were split 1:20 or 1:40 every 3-4 days. 
3.3.3 B16 tumor inoculation, iBIP2 tumor induction, and measurements 
For B16 tumor inoculation, mice were anesthetized with isoflurane and their backs were shaved. 
2.5x105 cells were resuspended in 30 μl PBS and then injected intradermally on the front, dorsolateral 
side. To induce iBIP2 tumors, mice received one microliter of 5mM 4-hydroxy-tamoxifen (70% Z-
isomer, 30% E-isomer, H6278; Sigma-Aldrich) dissolved in 70% EtOH topically applied on the ventral 
side of the ear. Upon topical application of tamoxifen, Cdkn2a and Pten were specifically deleted only 
in the treated melanocytes, and rtTA was activated. Subsequent continuous administration of 
doxycycline in the drinking water (1mg/ml) (D43020; Research Products International) activated the 
BRAFV600E transgene only in the cells in which the LSL-Stop-rtTA cassette as well as Cdkn2a and 
Pten were codeleted. Both B16 and iBIP2 tumors were measured with a caliper, and volumes (V) 
were calculated as ellipsoids (V=4/3*π*length*width*height/8). Mice were sacrificed when mice 
reached a humane end-point according to an animal well-being score sheet or when tumor volumes 
reached > 500mm3 (before reaching the legal limit of 1cm3). For long-term studies, they were then 
accounted dead the next day. In immunotherapy studies, mice that succumbed for unknown reasons 
prior to the regression phase were excluded. 
3.3.4 Antibody injections 
For VEGFR3 blocking studies, mice received i.p. injections of 500μg anti-VEGFR3 antibody (mF4-
31C1; ImClone/Eli Lilly) or isotype rat IgG (I4131; Sigma) every 3-4 days starting the day of B16 
inoculation. For CCR7 blocking studies, mice received i.p. injections of 25μg anti-CCR7 antibody (16-
1971; eBioscience) or isotype rat IgG on day 0, 3, and 6 after tumor inoculation. For combination 
therapy of PD1 and CTLA4 checkpoint blockade, mice were treated with 250μg anti-CTLA4 antibody 
(BE0164; BioXCell) every 3 days and 100μg anti-PD1 antibody (BE0146; BioXCell) every 2 days both 
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starting on day 4. For combination therapy of PD1 checkpoint blockade and ACT, mice were treated 
with 250μg anti-PD1 antibody every 3-4 days starting on the day of ACT.  
3.3.5 Therapeutic vaccination 
Mice received 50μg CpG-B (5’-TCCATGACGTTCCTGACGTT-3’; Microsynth) + 10μg OVA grade V 
(A5503; Sigma) in two i.d. doses 25μl per hind footpad (targeting tumor non-draining lymph nodes) on 
day 4, 7, and 10 after tumor inoculation.  
3.3.6 OT-I ex vivo activation and therapeutic adoptive transfer  
Spleens and lymph nodes were recovered from OT-I mice. Spleens were placed in a petri dish 
containing 10ml basal IMDM medium (31980-022; Gibco) and disrupted with a scalpel before being 
transferred through a 70μm filter (22363548; Fisher Scientific) into a 50ml conical tube. Cells were 
then spun down at 2000rpm for 5’ and resuspended in 1ml ACK red blood cells lysis buffer (150mM 
NH4Cl + 10mM KHCO3 + 0.1mM Na2EDTA dissolved in H20, pH 7.2). After 5’ incubation, 10ml basal 
IMDM was added, and the cells spun down at 2000rpm for 5’. Lymph nodes were placed in a well of a 
twelve well plate containing 2ml digestion medium (IMDM + 1mg/ml Collagenade D (1108886600; 
Roche)). The lymph node capsules were gently opened with two syringe needles (26G) to allow better 
digestion, and then incubated for 15’ at 37°C. Lymph node cells were then spun down at 2000rpm for 
5’ and pooled in 10ml basal IMDM with the splenocytes for further processing. CD11c+ dendritic cells 
(DCs) were first isolated by positive magnetic cell sorting (130-052-001; Milteny Biotec) before CD8+ 
T cells were isolated from the remaining cells by negative magnetic cell sorting (130-095-236; Milteny 
Biotec) according to the manufacturer’s protocol. Next, isolated CD11c+ DCs and CD8+ T cells were 
plated 1:10 on a 96 well plate (10’000 CD11c+ DCs and 100’000 CD8+ T cells per well) in stimulation 
medium (IMDM + 10%FBS + Pen/Strep + 1nM SIINFEKL peptide + 10U/ml mIL-2 (212-12; 
PreproTech)). Cells were collected after 4 days and injected i.v. into tumor-bearing mice (1x106 cells 
in 200μl in basal IMDM). 
3.3.7 Therapeutic dendritic dell vaccination 
BMDCs were generated from the bone marrow of C57BL/6 mice as previously described (Lutz et al., 
1999). At day 8 of BMDC culture, 10ng/ml LPS was added for 12h. The activated BMDCs were then 
washed 1x with 20ml full medium (IMDM + 10% FBS) and plated at 2-5x106 cells/ml in 10cm petri 
dishes. The cells were then pulsed with 1μM of SIINFEKL for 1h. Cells were then collected and 
washed 3x with 20ml PBS. Finally, cells were resuspended in PBS at 10x106 cells/ml, and 100μl 
injected intraperitoneally per mouse. 
3.3.8 Lymph node and tumor cell isolation 
Stromal cells (CD45-) and CD45+ immune cells were recovered from tumors, and tumor draining and 
non-draining lymph nodes (LNs) according to the “Broggi Style” protocol (Broggi, Schmaler, Lagarde, 
& Rossi, 2014). Lymph nodes were placed in a well of a 24 well plate containing 500μl digestion 
medium consisting of DMEM (41965-062; GIBCO, no pyruvate) + 1% Pen/Strep + 1.2mM CaCl2 + 2% 
FBS. The lymph node capsules were then gently opened with two syringe needles (26G) to allow 
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better digestion. The opened LNs were then transferred into a 5ml round-bottom tube (Falcon-BD 
Bioscience) containing 750μl digestion buffer I, which consisted of digestion medium + 1mg/ml 
Collagenase IV (CLS4 LS004188; Worthington) + 40μg/ml DNAse I (11284932001; Roche). Digestion 
was done for 30’ at 37°C in a beaker with water on a heating plate with magnetic stirring (~1turn/sec). 
The supernatant was then carefully collected into a 5ml round-bottom filter tube (Falcon-BD 
Bioscience), and 750μl digestion buffer II, which consisted of digestion medium + 3.3mg/ml 
Collagenase D (1108886600; Roche) + 40μg/ml DNAse I, was added to the 5ml tube with the 
remaining tissue pieces. Digestion was then continued for 5’, before pipetting 10 times using an 
electronic pipette. Digestion was then continued for 10’, before pipetting 100 times. 7.5μl EDTA 
(500mM) was added to each tube to reach a final concentration of 5mM (pH 7.2), before pipetting 
again 100 times. The entire cell suspension was then collected into a 5ml round-bottom filter tube 
(Falcon-BD Bioscience), and spun down at 2000rpm for 5’. Cells were then resuspended in an 
appropriate volume of FACS buffer (PBS + 2% FBS) to proceed for FACS staining. For the tumors, 
the Broggi Style protocol was slightly adapted. Approximately 100mg of tumor tissue was placed in a 
5ml round-bottom tube containing 750μl digestion buffer I. The tumor piece was then cut into small 
pieces using scissors, before being digested for 30’ at 37°C in a beaker with water on a heating plate 
with magnetic stirring (~1turn/sec). The supernatant was then carefully collected through a 70μm 
nylon filter into a 50ml conical tube and 750μl digestion buffer II was added to the 5ml tube with the 
remaining tissue pieces. Three cycles of 15’ digestion, followed by 100 times pipetting were then 
done. After the last cycle, 7.5μl EDTA (500mM) was added to each tube to reach a final concentration 
of 5mM (pH 7.2), before pipetting again 100 times. The entire cell suspension was then collected 
through the 70μm into the 50ml conical tube. Remaining tissue pieces were smashed through the 
filter using the plunger of a 3ml syringe, and the filter subsequently washed with 10ml HBSS. The cell 
suspension was then spun down at 2000rpm for 5’ and resuspended in an appropriate amount of 
FACS buffer to proceed for FACS staining. 
3.3.9 Immunohistochemistry 
Mouse tumor samples were fixed in Zinc fixation buffer (4.5mM CaCl2 + 51.5mM ZnCl2 + 32mM 
Zn(CF3CO2)2 + 38.5mM glycine in H20, pH 6.5) (Kilarski et al., 2012), paraffin-embedded and cut into 
8μm sections. Formalin-fixed human tumors were, paraffin-embedded and cut into 4-5μm sections. 
For immunolabeling, paraffin-embedded tissue sections were deparaffinized and rehydrated. Antigen 
retrieval was done on PFA-fixed samples at 98°C for 15min in TRIS/EDTA buffer (pH 9.0). Sections 
were then stained according to standard immunohistochemistry protocols. Primary antibodies used 
were: rabbit anti-msLyve1 (103-PA50; RELIATech, 1:200), biotinylated rat anti-msCD45 (13-0451-85; 
eBioscience, 1:100), anti-huD2-40 (SIG-3739; Covance), anti-huCCL21 (HPA051210; Sigma,), anti-
huCD8 (M7103; DakoCytomation), anti-huProx1 (AF2727, RnD System). Quantification of lymphatic 
vessels was done manually on entire tumor tile images using Fiji. Single positive Lyve1 nuclei were 
excluded as macrophages. The iBIP2 peritumoral space was defined as 250μm inwards from the 
tumor border, corresponding to approximately half the thickness of the ear skin adjacent to the 
tumors. A trained medical doctor defined the tumor areas in primary human melanoma. 
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3.3.10 Flow cytometry 
Antibody stainings for surface targets were done in FACS buffer (PBS + 2% FCS), and intracellular 
stainings were done after fixation and permeabilization according to the manufacturers protocol. The 
following anti-mouse antibodies were used for flow cytometry: CD45-APC (17-0451-82; eBioscience) 
or biotinylated CD45 (13-0451-85; eBioscience), CD4-PacBlue (100531; Biolegend) or CD4-PE-Cy7 
(100528; Biolegend), CD8α-PacOrange (MCD0830; Invitrogen), F4/80-PerCPCy5.5 (123128; 
Biolegend), CD25-FITC (101908; Biolegend), FoxP3-PerCPCy5.5 (45-5773-82; eBioscience), CD62L-
PE (12-0621-82; eBioscience), CD44-APCeF780 (47-0441-82; eBioscience), CCR7-PE-Cy7 (25-
1971-82; eBioscience) or CCR7-PerCPCy5.5 (45-1971-82; eBioscience), biotinylated CD11b (13-
0112-82; eBioscience). Pentamer staining for H-2kb-Trp2-PE (SVYDFFVWL; TC Metrix), H-2Db-
gp100-PE (KVPRNQDWL; TC Metrix) and H-2kb-SIINFEKL-PE (F093-2B; ProImmune) was 
performed according to manufacturers guidelines. Cell viability was determined using live/dead aqua 
(L34957; Invitrogen) or red (L23102; Invitrogen) dyes. Flow cytometry acquisition was performed on a 
Cyan flow cytometer (Beckman Coulter) and data analysis was performed with FlowJo (Version 
9.7.7.).  
3.3.11 Analysis of TCGA data set containing 469 skin cutaneous melanoma patients 
TCGA level 3 gene expression data were downloaded for skin cutaneous melanoma (SKCM) from the 
Broad GDAC Firehose database (http://gdac.broadinstitute.org/). The RNAseq data set called 
“illuminahiseq_rnaseqv2-RSEM_genes_normalized (MD5)” with release date 20151101 contained 
upper quartile normalized RSEM values summarized at the gene level (Li and Dewey, 2011). The 
data was log2 transformed after the addition of one pseudoread. The total of 469 SKCM samples 
were split into two groups according to whether the tissue biopsy was retrieved from the primary 
melanoma site (103 samples) or a metastatic site (369 samples) including sentinel lymph nodes and 
distant organ metastasis. 
3.3.12 Statistical analysis  
Statistical analysis was done using Prism (v5.0d, GraphPad). Except mentioned differently, 
statistically significant differences between two experimental groups were determined by an unpaired 
student’s t-test, and by one-way ANOVA followed by Tukey’s post-test when more than two groups 
were compared. * p<0.05, ** p<0.01, *** p<0.001, ns: not significant.  
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3.4 Results 
3.4.1 Lymphangiogenic B16 melanomas are highly sensitive to antigen-specific 
immunotherapy. 
Tumor lymphangiogenesis correlates with poor prognosis in human cancer patients (Dadras et al., 
2010; Pasquali et al., 2013; Shayan et al., 2012). Apart from offering routes for metastatic spread 
(Karaman and Detmar, 2014; Stacker et al., 2014; Tammela and Alitalo, 2010), tumor-associated 
lymphangiogenesis has been shown to suppress the activation of anti-tumor immunity in the tumor 
draining lymph node (Lund et al., 2012). We thus hypothesized that blocking lymphangiogenesis 
using anti-VEGFR3 antibodies might reverse the immunosuppressive microenvironment, thereby 
increasing the efficacy of cancer immunotherapy. To test this, we adoptively transferred ex vivo 
activated OVA-specific CD8+ OT-I cells into tumor bearing mice and assessed tumor growth over time 
(Figure 3.1A-B). In line with our previous findings (Lund et al., under review), non-lymphangiogenic 
B16 tumors were more sensitive to adoptive T cell therapy (ACT) in the short-term, leading to an 
almost 2 fold decreased tumor size on day 12 (Figure 3.1B). However, to our surprise, B16-OVA 
tumors and anti-VEGFR3 treated B16-OVA/VC tumors started progressing shortly after peak 
regression on day 16, while IgG treated B16-OVA/VC tumors showed a profound and long lasting 
response to ACT. This translated into significantly decreased tumor volume in the progression phase 
and into increased survival of control treated B16-OVA/VC tumor bearing mice. To control for 
potential intrinsic differences of the tumor cell lines in terms of their susceptibility to immunotherapy, 
we performed the same ACT experiment in mice that lack dermal lymphatic vessels (K14 mice).  
There was no difference between B16-OVA and B16-OVA/VC tumor growth or host survival in K14 
mice (Figure 3.2A-B), confirming that the observed therapeutic benefit after ACT in B16-OVA/VC 
tumors was dependent on host lymphangiogenesis. We next asked whether the lymphangiogenic 
status of B16 melanomas also modulates the response towards an antigen-specific immunotherapy 
approach that relies on raising an endogenous anti-tumor response. We thus performed a therapeutic 
dendritic cell vaccination (DC vax) protocol, in which dendritic cells are activated with LPS and then 
pulsed with the immunodominant OVA peptide SIINFEKL ex vivo, before being intraperitoneally 
injected into recipient mice on day four and ten after tumor inoculation (Figure 3.1C). As for ACT, 
lymphangiogenic tumors grew significantly larger in the short-term response to DC vax, but then 
underwent profound regression (Figure 3.1D). Accordingly, the median survival increased from 21.5 
days for anti-VEGFR3 treated to 72 days for control treated B16-OVA/VC tumors bearing mice. Based 
on the observations in the models of antigen-specific immunotherapy, we wanted to determine 
whether the lymphangiogenic status of B16 tumors modulates non-antigen-specific immunotherapy 
approaches. We performed a therapeutic checkpoint inhibition protocol that has been described to 
induce delayed tumor outgrowth, but not regression, in the B16 model of melanoma (Figure 3.1E) 
(Spranger et al., 2014). We found that while combinatorial treatment of tumor bearing mice with anti-
PD1 and anti-CTLA4 antibodies did lead to delayed tumor outgrowth, the lymphangiogenic status of 
B16 tumors did not influence the magnitude of response (Figure 3.1F). However, when PD1 inhibition 
was performed in combination with ACT, the therapeutic benefit of lymphangiogenic tumors could be 
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Figure 3.1 Lymphangiogenic B16 melanomas respond to antigen-specific immunotherapy with
increased growth in the short-term, but with profound regression in the long-term. (A-B)
Antigen-specific adoptive T cell therapy (ACT) in B16 tumor-bearing wildtype C57BL/6 mice. (A) Mice
received transfer of 1x106 ex vivo activated effector OT-I cells injected intravenously on day nine after
tumor cell inoculation. (B) Tumor growth profiles and survival curves for B16-OVA and B16-OVA/VC
tumor-bearing mice treated with ACT in combination with isotype (IgG) or anti-VEGFR3 (αVR3)
antibodies. Data pooled from 3 independent experiments, n≥20. (C-D) Antigen-specific dendritic cell
vaccination (DC vax) in B16 tumor-bearing wildtype C57BL/6 mice. (C) Mice received i.p. injections of
1x106 ex vivo SIINFEKL peptide pulsed dendritic cells on day four and ten after tumor cell inoculation. 
(D) Tumor growth profiles and survival curves for B16-OVA/VC tumor-bearing mice treated with DC
vax in combination with isotype (IgG) or anti-VEGFR3 (αVR3) antibodies. n=6. (E-F) Non antigen-
specific immunotherapy by combined checkpoint inhibition of PD1 and CTLA4 in B16 tumor-bearing
wildtype C57BL/6 mice. (E) Mice received i.p. injections of anti-PD1 and anti-CTLA4 antibodies every
2-3 days starting on day four after tumor cell inoculation. (F) Tumor growth profiles and survival
curves for B16-OVA/VC tumor-bearing mice treated with checkpoint in combination with isotype (IgG)
or anti-VEGFR3 (αVR3) antibodies. Data representative of 2 independent experiments, n≥5. (G-H)
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Combinatorial immunotherapy with ACT and checkpoint inhibition in B16 tumor-bearing wildtype
C57BL/6 mice. (G) Mice received i.p. injections of anti-PD1 starting at the same time as ACT was
performed, nine days after tumor cell inoculation. (H) Tumor growth profiles and survival curves for
B16-OVA/VC tumor-bearing mice treated with ACT only (IgG) or ACT + checkpoint inhibition (αPD1,
data pooled from 2 independent experiments, n=8). Growth curves shown as mean ± SEM over time
(* p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001). 
even further increased (Figure 3.1G-H), suggesting that checkpoint inhibition has most impact in 
combination with potent tumor antigen-specific immunity. Even though there was no significant 
difference in tumor size on day 40, 4 out of 8 (50%) mice that received ACT together with checkpoint 
inhibition were tumor free as compared to 1 out of 9 (11.1%) mice that received ACT only (Figure 
3.1H). This translated into significantly increased survival, with 50% of mice receiving combinatorial 
treatment still alive 100 days after inoculation. Altogether, these data demonstrate that mice with 
lymphangiogenic B16 melanoma benefit significantly more from antigen-specific immunotherapy as 
compared to mice with non-lymphangiogenic B16 tumors. 
3.4.2 Lymphangiogenic B16 melanomas show increased TILs of regulatory and naïve 
phenotype. 
Having found that lymphangiogenic B16 melanomas are more sensitive towards antigen-specific 
immunotherapy, we wondered whether there are any changes to the local tumor microenvironment 
that could render them more permissive to therapy. We first assessed whether anti-VEGFR3 
treatment had a specific effect on peri-and intratumoral lymphatics. Consistent with previous reports 
(Lund et al., 2012), primary tumor growth of isotype treated B16-OVA and B16-OVA/VC tumors was 
unaffected, while treatment of B16-OVA/VC tumors with VEGFR3 antibodies led to a slight decrease 
in tumor size on day 9 (Figure 3.4A). Intratumoral VEGFC expression was confirmed in B16-OVA/VC 
tumors (Figure 3.4B). Interestingly, blocking VEGFR3 signaling in these tumors lead to increased 
VEGFC levels, suggesting that the growth factor might accumulate because of decreased receptor-
ligand internalization (Karpanen, 2006). As expected, VEGFC expression increased the density of 
 
Figure 3.2 (Supplementary Figure 3.1). Increased efficacy of immunotherapy in B16-OVA/VC
tumor-bearing mice depends on host lymphangiogenesis. (A-B) Antigen-specific adoptive T cell
therapy (ACT) in B16 tumor-bearing mice lacking dermal lymphatics (K14 mice). (A) Mice received
transfer of 1x106 ex vivo activated effector OT-I cells injected intravenously on day nine after tumor
cell inoculation. (B) Tumor growth profiles and survival curves for B16-OVA and B16-OVA/VC tumor-
bearing K14 mice that did or did not receive ACT (OT-I). n=4. 
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intratumoral Lyve-1 positive lymphatic vessels, while anti-VEGFR3 treated tumors were devoid of 
them (Figure 3.4C). This was confirmed by flow cytometry, where gp38+CD31+ lymphatic endothelial 
cells (LECs) (Figure 3.4D and 3.4E) but not gp38-CD31+ blood endothelial cells (BECs) were enriched 
only in lymphangiogenic tumors. Even though subpopulations of monocytes and macrophages can  
express VEGFR3 (Schoppmann et al., 2002), we could not detect a significant change in the 
abundance of intratumoral F4/80+ macrophages in the different treatment groups (Figure 3.4E). We 
next analyzed tumor infiltrating lymphocytes (TILs) (Figure 3.3A). In line with previous reports, we 
found a trend towards increased CD45+ immune cell density in B16-OVA/VC tumors, including 
CD4+FoxP3+ regulatory T cells (Figure 3.3B). This shifted the balance of regulatory versus effector T 
cells in favor of the former ones, indicating that the environment is immunosuppressed (Figure 3.4F). 
Interestingly, there was also a significant increase (~2.5 fold) of conventional CD4+FoxP3- T cell 
density as well as a trend of increased CD8+ T cell density in lymphangiogenic as compared to non-
 
Figure 3.3 Lymphangiogenic B16 melanomas contain increased regulatory and naïve TILs.
B16-OVA and B16-OVA/VC tumor bearing mice treated with isotype (IgG) or anti-VEGFR3 (αVR3)
antibodies were euthanized 9 days (A-E) or 14 days (D-E, right graphs) after inoculation, and tumor 
single cell suspensions analyzed by flow cytometry. Representative flow cytometry plots (A) and
quantification (B) of overall CD45+ immune cells (gated on live), regulatory CD4+ T cells
(CD45+CD4+FoxP3+), conventional CD4+ T cells (CD45+CD4+FoxP3-) and CD8+ T cells (CD45+CD8+).
(C) Phenotype of TILs according to CD44 and CD62L expression status. Naïve (Tnaive): CD44-
CD62L+, effector/effector memory (TEM): CD44+CD62L-, central memory (TCM): CD44+CD62L+T. (D-E)
Ratio of naïve versus effector CD4+ (D) or CD8+ (E) T cells on day 9 and 14 after tumor inoculation.
Bar graphs shown as mean ± SEM (representative of 2 independent experiments, n=5 for day 9, n≥4
for day 14).  
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lymphangiogenic tumors. TILs infiltrating lymphangiogenic B16 melanomas were mostly of a naïve 
(CD62L+CD44-) phenotype (Figure 3.3C), shifting the balance between naïve and effector  
 
Figure 3.4 (Supplementary Figure 3.3). VEGFR3 blocking specifically abrogates intratumoral 
lymphatic endothelial cells within VEGFC overexpressing B16 melanomas. (A-F) B16-OVA and
B16-OVA/VC tumor bearing mice treated with isotype (IgG) or anti-VEGFR3 (αR3) antibodies were
euthanized nine days after inoculation. (A) Tumor size on day 9 (data pooled from ≥ 2 independent
experiments, n≥10). (B) Intratumoral VEGFC concentration as assessed by ELISA (normalized to
1mg/ml total protein, n=5). (C) Representative immunofluorescence images of whole tumor sections
(10X tiles, scale bar = 500μm and 200μm in zoom-in images) showing nuclei (DAPI, cyan) and LECs 
(Lyve-1, green). (D-F) Tumor single cell suspensions were analyzed by flow cytometry (representative
of 2 independent experiments, n=5). Representative flow cytometry plots (D) and quantification (E) of
LECs (CD45-gp38+CD31+), BECs (CD45-gp38-CD31+), and macrophages (CD45+F4/80+). (F) Ratio of
regulatory CD4+ T cells versus effector T cells. Bar graphs shown as mean ± SEM. 
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(CD62L-CD44+) T cells in favor of naïve ones (Figure 3.3D-E). This trend was even more pronounced 
when TILs were analyzed at a later stage of tumor development (day 14 after inoculation), suggesting 
that naïve immune cell infiltration might be proportional to tumor size and thus to the total amount of 
released VEGFC and CCL21. Taken together, these data demonstrate that apart from increased 
regulatory CD4+ T cells, there is an accumulation of naïve TILs within lymphangiogenic tumors.  
 
Figure 3.5 CCL21 secretion is upregulated in lymphangiogenic B16 melanomas and CCR7 
signaling is essential to increased naïve T cell tumor infiltration. (A) B16-OVA and B16-OVA/VC
tumor bearing mice treated with isotype (IgG) or anti-VEGFR3 (αVR3) antibodies were euthanized 
nine days after inoculation, and tumor tissue as well as draining (dLN) and non-draining (ndLN) lymph
nodes snap frozen for subsequent protein extraction. CCL21 concentration as assessed by ELISA in
the tumor (normalized to 1mg/ml total protein), dLNs, and ndLNs (normalized to 0.025mg/ml total
protein) (n=5). (B) B16-OVA and B16-OVA/VC tumor bearing mice were euthanized 14 days after
inoculation, and tumor single cell suspensions analyzed by flow cytometry. Quantification of CCR7+
conventional CD4+, regulatory CD4+, and CD8+ T cells (n≥4). (C-E) B16-OVA and B16-OVA/VC tumor
bearing mice treated with isotype (IgG) or anti-CCR7 (αCCR7) antibodies were euthanized 9 days
after inoculation, and tumor single cell suspensions analyzed by flow cytometry (n=6). (C)
Representative flow cytometry plots of TIL naïve and effector phenotype based on CD62L and CD44 
expression, and (D) quantification thereof. (E) Ratio of naive versus effector T cells. (F) Control B16-
OVA and control or anti-CCR7 (αCCR7) treated B16-OVA/VC tumor bearing mice (CD45.1) received
adoptive transfer of 1x106 naïve CD45.2+ OT-I T cells on day nine after inoculation and were
euthanized 24h later. Tumor single cell suspensions were analyzed by flow cytometry and
intratumoral OT-I (CD45+CD3+CD8+CD45.2+) cells plotted as percentage of overall CD8+ T cells
(n≥6). Bar graphs shown as mean ± SEM. 
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3.4.3 CCL21 secretion is upregulated in lymphangiogenic B16 and iBIP2 melanomas. 
Naïve, regulatory and central memory T cells as well as dendritic cells express the chemokine 
receptor CCR7 to home towards gradients of CCL21 chemokine. CCL21 is classically expressed by 
lymph node stromal cells to guide these immune cell subsets into the lymph node parenchyma, either 
from the blood stream (T cells) or from peripheral tissues (DCs) (Cyster, 1999; Förster et al., 2008). 
However, CCL21 has previously also been implicated in the regulation of anti tumor immunity (Peske 
et al., 2015; Shields et al., 2010). Because CCL21 can be expressed by lymphatic endothelial cells 
(Förster et al., 2008; Gunn et al., 1998; Kriehuber et al., 2001; Kuroshima et al., 2004; Shields et al., 
2007), we asked whether changing the extent of tumor-associated lymphangiogenesis in B16 
melanomas would lead to altered CCL21 levels. Indeed, CCL21 protein concentrations within tissue 
lysates of isotype treated B16-OVA/VC tumors were significantly increased as compared to isotype 
B16-OVA or anti-VEGFR3 treated B16-OVA/VC tumors (Figure 3.5A). This effect was restricted to the 
local tumor microenvironment as no change in CCL21 levels could be detected in the tumor draining 
(dLN) or non-draining (ndLN) lymph nodes. Accordingly, there were higher numbers of CCR7+ 
conventional CD4+ and CD8+ T cells in B16-OVA/VC as compared to B16-OVA tumors (Figure 3.5B). 
To test whether CCL21/CCR7 signaling was indeed a mechanism underlying increased recruitment of 
naïve T cells into lymphangiogenic tumors, B16-OVA/VC tumor bearing mice were treated with CCR7 
blocking antibodies (Figure 3.5C-E). As expected, naïve tumor infiltrating CD4+ and CD8+ T cells had 
higher surface levels of CCR7 as compared to effector ones (Figure 3.5C), and CCR7 bloackade 
significantly decreased naïve T cell infiltration (CD4+: 40.7 fold, CD8+: 11.9 fold) while affecting 
effector T cell infiltration to a lesser extent (CD4+: 3.5 fold, CD8+: ns) (Figure 3.5D-E). To further 
strengthen the role of CCL21/CCR7 dependent recruitment of naïve T cells into lymphangiogenic 
tumors, we adoptively transferred allogeneic (CD45.2), naïve CD8+ T cells into wildtype B16-OVA or 
B16-OVA/VC tumor bearing CD45.1 mice. 24h later, tumors were harvested and TILs analyzed by 
FACS. Consistent with the previous results, significantly higher numbers of transferred cells were 
detected in B16-OVA/VC as compared to B16-OVA or anti-CCR7 treated B16-OVA/VC tumors 
(Figure 3.5F), suggesting that CCL21/CCR7 signaling is indeed a mechanism of naïve T cell 
recruitment into lymphangiogenic tumors. To investigate the broader relevance of CCL21-mediated 
chemoattraction of immune cells into lymphangiogenic melanomas, we investigated the same 
parameters in the genetically engineered mouse model iBIP2 (inducible BRAF INK/ARK PTEN 2). We 
found that iBIP2 tumors are intrinsically lymphangiogenic, and that VEGFR3 blockade induced a 2.4 
fold reduction in the overall lymphatic vessels coverage as compared to isotype treated mice (18.5+/-
6.3 versus 7.7+/-3.4 LVs per mm2) (Figure 3.6A-B). While blocking VEGFR3 did not have any effect 
on primary iBIP2 tumor growth (Figure 3.6C), it did reduce the levels of intratumoral CCL21 (Figure 
3.6D), similarly to our findings in VEGFR3 blocked B16-OVA/VC tumors. Flow cytometry analysis 
confirmed these findings, showing that anti-VEGFR3 treatment decreased the intratumoral LEC 
density, while BECs and CD11b+ macrophages were not significantly affected (Figure 3.6E-F). We 
found that control iBIP2 tumors are highly infiltrated by CD45+ immune cells (Figure 3.6E and 3.6G), 
and that VEGFR3 blockade decreased the infiltration of CD4+Foxp3+ regulatory T cells (Figure 3.6G), 
and central memory but not naïve CD4+ T cells (Figure 3.6H). As iBIP2 mice are on the FVB/n  
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Figure 3.6 (Supplementary Figure 3.5). VEGFR3 blocking in the iBIP2 mouse model of
melanoma decreased intratumoral CCL21 expression and infiltration of central memory CD4+
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T cells. (A-H) Isotype (IgG) or anti-VEGFR3 (αR3) antibody treated iBIP2 mice were euthanized 12-
14 days after enrollment (enrollment criteria: tumor ≥ 7mm3). (A) Representative immunofluorescence
images of whole tumor sections (10X tiles, scale bar = 500μm and 200μm in zoom-in images)
showing nuclei (DAPI, cyan) and LECs (Lyve-1, green). (B) Quantification of lymphatic vessel density
based on peritumoral (PT) and intratumoral (IT) location (n=7). (C) Tumor volume over time (mean ±
SEM, data pooled from ≥ 2 independent experiments, n≥17). (D) Intratumoral CCL21 concentration as
assessed by ELISA (normalized to 1mg/ml total protein, data pooled from ≥ 2 independent
experiments, n≥11). (E-H) Tumor single cell suspensions were analyzed by flow cytometry (n=6). (E)
Representative flow cytometry plots, and (F) quantification of LECs (CD45-gp38+CD31+), BECs
(CD45-gp38-CD31+) and macrophages (CD45+CD11b+). (G) quantification of overall CD45+ immune
cells (gated on live), conventional CD4+ (CD45+CD4+FoxP3-), regulatory CD4+ (CD45+CD4+FoxP3-),
and CD8+ (CD45+CD8+) T cells. (H) Phenotype of CD4+ (CD45+CD3+CD8-) and CD8+
(CD45+CD3+CD8+) TILs according to CD44 and CD62L expression status. Naïve (Tnaive): CD44-
CD62L+, effector/effector memory (TEM): CD44+CD62L-, central memory (TCM): CD44+CD62L+T. (I-J)
Non antigen-specific immunotherapy in iBIP2 mice treated with isotype (IgG) or anti-VEGFR3 (αR3)
antibodies. (I) Mice received i.d. injections of CpG into all four footpads (40μg in total) every 3 days,
starting on day 7. Shown is the tumor volume over time (mean ± SEM, CpG groups: n ≥ 4). (J) Mice
received i.p. injections of anti-PD1 (αPD1) antibodies (250μg per injection) every 3 days, starting on
day 10. Shown is the tumor volume over time (mean ± SEM, αPD1 groups: data pooled from 2
independent experiments, n ≥ 11). Bar graphs shown as mean ± SEM.  
background and do not express any common tumor antigens (data not shown), we were limited to 
non-antigen specific immunotherapy approaches. Both therapeutic adjuvant therapy using CpG 
oligonucleotides (Figure 3.6I) and checkpoint inhibition using anti-PD1 antibodies (Figures 3.6J) 
delayed iBIP2 tumor growth. However, similarly to non-antigen-specific approaches in the B16-
OVA/VC model, the efficacy did not depend on the lymphangiogenic status of iBIP2 tumors. 
Collectively, these data demonstrate that tumor VEGFC/VEGFR3 signaling influences the quantity 
and quality of TILs both in B16 and iBIP2 melanomas, and that lymphangiogenic B16 melanomas are 
specifically infiltrated by naïve T cells in a CCR7 dependent manner. 
3.4.4 VEGFC expression correlates with CCL21 and CCR7 in human primary and metastatic 
melanoma. 
Because we demonstrated that lymphangiogenesis drives CCL21 dependent chemoattraction in two 
mouse models of melanoma, we next wanted to determine whether similar mechanisms might be 
relevant for disease progression in human melanoma. We first analyzed the expression of the 
lymphatic marker podoplanin in tissue sections of 14 primary human melanomas (Figure 3.7A). The 
lymphatic density was significantly higher in peritumoral areas and the invasive margin and compared 
to healthy skin in a subset of patients, confirming that human primary melanomas have 
lymphangiogenic potential (Figure 3.7B). Strikingly, the average overall density of lymphatic vessels 
within human primary melanoma (20.9+/-8.3 LVs per mm2) closely resembled the one of iBIP2 mouse 
melanoma (18.5+/-6.3 LVs per mm2). To investigate whether CCL21 could be driven by VEGFR3 
signaling in human melanoma, we analyzed a dataset from The Cancer Genome Atlas (TCGA) 
containing expression data from skin cutaneous melanoma (SKCM) patients. In line with our findings 
in mice, expression of VEGFC correlated with CCL21 in human primary melanoma, while expression 
of the alternative VEGFR3 ligands VEGFA and VEGFD did not (Figure 3.7C). Interestingly, we 
observed the same trends in metastatic sites, suggesting that VEGFC driven CCL21 expression might 
also be relevant for metastatic disease. Furthermore, we co-stained sections of human primary  
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Figure 3.7 VEGFC expression correlates with CCL21 and CCR7 in human primary and
metastatic melanoma. (A) Representative immunofluorescence images of whole tumor sections
(10X tiles, scale bar = 500μm and 200μm in zoom-in images) showing nuclei (DAPI, cyan) and LECs
(podoplanin, green). (B) Quantification of lymphatic vessel density based on peritumoral (PT),
invasive margin (IV) and intratumoral (IT) location. Normal skin was analyzed on the same section if 
available. Scatter dot plots shown with mean ± SEM (n=7 for normal skin, n=14 for tumors, *p<0.05,
**p<0.01 with Student’s t-test). (C) Gene expression data of human primary metastatic melanoma
samples from the cancer genome atlas (TCGA) correlating VEGFA, VEGFC, and VEGFD with CCL21
expression. (D) Representative immunofluorescence image of an intratumoral lymphatic vessel
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(podoplanin, green) expressing CCL21 (gray) in a section of human primary melanoma (63X, scale
bar = 10μm). (E) Data from (C) was used to correlate VEGFA, VEGFC, and VEGFD with CCR7
expression. Dot plots shown with linear regression curve (n=103 for primary melanoma, n=369 for 
metastatic melanoma sites, correlation was tested using non-parametric Spearman’s test).  
melanoma with fluorescent antibodies specific for podoplanin and CCL21, and found that intratumoral 
lymphatic endothelial cells (LECs) can be a source of CCL21 in human melanoma (Figure 3.7D). 
Finally, expression of VEGFC, but not VEGFA or VEGFD positively correlated with CCR7 both in 
human primary melanoma as well as in metastatic sites (Figure 3.7E). Taken together, these data 
suggest that VEGFC driven upregulation of CCL21 and subsequent infiltration of CCR7+ immune cells 
might be relevant for shaping the tumor microenvironment in human melanoma. 
3.4.5 Lymphangiogenic potentiation of antigen-specific immunotherapy depends on 
intratumoral activation of naïve TILs. 
It has been previously been shown that naïve T cells can be recruited and primed within primary 
tumors (Schrama et al., 2007; Thompson et al., 2010; Yu et al., 2004), and that adoptive transfer of 
naïve OT-I cells into B16-OVA tumors can delay primary tumor growth (Peske et al., 2015). We thus 
wanted to assess whether there was a mechanistic link between the increased susceptibility to  
 
Figure 3.8 Intratumoral activation of CCR7+ immune cells following antigen-specific
immunotherapy is responsible for increased efficacy in lymphangiogenic B16 melanomas.
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(A-B) B16-OVA and B16-OVA/VC tumor-bearing mice treated with isotype (IgG) or anti-VEGFR3
(αVR3) antibodies were euthanized three days after ACT, and tumor single cell suspensions analyzed
by flow cytometry (n=5). (A-B) Quantification of overall OT-I (CD45+CD8+CD45.1+), naïve CD8+
(CD45+CD8+CD44-CD62L+) and effector CD8+ (CD45+CD8+CD44+CD62L-) T cells in the tumor (A)
and draining lymph node (B). (C-D) Role of CCR7 dependent T cell homing prior to immunotherapy.
(C) B16-OVA/VC tumor-bearing mice were treated with anti-CCR7 (αCCR7) antibodies on day 0, 3,
and 6 prior to receiving adoptive T cell transfer on day 9. (D) Tumor growth profiles and survival curve
for isotype (IgG), anti-CCR7 (αCCR7) or anti-VEGFR3 (αVR3) treated B16-OVA/VC tumor-bearing
mice (αCCR7 group: data pooled from 2 independent experiments, n=15). (E-G) Role of lymphocyte
egress from secondary lymphoid organs post immunotherapy. (E) B16-OVA/VC tumor-bearing mice
treated with isotype (IgG) or anti-VEGFR3 (αVR3) antibodies received injections of the small
molecular S1P inhibitor FTY720 daily (1mg/kg i.p.), starting on the same day as ACT was performed
(day 9) (n≥5). (F) Tumor growth profiles. (G) Representative flow cytometry plots of a CD4+ and CD8+
cell staining of blood taken on day 26. Cells were gated on CD45+B220-. Statistics represent
differences between IgG and αVR3 groups. 
antigen-specific immunotherapy and the increased accumulation of naïve TILs within 
lymphangiogenic B16 tumors. We hypothesized that naive CCR7+ cells within lymphangiogenic 
tumors might be locally activated following immunotherapy-induced release of tumor antigen and 
innate immune activation (“danger signals”). In line with this, we found that three days after ACT, 
lymphangiogenic tumors but not their draining lymph nodes contained significantly higher numbers of 
endogenous naïve and effector CD8+ T cells as well as OT-I cells (Figure 3.8A-B), suggesting that 
local activation and expansion of naïve T cells may potentiate both the endogenous and exogenous 
anti-tumor immune response. To test whether the efficacy of ACT in B16 melanoma indeed relied on 
VEGFC-induced recruitment of naïve immune cells, B16-OVA/VC tumor-bearing mice were treated 
with CCR7 blocking antibodies during tumor development prior to therapy (Figure 3.8C). We found 
that after the initial response to ACT, B16-OVA/VC tumors of CCR7 blocked mice progressed similar 
to B16-OVA tumors, both in terms of tumor growth and survival (Figure 3.8D). To exclude that 
increased T cell activation in and egress from secondary lymphoid organs (SLOs) was responsible for 
the enhanced sensitivity of lymphangiogenic tumors, we next performed ACT while blocking 
lymphocyte egress from SLOs using the small molecular inhibitor FTY720 (Figure 3.8E). Indeed, 
tumor growth in the progression phase after ACT was only dependent on VEGFR3 signaling, but 
independent of lymphocyte egress (Figure 3.8F). Accordingly, the blood of FTY720 treated mice was 
essentially devoid of lymphocytes (Figure 3.8G), further indicating that in this phase of disease 
progression, anti-tumor immunity did not rely on circulating lymphocytes but on intratumoral activation 
and expansion of TILs. 
3.4.6 Mice that rejected lymphangiogenic B16 melanomas after antigen-specific 
immunotherapy show antigen spreading and protection to re-challenge. 
Immunotherapy has previously shown to broaden the endogenous anti-tumor immune response to 
tumor epitopes that were previously not or not sufficiently visible, a process called antigen spreading 
(Corbière et al., 2011; GuhaThakurta et al., 2015; Kreiter et al., 2015). Because we found that naïve 
endogenous T cells are activated and expanded within lymphangiogenic B16 melanomas in response 
to antigen-specific immunotherapy, we hypothesized that spreading of the anti-tumor immune 
response to antigens other than ovalbumin could occur in these settings. To determine whether this  
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was the case, we performed a therapeutic vaccination protocol using OVA protein in combination with 
CpG adjuvant (Figure 3.9A). The vaccines were injected on days four, seven, and ten after inoculation 
intradermally into the hind food pats, deliberately avoiding the suppressive microenvironment present 
in the brachial tumor draining lymph nodes (Lund et al., 2012). We found that while B16-OVA and 
anti-VEGFR3 treated B16-OVA/VC tumors only showed a short-term response to vaccination, 
lymphangiogenic tumors underwent profound regression so that a majority of mice were tumor free 15 
days after the last boost vaccination (Figure 3.9B). Intriguingly, we found that mice that rejected B16-
OVA/VC tumors had increased numbers of overall effector CD4+ and CD8+ T cells as well as of 
SIINFEKL-specific CD8+ T cells in blood as compared to mice that had progressing B16-OVA tumors  
 
Figure 3.9 Mice that rejected primary lymphangiogenic B16 tumors in response to antigen-
specific immunotherapy show antigen spreading and protection to re-challenge in a model of
lung metastasis. (A-B) Antigen-specific protein vaccination in B16 tumor-bearing wildtype C57BL/6
mice. (A) Mice received CpG-B (50μg) + OVA (10μg) vaccinations i.d. into hind footpads on day four,
seven and ten after tumor cell inoculation. (B) Tumor growth profiles and survival curves for isotype
(IgG) treated B16-OVA and isotype (IgG) or anti-VEGFR3 (αVR3) treated B16-OVA/VC tumors. (C)
Blood was drawn on day 23 after inoculation and lymphocytes analyzed by flow cytometry. Effector 
CD4+ (CD45+B220-CD4+CD44+CD62L-), effector CD8+ (CD45+B220-CD8+CD44+CD62L-), and
SIINFEKL-specific CD8+ (CD45+B220-CD8+SIINFEKL-pentamer+) T cells were quantified). (D-G) B16-
OVA/VC tumor bearing mice that rejected the primary tumor following therapeutic vaccination were
re-challenged with intravenous injections of 0.2x106 B16 WT or B16-OVA/VC cells (2° i.v. challenge)
at least ten days after complete regression. Mice that either received no treatment (naïve) or 
vaccination only (Vax only) served as control for the first challenge (1° i.d. challenge). (D-E) Mice
were euthanized 9 days after the 2° i.v. challenge and lung metastasis analyzed. (D) Representative
images of lungs and (E) quantification of metastatic nodules per lung. (F-G) Flow cytometry analysis
of circulating tumor antigen-specific CD8+ T cell responses nice days after metastatic challenge. (F) 
Quantification of SIINFEKL-specific CD8+ T cells (CD45+CD8+SIINFEKL-pentamer+) and (G)
representative dot plots of Trp2 (CD45+B220-CD8+Trp2-pentamer+) and gp100 (CD45+B220-
CD8+gp100-pentamer+) specific T cell responses. Bar graphs shown as mean ± SEM (data pooled
from 2 independent experiments, n≥5). 
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Figure 3.10 (Supplementary Figure 3.9). Antigen-specific immunotherapy in B16-OVA/VC
tumor bearing mice induces high levels of circulating SIINFEKL+ and rare populations of
gp100+ and Trp2+ CD8+ T cells. Experiment from Figure 3.9. (A) Blood was drawn 23 days after
inoculation and effector CD4+ (CD45+B220-CD4+CD44+CD62L-), effector CD8+ (CD45+B220-
CD8+CD44+CD62L-), and SIINFEKL-specific CD8+ (CD45+B220-CD8+SIINFEKL-pentamer+) T cells
quantified by flow cytometry. (B-C) Flow cytometry analysis of circulating tumor-specific CD8+ T cell
responses 9 days after metastatic challenge. (B) Quantification of SIINFEKL-specific
(CD45+CD8+SIINFEKL-pentamer+) and (C) representative dot plots of rare Trp2 (CD45+B220-
CD8+Trp2-pentamer+) and gp100 (CD45+B220-CD8+gp100-pentamer+) specific responses. Bar
graphs shown as mean ± SEM (data pooled from 2 independent experiments, n≥5). (D)
Representative H&E stainings of tumor draining lymph node sections (10X tiles, scale bar = 500μm
and 200μm in zoom-in images). 
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(Figure 3.10A). To assess whether the increased numbers of effector T cells were the result of 
antigen spreading within the tumor microenvironment, we re-challenged mice that were tumor free for 
at least ten days with experimental pulmonary metastasis (2° i.v. challenge). To evaluate whether 
anti-tumor responses did spread to other antigens apart from OVA, one group of survivor mice was 
challenge with B16-OVA cells, while another group was challenged with B16 wildtype (WT) cells that 
only express endogenous tumor antigens. Strikingly, while control mice that only received OVA + 
CpG vaccinations were only partially protected against B16-OVA but not B16 wildtype metastasis, 
mice that previously rejected B16-OVA/VC tumors were completely protected against both B16-OVA 
and B16 wildtype metastasis (Figure 3.9C-D). The resistance to pulmonary metastasis was 
accompanied by increased levels of circulating SIINFEKL-specific CD8+ T cells (Figure 3.10B), but 
also by the presence of novel CD8+ T cell specificities against the endogenous B16 antigens Trp2 and 
gp100 in a subset of mice (Figure 3.10C). Mice that rejected both lymphangiogenic B16 melanomas 
as well as pulmonary metastasis challenge had black tumor draining lymph nodes, indicating 
enhanced drainage of melanin and/or B16 tumor cells from lymphangiogenic tumors (Figure 3.10D). 
However, nuclear stainings did not localize into these areas, suggesting that it was accumulation of 
melanin rather than live metastatic B16 cells. Taken together, these data suggest that antigen-specific 
immunotherapy of lymphangiogenic B16 tumors induces secondary immune responses against a 
variety of endogenous tumor antigens, conferring long-term memory and protection against 
pulmonary metastasis re-challenge. 
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3.5 Discussion 
Even though tumor-associated lymphangiogenesis generally correlates with poor prognosis in 
melanoma patients, we here introduce an unexpected role of lymphangiogenesis in enhancing 
systemic antigen-specific immunotherapy. In contrast to our original hypothesis, lymphangiogenic 
B16-OVA/VC tumors are more sensitive to systemic antigen-specific immunotherapy as compared to 
non-lymphangiogenic ones (Figure 3.1, Figure 3.9A-B). We demonstrate that this lymphangiogenic 
potentiation of immunotherapy depends on CCL21-mediated recruitment of CCR7+ immune cells into 
primary melanoma tumors (Figure 3.5, Figure 3.8C-D). Our results suggest that the naïve fraction of 
these cells can be locally activated by immunotherapy-induced release of antigens and danger 
signals, leading to a diversification of the endogenous anti-tumor response and long lasting immune 
memory against tumor re-challenge (Figure 3.9, Figure 3.10). Considering that immunotherapy has 
been revolutionizing the treatment of metastatic melanoma, our findings attribute a completely novel 
role to tumor-associated lymphangiogenesis that could potentially be therapeutically exploited. 
Pre-existing immune infiltration within the tumor microenvironment is associated with clinical 
response to immunotherapies (Ji et al., 2011; Spranger et al., 2015; Tumeh et al., 2014). Interestingly, 
T cell-inflamed tumor microenvironments usually express hallmarks of immunosuppression (Gajewski, 
2015; Munn and Bronte, 2016). In response to sensing effector cytokines such as interferon-γ, the 
tumor microenvironment upregulates immunosuppressive molecules such as IDO, PD-L1 and 
increases the influx of Treg cells, a process called adaptive resistance (Spranger et al., 2013). Thus, 
tumor microenvironments with pre-existing T cell infiltrates are more permissive to immunotherapy 
than non-T cell-inflamed ones, even if the former presents hallmarks of immunosuppression 
(Gajewski, 2015; Spranger et al., 2015). We have previously shown that primary lymphangiogenic 
B16-OVA/VC tumors contain high number of regulatory T cells, and that they establish an 
immunosuppressive microenvironment in the draining lymph node (Lund et al., 2012). Here, we found 
that in addition, they also contain high densities of naïve CD4+ and CD8+ T cells (Figure 3.3), a subset 
of immune cells that is not classically considered of directly contributing to anti-tumor immunity 
(Gajewski et al., 2013). However, naïve T cells in the tumor might indirectly alter the immune-
microenvironment. For example, one might speculate that naïve T cells affect immune cell subsets by 
competing for (1) local nutrients (Chang et al., 2015; Delgoffe and Powell, 2015; Ho et al., 2015) or (2) 
homeostatic cytokines such as IL-7 (Schmaler et al., 2015). Moreover, it is known that naïve T cells 
can also be activated directly within primary tumors (Schrama et al., 2007; Thompson et al., 2010; Yu 
et al., 2004). Activation of naïve T cells in the LN depends on three signals: TCR engagement with 
cognate antigen presented by MHC molecules, costimulation, and stimulatory cytokines, provided by 
DCs upon innate immune stimulation (Sckisel et al., 2015). This led us to the hypothesis that release 
of antigen combined with innate immune stimulation following immunotherapy-induced tumor cell 
death might provide all three signals needed for naïve T cell activation within the primary tumor itself.  
Because cancer immunotherapy seems to be most efficient when targeting neoantigens 
(Schumacher and Schreiber, 2015; Snyder et al., 2014; Van Allen et al., 2015), we mainly used 
immunotherapy approaches that target the model antigen ovalbumin, to which there is no central 
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tolerance similar as to neoantigens. In addition, by delivering immunotherapies systemically rather 
than to the tumor draining lymph nodes, we deliberately avoided the immunosuppressive 
microenvironment that is specifically present within these organs (Lund et al., 2012). Strikingly, 
lymphangiogenic B16-OVA/VC tumors were much more sensitive to ovalbumin-specific 
immunotherapy including ACT, dendritic cell and protein vaccination as compared to non-
lymphangiogenic control tumors (Figure 3.1A-B, Figure 3.9A-B). The beneficial outcome was at least 
partially dependent on naïve T cell homing into the tumor prior to therapy, as CCR7 blocking prior to 
ACT almost completely reversed this effect (Figure 3.8C-D). In contrast, lymphangiogenic tumors did 
not show an increased benefit to non-antigen specific immunotherapy such as checkpoint inhibition 
(Figure 3.1E-F, 3.6I-J). In our models, these treatments induce tumor control rather than tumor cell 
death, thus supporting our hypothesis that release of antigen and danger signal is necessary to 
activate tumor resident naïve T cells. In line with this, we found that lymphangiogenic potentiation was 
independent from the ability to recruit lymphocytes from secondary lymphoid organs (Figure 3.8E-G). 
It has previously been shown that antigen-specific immunotherapy induces antigen spreading, thereby 
initiating secondary humoral and cellular tumor-specific immune responses that enhance therapy 
outcome (Corbière et al., 2011; GuhaThakurta et al., 2015; Kreiter et al., 2015). Our data add a novel 
mechanism by which immunotherapy-induced cell death leads to antigen spreading. Specifically, we 
found that antigen-specific immunotherapy induces secondary immune responses via the activation of 
tumor resident naïve CD4+ and CD8+ T cells, which conferred long-term memory and protection 
against tumor re-challenge with wildtype B16 tumor cells in a model of lung metastasis (Figure 3.9C-
D, Figure 3.10).  
Our data suggest that intra- and peritumoral lymphatics can actively influence primary tumor 
inflammation by secreting CCL21. The lymphocyte homing chemokine CCL21 is best known for its 
function within the lymph node where it attracts CCR7+ cells including activated, antigen-loaded 
dendritic cells from the periphery as well as naïve T cells from circulating blood (Cyster, 1999; Förster 
et al., 2008). This allows these two cells types to co-localize within the T cell zone of lymph nodes, 
allowing TCR/MHC-peptide interactions necessary to raise immune responses (Andrian and Mempel, 
2003). Interestingly, similar functions have been attributed to CCL21 within primary tumors. 
Intratumoral injection of exogenous CCL21 leads to increased recruitment of T cells and DCs into the 
primary tumor, resulting in better tumor control (Sharma et al., 2000; 2001). Our lab has previously 
published that endogenous expression of CCL21 by B16F10 melanoma cells leads to the 
development of an immunosuppressive lymph-node like tumor stroma characterized by the presence 
of high-endothelial venules (HEVs) and CCR7+ immune cells such as Treg cells (Shields et al., 2010). 
Similarly, production of CCL21 by intratumoral blood endothelial cells and fibroblasts leads to naïve 
CCR7+ T cell infiltration into non-lymphangiogenic tumors (Peske et al., 2015). While these studies 
have established CCL21 as a major factor for immune cell homing into primary tumors, it has been 
elusive what the endogenous source of this chemokine is within lymphangiogenic melanoma. Since 
CCL21 can be expressed by LECs (Förster et al., 2008; Gunn et al., 1998; Kuroshima et al., 2004; 
Shields et al., 2007), we wondered whether they contribute to CCL21 in the tumor microenvironment. 
Indeed, we observed that CCL21 expression within lymphangiogenic mouse melanomas depends on 
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VEGFR3 signaling (Figure 3.5A, 3.6B), and that VEGFC expression correlates with CCL21 
expression within primary human melanomas (Figure 3.7C). However, extravasation of immune cells 
into the tumor depends not only on chemokine gradients but also on the phenotype of the tumor 
vasculature including the presence of adhesion molecules (Lanitis et al., 2015; Motz et al., 2014). This 
might explain why VEGFR3 signaling differentially affects tumor immune cell infiltration in iBIP2 and 
B16-OVA/VC melanomas (Figure 3.3, 3.63).  
We found an unexpected discrepancy between the short-term and the long-term responses to 
antigen-specific immunotherapy in B16-OVA/VC tumors. While in the short-term, lymphangiogenic 
tumors grew significantly larger than anti-VEGFR3 blocked ones, they had the most durable 
responses in the long-term, many of which regressed completely. This was especially striking after 
adoptive T cell transfer (Figure 3.1A) and DC vaccination (Figure 3.1B). Interestingly, increased tumor 
growth before regression can be indicative of effective immunotherapy in clinics, indicating that 
effector immune cells might be infiltrating into and expanding within tumor lesions (Hoos et al., 2010). 
Our findings that more endogenous T cells and transferred OT-I cells infiltrated into lymphangiogenic 
tumors 3 days after ACT (Figure 3.8A) are in line with these observations. In the clinic, the immune-
related response criteria (irRC) was developed to better predict patient outcome by taking into 
account the distinct tumor growth patterns specific to immunotherapy (Wolchok et al., 2009). 
However, in pre-clinical studies, researchers are often limited to the evaluation of short-term 
responses, mainly because the treatment window of many tumor models is only a few days to weeks 
before the animals need to be euthanized. Because adaptive immune responses take five to seven 
days to impact the host, and because tumor immune infiltration might initially lead to an increase 
instead of decrease in tumor growth, it is questionable whether short-term tumor growth is indeed a 
valid endpoint to measure the efficacy of immunotherapies in mice. Phenotypical and functional 
analysis of TILs might be more indicative of the quality of response to immunotherapy in such short 
trials.  
Our study has limitations. First of all, even though VEGFC may be one of the major growth 
factor for lymphangiogenic signaling, it is not the only one. Other factors include VEGFA and VEGFD 
(Zheng et al., 2014), fibroblast growth factor (FGF) (Cao et al., 2004b), angiopoietins (Ang1/2) 
(Thurston, 2003), platelet-derived growth factors (PDGF) (Cao et al., 2004a), hepatocyte growth 
factor (HGF) (Kajiya et al., 2005), and insulin-growth factors (IGF1/2) (Björndahl et al., 2005). This 
might explain some of the differences between the B16 and iBIP2 model. While lymphangiogenesis in 
the B16-OVA/VC model is mainly VEGFC driven, it is most likely a combination of different factors in 
the iBIP2 model, offering an explanation why VEGFR3 blockade only led to a partial abrogation of 
intratumoral LECs (Figure 3.6F). Approaches that target multiple lymphangiogenic pathways should 
have a more profound effect on lymphatic density within primary iBIP2 tumors. Secondly, we did not 
assess gene expression of lymphangiogenic versus non-lymphangiogenic tumors in an unbiased 
manner. Even though we did an unbiased protein analysis of some of the most prominent chemokines 
and cytokines that would likely be involved in immune regulation, there is a multitude of other 
candidates that might be differentially expressed. Performing RNA sequencing experiments might 
offer a broader and more unbiased view in the future. Nevertheless, having shown that CCR7 
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blockade completely or at least partially inhibited the observed phenomena indicates that the 
CCL21/CCR7 axis is indeed one of the major drivers thereof. Thirdly, LECs might not be the only 
source of CCL21 as other cells including gp38+ fibroblasts and CD31+ endothelial cells have shown to 
express this chemokine within tumors (Peske et al., 2015). However, in both of our lymphangiogenic 
melanoma models, CCL21 expression decreased to a similar extent as VEGFR3 blocking decreased 
LEC density, suggesting that the main producer of CCL21 within this type of tumors might indeed be 
the lymphatic endothelium. It remains to be determined whether LECs are the main source of CCL21 
within primary human lymphangiogenic melanoma, but our finding that VEGFC expression correlates 
with CCL21 (Figure 3.7C), and that LECs can express CCL21 (Figure 3.7D) establishes a strong link 
between the two. 
We conclude that secretion of CCL21 is a novel mechanism by which tumor associated 
lymphatics actively increase naïve immune cell infiltration. Activation of naïve T cells can be induced 
by immunogenic cell death following antigen-specific immunotherapy, resulting in a broad and long 
lasting anti-tumor immune response. Considering our pre-clinical results, the immune 
microenvironment specific to lymphangiogenic melanoma might represent a window of opportunity to 
jumpstarting an immunosuppressed Cancer-Immunity Cycle in clinics (Chen and Mellman, 2013). We 
therefore propose lymphangiogenesis to be a biomarker to stratify patients eligible for antigen-specific 
immunotherapy and speculate that engineering lymphangiogenesis within primary melanoma might 
improve response rates of patients with non-T cell-inflamed primary melanomas. 
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4.1 Abstract 
The lymphatic network is of vital importance to appropriate fluid homeostasis and immune regulation 
in steady-state and disease. Lymphatic vessels (LVs) form a one-way drainage system that transports 
cells, macromolecules, ions, and interstitial fluid from peripheral tissues to secondary lymphoid organs 
(SLOs). Within SLOs, information coming from the periphery is systematically scanned for 
abnormalities such as cancer and pathogens, and countermeasures in the form of adaptive immune 
responses are induced when needed. Although the role of lymphatic vessels in shaping immunity via 
passive transmission of peripheral information has been well established, the notion that lymphatic 
endothelial cells (LECs) can be actively involved in immune cell education and trafficking has only 
recently emerged. LEC-secreted chemokines such as CCL21 are essential for the orchestration of 
immune cell trafficking from peripheral tissues to SLOs, from the blood circulations to SLOs, within 
SLOs themselves, as well as for the egress from SLOs back into blood circulation. However, it is not 
well understood whether LECs secrete cytokines to regulate trafficking of immune cells in peripheral 
tissues themselves. We thus asked whether engineered lymphangiogenesis induces chemokine 
mediated immune cell recruitment into skin, and if so, whether this can be therapeutically exploited. 
We first show that an injectable hydrogel system for the sustained and highly localized delivery of the 
lymphatic growth factor VEGFC is able to induce local lymphangiogenesis with minimal induction of 
bystander inflammation in the mouse dermis. Furthermore, we found that lymphangiogenic sites 
resemble tertiary lymphoid organs (TLOs) in that they express higher levels of CCL21 and contain 
more CD4+ and CD8+ T cells infiltrates as compared to non-lymphangiogenic sites. Interestingly, 
delivery of the model antigen ovalbumin (OVA) into engineered lymphangiogenic sites led to 
increased numbers of IFNγ secreting effector cells upon antigen re-challenge, indicating that this 
environment could be permissive for therapeutic modulation of immune responses. We thus propose 
that LECs might have an underappreciated role in driving the formation of tertiary lymphoid organs in 
peripheral tissues such as skin, and that engineered peripheral lymphangiogenesis might create 
therapeutic applications for the modulation of immune responses. 
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4.2 Introduction 
Lymphatic vessels (LVs) are essential for fluid homeostasis and immune regulation in steady-state 
and disease (Lund et al., 2016). LVs form a one-way drainage system consisting of a hierarchical 
network of open-ended, permeable initial lymphatics that lead into collecting vessels characterized by 
a continuous basement membrane, pericyte coverage, and a system of valves that prevents 
retrograde fluid flow (Kerjaschki, 2014). By transporting cells, macromolecules, ions, and interstitial 
fluid through this network, LVs transfer information from peripheral tissues to secondary lymphoid 
organs (SLOs) and then relay it back into the blood circulation via efferent lymphatics that drain into 
the subclavian veins. The information that reaches the SLOs via lymphatics contains important cues 
essential to regulating adaptive immunity including soluble antigens (Clement et al., 2011), antigen-
loaded dendritic cells (Randolph et al., 2005), danger signals and cytokines (Card et al., 2014). 
Depending on the tissue context such as homeostasis, inflammation, cancer, or infection, these cues 
lead to either tolerogenic adaptive immune mechanisms that maintain tolerance to self-antigens, or to 
the induction or resolution of effector mechanisms that try to battle tumor cells and invading 
pathogens (Lund et al., 2016). Although the role of lymphatic vessels in shaping immunity as passive 
conduits has been well established, the concept that LVs can also be actively involved in immune cell 
education and trafficking has only recently emerged (Card et al., 2014). However, as long as there is 
no better understanding of how lymphatic vessels actively regulate immunity, no rational approaches 
can be designed to exploit this biology for therapeutic interventions. 
Lymphatic endothelial cells (LECs) actively participate in regulating immunity by influencing 
immune cell trafficking (Johnson and Jackson, 2013). LECs orchestrate immune cell trafficking via 
differential expression of chemokines and cell adhesion molecules (Card et al., 2014). CC-chemokine 
ligand 21 (CCL21) is the most thoroughly studied chemokine secreted by LECs (Gunn et al., 1998; 
Kriehuber et al., 2001; Vigl et al., 2011). In peripheral tissues, initial lymphatics secrete CCL21 to 
create a peri-lymphatic gradient, which attracts activated, antigen-loaded DCs via their expression of 
the CCL21 receptor, CCR7 (Teijeira et al., 2014). Once in contact with the LVs, dendritic cells 
transmigrate into lymphatic capillaries with the help of cell-cell interactions between integrins such as 
Mac-1 and LFA-1, and LEC-expressed adhesion molecules such as ICAM-1 and VCAM-1 which are 
upregulated by pro-inflammatory cytokines (Johnson et al., 2006). Inside initial lymphatics, DCs first 
actively crawl along the luminal vessel wall, before they reach collecting lymphatics from where they 
are passively transported to the draining lymph node by flow (Tal et al., 2011). When they arrive in the 
lymph node, DCs are further guided to the T cells zones via CCL21 gradients established by lymph 
node stromal cells including LECs. This is where DCs encounter naïve T cells, which are similarly 
guided to these areas by CCL21 gradients. In contrast to DCs, naïve CCR7+ T cells arrive from the 
blood circulation via extravasation along CCL21 chemokine gradients present on high endothelial 
venules (HEVs), specialized blood endothelial cells that are present in SLOs (Andrian and Mempel, 
2003), tertiary lymphoid organs (Ruddle, 2014) and tumors (Martinet et al., 2012). Interestingly, HEVs 
can translocate perivascular chemokine to their luminal surface, suggesting that extravasation can be 
influenced by chemokine producing stromal cells adjacent to HEVs (Baekkevold et al., 2001; Carlsen 
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et al., 2005). In the absence of their cognate antigen, typically lymphocytes are thought to spend 24h 
in a single lymph node, although the transit time may increase to 3-4 days if the cognate antigen is 
present (Bousso, 2008). Naïve and activated lymphocytes then both upregulate sphingosine-1-
phosphate receptors (S1PRs), which allows them to egress into efferent lymphatics by sensing a 
gradient of sphingosine-1-phosphate (S1P) - itself a LEC-secreted sphingolipid with chemokine-like 
function (Cyster and Schwab, 2012). In contrast, dendritic cells have a short half-life (1.5-3 days) once 
activated and undergo apoptosis within the lymph node (Kushwah and Hu, 2010). Taken together, 
chemokine secretion by LECs is crucial for immune cell trafficking from peripheral tissue or the blood 
circulation to SLOs, within SLOs themselves, as well as for the egress from SLOs back into blood 
circulation. However, to our knowledge, it has not been explored whether initial lymphatics might 
regulate extravasation of immune cells from the circulation into peripheral tissues by means of 
chemokine secretion. Uncovering LEC mediated mechanisms that govern immune cell extravasation 
in peripheral tissues could enable the development of novel therapeutic strategies to regulate immune 
responses. 
The purpose of this study was to determine whether engineered tissue lymphangiogenesis 
induces chemokine mediated immune cell recruitment into peripheral tissues and if so, whether this 
could be therapeutically exploited. To this end, we designed an injectable hydrogel system for the 
sustained and highly localized delivery of the lymphatic growth factor VEGFC into the mouse dermis. 
We used either the natural polymer fibrinogen, or functionalized poly(ethylene glycol) (PEG), a 
synthetic polymer with very low protein adsorption and complement activation levels in vivo, to form 
the hydrogel matrices. To increase retention of VEGFC and other proteins of interest within the 
hydrogels, they were engineered as a fusion protein with a transglutaminase (TG) targeting tag, which 
enables it to be covalently cross-linked into the fibrinogen or functionalized PEG matrix. Because we 
observed that fibrinogen based matrices induce inflammation in the draining lymph node, we did not 
further pursue this system. However, following intradermal injection into healthy wild-type mice, local 
delivery of VEGFC-TG from PEG gels led to increased local lymphangiogenesis, while delivery of 
soluble VEGFC did so in the draining lymph nodes. At the gel site, this was accompanied by 
increased local expression of CCL21, similar to observations in lymphangiogenic tumors, and 
associated with increased recruitment of CD4+ and CD8+ T cells. In the draining lymph node, even 
though no notable changes in cytokine expression could be detected following lymphangiogenesis, 
we found increased numbers of CCR7+ immune cells including CD4+ T cells, CD8+ T cells, and 
CD11c+ dendritic cells. To further examine the immunological relevance of these observations on 
antigen-specific T cell populations, mice were conditioned with hydrogels delivering both VEGFC-TG 
and the model antigen ovalbumin (OVA-TG). When mice were challenged with a local injection of 
OVA into the lymphangiogenic skin site, increased number of IFNγ producing cells were detected as 
compared to the control groups. Our studies suggest a role for lymphangiogenesis in the 
extravasation of immune cells into peripheral tissues such as the skin, and that engineered 
lymphangiogenesis could potentially be exploited to modulate therapeutic immune responses. 
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4.3 Materials and methods 
4.3.1 Hydrogel-binding protein variants 
Cloning of VEGFC-TG: a matrix metalloproteinase (MMP)-cleavage site followed by the fibrin-binding 
domain (TG: NQEQVSPL) was added at the C-terminus of the mouse VEGFC sequence (accession 
NM_009506.2, mature peptide, amino acid 108-223) by sequential polymerase chain reactions. 
Similarly, a poly-His tag followed by a thrombin-cleavage site was added at the N-terminus of VEGFC 
(VEGFC-TG final design: “polyHis-thrombin-VEGFC-MMP-TG”). The resulting sequence of VEGFC-
TG was then inserted in pSeqTagA plasmid backbone. Cloning of aprotinin-TG: the fibrin-binding 
domain (TG: NQEQVSPL) was added at the C-terminus of the bovine aprotinin sequence (as 
described by Lorentz et al. 2011) by sequential polymerase chain reactions. Similarly, a poly-His tag 
followed by a thrombin-cleavage site was added at the N-terminus of aprotinin (aprotinin-TG final 
design: “polyHis-thrombin-aprotinin-TG”). The resulting sequence of aprotinin-TG was then inserted in 
pSeqTagA plasmid backbone. Cloning of OVA-TG: the fibrin-binding domain (TG: NQEQVSPL) was 
added at the C-terminus of the chicken ovalbumin (OVA) sequence (accession P01012, full length), 
and a poly-His tag followed by a thrombin-cleavage site was added at the N-terminus of OVA, by 
sequential polymerase chain reactions (OVA-TG final design: “polyHis-thrombin-OVA-TG”). The 
resulting sequence of OVA-TG was inserted into pSeqTagA plasmid backbone. Production of 
proteins: VEGFC-TG, aprotinin-TG, and OVA-TG have been produced as follows. The plasmid was 
transfected into HEK-293E using 25kDa polyethyleinimine as a transfection agent and cells and 
cultured in FreeStyle medium (Invitrogen, Carlsbad, USA) supplemented with glutamine (4mM) and 
valproic acid (3.75mM). At 7 days post-transfection, the expressed protein was isolated from the cell 
culture supernatants using Ni2+-affinity chromatography (for the poly-His tag). The poly-His tag was 
then cleaved with a commercial agarose bead-bound thrombin cleavage kit (Sigma-Aldrich, St. Louis, 
USA), and purified using size-exclusion chromatography. The purified proteins were further dialyzed 
against Tris-buffer saline, sterilized through 0.22μm filtration and stored at -80°C. 
4.3.2 Hydrogel synthesis, preparation, and injection 
Fibrin hydrogels: human fibrinogen (10mg/ml, F3879; Sigma), aprotinin-TG, fluorescently labeled TG-
factors, as well as human thrombin (2U/ml, T4394; Sigma), human factor XIII (2U/ml, 00671; CSL 
Behring), and CaCl2 (2mM) were mixed and immediately injected intradermally using 0.3ml insulin 
syringes. PEG hydrogels: 8-arm, 40kDa poly(ethylene glycol) (PEG)-maleimide was reacted with 9.6x 
molar excess of either Ac-FKGGVPMSMRGGERCG-Amide or NQEQVSPLERCG-Amide peptides in 
dimethylformamide, in the presence of 10x molar excess of triethylamine. The reaction was allowed to 
proceed for at least 4h at 37°C with agitation, after which the completed polymer-peptide conjugates 
(8APEG-FKGG & 8APEG-NQEQVSPL) were isolated using a size-exclusion chromatography and 
characterized by NMR and BCA assay to confirm peptide conjugation. 5%wt hydrogels were prepared 
by mixing 1mg of 8APEG-FKGG & 1mg of 8APEG-NQEQVSPL with desired bioactive TG-proteins, 
Factor XIII (0.2U), and thrombin (0.075U), adjusted to a final volume of 40μL in TBS with 50mM 
CaCl2. This mixture was pipetted to mix and injected into the interscapular region of isoflurane-
anesthesized, healthy wild-type mice intradermally, where it polymerizes within 10-15 min of injection.  
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4.3.3 VEGFR3 phosphorylation assay 
Bioactivity of VEGFC-TG was determined using a VEGFR3 phosphorylation assay. Human LECs 
(about 70-80% confluent) were starved for 16h in 10cm petri dishes containing starving media (EBM + 
2% FBS + 1% penicillin/streptomycin + 50μM DBcAMP + 1μg/ml hydrocortisone acetate + 1% L-Glut). 
VEGFC-TG was added to the starving media for 10 minutes (100ng/ml and 500ng/ml respectively), 
before the media was replaced with 10ml ice cold PBS. Cells were washed twice in ice cold PBS and 
then lysed by the addition of 500μl RIPA protein extraction buffer (R0278; Sigma). Lysates were 
collected in 1.5ml microcentrifuge tubes, spun down at 12’000g for 10’ to get rid of cell debris, and the 
supernatant transferred into new 1.5ml microcentrifuge tubes. BCA assay was performed to measure 
total protein concentration, and all samples normalized to the same concentration (0.2-1mg/ml 
depending on how much total protein was available) in a total volume of 1ml RIPA buffer. Next, 
immunoprecipitation of VEGFR3 was performed. 40μl Protein A/G plus agarose (sc-2003, Santa Cruz 
Biotechnology) was added and incubated for 4h with rotation at 4°C to remove unspecific binders. 
Beads were spun down at 2500g for 3’, and the supernatant transferred into new 1.5ml 
microcentrifuge tubes. 2μl of anti-VEGFR3 antibody (sc-321; Santa Cruz Biotechnology) was added 
and incubated for 1h with rotation at 4°C. Next, 20μl of Protein A agarose was added and incubated 
O/N with rotation at 4°C. Beads were spun down at 2500g for 3’, the supernatant discarded, and the 
beads washed 3x with 500μl RIPA buffer. After the last wash, all liquid was removed using a 0.3ml 
insulin syringe, before 20μl Laemmli sample buffer (161-0764; BioRad) was added. Samples were 
then loaded on a 7.5% acrylamide gel, and standard SDS-page followed by Western Blot analysis 
performed. Antibodies used or Western Blot: anti-pTyr (sc-7020, Santa Cruz Biotechnology), and anti-
VEGFR3 (sc-321; Santa Cruz Biotechnology).  
4.3.4 Plasmin inhibition assay  
Bioactivity of aprotinin-TG was determined using a plasmin inhibition assay. 2.61μM of aprotinin-TG 
or WT aprotinin were incubated with 0.1U/mL human plasmin (10602361001; Roche) in the presence 
of 100μm fluorogenic plasmin substrate, N-Succinyl-Ala-Phe-Lys-7-amido-4-methylcoumarin acetate 
salt (s0763; Sigma-Aldrich) in phosphate-buffered saline (PBS) at pH 8.5. Fluorescence emission was 
measured at 438nm with a plate reader (Safire II, Tecan). 
4.3.5 OT-I proliferation assay 
Bioactivity of OVA-TG was determined using an OT-I proliferation assay. Briefly, bone marrow-
derived DCs (BMDCs) were harvested from C57BL/6 mice, differentiated in GM-CSF as described 
(Lutz et al., 1999). 7 days later, 1x104 DCs were put in a coculture with naïve, CFSE-labeled CD8+ T 
cells from OT-I mice (1:10 ratio) in 96-well plates for 72 hours in 200μl coculture media (IMDM with 
10% FBS and 1% penicillin/streptomycin). Cells were then processed and analyzed by flow 
cytometry. Cellular proliferation was monitored by CFSE dilution. 
4.3.6 In vitro VEGFC-TG release assay 
To assess the in vitro cross-linking efficiency of TG-factor into fibrin hydrogels, matrices with a total 
volume of 200μl containing VEGFC-TG (1μg/ml or 0.2μg/ml), as well as thrombin (2U/ml), factor XIII 
 69 
(2U/ml), and CaCl2 (2mM) were mixed in ultralow protein-binding polystyrene 96 well plates (Costar 
#3474) and polymerized at 37°C for 45 minutes. Ultralow protein-binding polystyrene 24 well plates 
(Costar #3473) were blocked at 37°C with PBS + 2% BSA in the meantime. The preformed gels were 
then transferred into the blocked 24 well plates, where they were rinsed with 500μl release buffer 
(PBS + 0.1% BSA). The release buffer was collected and replaced every 12 hours. The concentration 
of VEGFC-TG in the release buffer was quantified using ELISA. 
4.3.7 Mice  
Gender-matched wild-type mice (Harlan), all on the C57BL/6 or BALB/c background, were used 
between 8-12 weeks of age. All experiments were performed with approval from the Veterinary 
Authority of the Canton de Vaud, Switzerland. 
4.3.8 Intravital imaging and analysis 
Mice were anesthetized using isoflurane and imaged with a fluorescent-mediated tomography (VisEn 
FMT1500, PerkinElmer) or Xenogen IVIS Spectrum (Caliper LifeSciences / Perkin-Elmer, Waltham, 
MA, United States) in vivo imaging system. For the VisEn system, AlexaFluor650-tagged fibrinogen 
was detected using the appropriate excitation and emission channel. 3D ROIs were set and the voxel 
density quantified using the manufacturer’s software (Perkin-Elmber, TrueQuant 3.1). For the IVIS 
system, AlexaFluor750-tagged VEGFC-TG was detected via excitation and emission filters set at 
745/800nm and exposure time at 0.5 seconds. To quantify protein release from the hydrogels, ROIs 
were defined for each gel injection site using images obtained at the time of gel implantation. For any 
given gel injection site, the same ROIs were kept for the duration of the experiment. Background-
corrected total photon counts within ROIs were quantified using Perkin-Elmer Living Image software 
(version 4.0) and normalized against total photon counts within the ROI at the time of injection in 
order to obtain release profiles of the fluorescently-labeled proteins over time. 
4.3.9 Lymph node and gel site cell isolation 
Stromal cells (CD45-) and CD45+ immune cells were recovered from gel sites (skin), and draining and 
non-draining lymph nodes (LNs) according to the previously published “Broggi Style” protocol (Broggi 
et al., 2014). Lymph nodes were placed in a well of a 24 well plate containing 500μl digestion medium 
consisting of DMEM (41965-062; GIBCO, no pyruvate) + 1% Pen/Strep + 1.2mM CaCl2 + 2% FBS. To 
facilitate the digestion process, the lymph node capsules were then gently disrupted with syringe 
needles (26G) and transferred into 5ml round-bottom tubes (Falcon-BD Bioscience) containing 750μl 
digestion buffer I, which consisted of digestion medium supplemented with 1mg/ml Collagenase IV 
(CLS4 LS004188; Worthington) and 40μg/ml DNAse I (11284932001; Roche). Digestion was done for 
30’ at 37°C in a beaker with water on a heating plate with magnetic stirring (~1turn/sec). The 
supernatant was then carefully collected into a 5ml round-bottom filter tube (Falcon-BD Bioscience), 
and 750μl digestion buffer II, which consisted of digestion medium supplemented with 3.3mg/ml 
Collagenase D (1108886600; Roche) and 40μg/ml DNAse I, was added to the 5ml tube with the 
remaining tissue pieces. Digestion was then continued for 5 minutes, before the suspension was 
disrupted by repeated pipetting with an electronic pipette. Digestion was then continued for another 
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10 minutes, before further disruption of the remaining cell aggregates by repeated pipetting. To 
inactivate the enzymes, 7.5μl EDTA (500mM) was added to each tube to reach a final concentration 
of 5mM (pH 7.2), and this mixture was pipetted thoroughly to mix, strained, and collected into a 5ml 
round-bottom filter tube (Falcon-BD Bioscience), and spun down at 2000g for 5min. Cells were then 
resuspended in an appropriate volume of FACS buffer (PBS + 2% FBS) to proceed for FACS 
staining. For the gel sites (skin), aforementioned protocol was slightly adapted. Skin pieces were first 
placed in a 10cm petri dish containing 2ml of basal IMDM, and minced with scalpel blades. Skin 
pieces were then transferred into a 5ml round-bottom tube containing 750μl digestion buffer I (+0.05U 
plasmin per gel). Digestion was done for 30’ at 37°C in a beaker with water on a heating plate with 
magnetic stirring (~1turn/sec). The supernatant was then carefully collected through a 70μm nylon 
filter into a 50ml conical tube and 750μl digestion buffer II (+0.05U plasmin per gel) was added to the 
5ml tube with the remaining tissue pieces. Three cycles of 15’ digestion, followed by 100 times 
pipetting were then done. After the last cycle, 7.5μl EDTA (500mM) was added to each tube to reach 
a final concentration of 5mM (pH 7.2), before pipetting again 100 times. The entire cell suspension 
was then collected through the 70μm into the 50ml conical tube. Remaining tissue pieces were 
smashed through the filter using the plunger of a 3ml syringe, and the filter subsequently washed with 
10ml HBSS. The cell suspension was then spun down at 2000g for 5’ and resuspended in an 
appropriate amount of FACS buffer to proceed for FACS staining. 
4.3.10 Flow cytometry 
Antibody stainings for surface targets were done in FACS buffer (PBS + 2% FCS), and intracellular 
stainings were done after fixation and permeabilization according to the manufacturers protocol. The 
following anti-mouse antibodies were used for flow cytometry: CD45-APC (17-0451-82; eBioscience) 
or biotinylated CD45 (13-0451-85; eBioscience), CD4-PacBlue (100531; Biolegend) or CD4-PE-Cy7 
(100528; Biolegend), CD8α-PacOrange (MCD0830; Invitrogen), F4/80-PerCPCy5.5 (123128; 
Biolegend), CD25-FITC (101908; Biolegend), FoxP3-PerCPCy5.5 (45-5773-82; eBioscience), CD62L-
PE (12-0621-82; eBioscience), CD44-APCeF780 (47-0441-82; eBioscience), CCR7-PE-Cy7 (25-
1971-82; eBioscience) or CCR7-PerCPCy5.5 (45-1971-82; eBioscience), biotinylated CD11b (13-
0112-82; eBioscience), MHCII-AF647 (107619; BioLegend), PD1-bio (13-9981-82, eBioscience), 
CD31-eFluor450 (48-0311-82; eBioscience), gp38-AF488 (127406; BioLegend). Cell viability was 
determined by staining with Fixable live/dead blue, aqua (L34957; Invitrogen) or red (L23102; 
Invitrogen) dyes according to manufacturer’s specifications. Flow cytometry acquisition was 
performed on a Cyan (Beckman Coulter) LSR2 flow cytometer (BD Bioscience) and data analysis was 
performed with FlowJo (Version 9.7.7.).  
4.3.11 ELISA and Luminex 
Protein lysates were generated from gel sites (skin) and lymph node by homogenizing the tissues in 
400μl (lymph nodes) or 700μl (skin) T-Per protein extraction buffer (78510; ThermoFisher) containing 
cOmplete protease inhibitor cocktail (1 tablet per 10ml, 11836145001; Roche). Tissue lysates were 
spun down at 2000g for 2min, and transferred into new 1.5ml microcentrifuge tubes. Tissue lysates 
were then spun at 12’000g for 10min to get rid of cell debris, and the supernatant was transferred into 
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new 1.5ml eppendorf tubes which were stored at -80°C. ELISAs were performed according to 
standard protocols. Custom chemokine/cytokine multiplexed Luminex assays were purchased from 
R&D Systems and performed according to manufacturer’s specifications. 
4.3.12 ELISPOT assay 
IFNγ Elispot 96 well filter plates (Millipore) were pre-wetted, coated, and blocked according to the 
manufacturer’s protocol. 1x106 lymph node cells or splenocytes, or 1x105 skin cells were then plated 
per well. Cells were stimulated with 1mg/ml full-length OVA grade V (A5503; Sigma) in 200μl co-
culture media (IMDM + 10% FBS + 1X PS + 1X Non-essential amino acids) per well for 36h at 37°C. 
Plates were then coated with secondary HRP-conjugated antibody, followed by the addition of AEC 
substrate. The reaction was stopped by washing the plate in MIlliQ water and the plates dried 
overnight at 4°C. Membranes were then analyzed using an automated ELISpot reading system. 
  
 
 
 72 
4.4 Results 
4.4.1 Purification and characterization of recombinant VEGFC-TG, aprotinin-TG, and OVA-
TG. 
In chapter one of this thesis, we found that tumor-derived VEGFC can influence local immune 
infiltration by inducing the secretion of CCL21 by LECs. To better understand the role of VEGFC in 
shaping immune responses in peripheral tissues, we wanted to use an in vivo platform in which 
VEGFC is released from a more controlled environment as compared to the tumor microenvironment. 
A platform that allows controlled release of bioactive factors from hydrogels has been previously 
described (Schense and Hubbell, 1999; Zisch et al., 2001). Controlled release is achieved by the 
addition of a transglutaminase (TG) substrate tag (NQEQVSPL) to the proteins of interest, which 
allows their enzymatic incorporation into fibrin scaffolds by the action of factor XIIIa. The in vivo 
release rate of TG-proteins can be manipulated by the addition of matrix metalloproteinase (MMP) 
cleavage sites into the protein sequence (Patterson and Hubbell, 2010). At the same time, the 
persistence of fibrin gels can be increased by incorporating aprotinin, an inhibitor of the fibrin 
degrading enzyme plasmin (Lorentz et al., 2011). To assess the effect of peripheral 
lymphangiogenesis on immune responses, we first engineered VEGFC-TG, aprotinin-TG, and OVA-
TG fusion proteins by cloning them into pSeqTagA vectors, and producing the recombinant TG-
proteins in mammalian HEK293E cells (Figure 4.1A). TG-proteins were isolated from the cell culture 
supernatants using Ni2+-affinity chromatography, followed by cleavage of the poly-His tag and size-
exclusion chromatography.  The purity of TG-protein batches was assessed by SDS-PAGE with 
Coommassie staining (Figure 4.1B). VEGFC-TG batches contained monomers and dimers, which 
were pooled as both forms can potentially be bioactive (Joukov et al., 1997). Dose-dependent 
phosphorylation of the VEGFC receptor VEGFR3 in LECs indicated that the recombinant VEGFC-TG 
was bioactive (Figure 4.1C). Aprotinin-TG showed comparable activity to commercial wildtype 
aprotinin as assessed by the efficiency of plasmin inhibition (Figure 4.1D). OVA-TG was able to 
induce T cell proliferation, however, to a lesser extent than wildtype OVA (Figure 4.1E), indicating that 
the processing and loading on MHCI might be less efficient. To determine how well VEGFC-TG would 
be cross-linked into a fibrin scaffold, an in vitro release assay was performed, which showed that most 
of the loaded VEGFC-TG was still retained after 36h (Figure 4.1F). Even though the initial burst 
release of VEGFC-TG was increased at the high concentrations (1μg/ml), a plateau of about 4% was 
reached after 36h. Because collagenase D or plasmin, both used to digest fibrin scaffolds, also 
cleaved VEGFC-TG (Figure 4.1F), we were not able to determine the amount of VEGFC-TG 
remaining within fibrin gels. These data demonstrate that bioactive VEGFC-TG, aprotinin-TG, and 
OVA-TG can be engineered and purified from a mammalian expression system, and that VEGFC-TG 
is largely retained in fibrin hydrogels in vitro. 
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Figure 4.1 Purification and characterization of recombinant TG-proteins. (A) Schematic
representation of recombinant VEGFC-TG, aprotinin-TG, and OVA-TG protein domains. (B)
Coomassie-stained SDS-PAGE gels of the purified TG-proteins. (C) Bioactivity of VEGFC-TG was
assessed by measuring its ability to induce VEGFR3 phosphorylation in human LECs. LECs were
starved for 16h in media containing 2% FBS, before VEGFC-TG was added to the media for 10
minutes (100ng/ml and 500ng/ml respectively). VEGFR3 was then immunoprecipitated from the cell
lysate, and a western blot for VEGFR3 and phosphorylated tyrosine (pTyr) performed. (D) Bioactivity
of aprotinin-TG was assessed by measuring its ability to inhibit the cleavage of the model plasmin 
substrate N-succinyl-Ala-Phe-Lys-7-amido-4-methylcoumarin in the presence of 0.1 U/mL plasmin, 
and either 2.61μM wiltdtype aprotinin or aprotinin-TG. (E) Bioactivity of OVA-TG. Shown are
percentages of proliferation of CFSE-labeled OT-I CD8+ T cells after 3 days of coculture with DCs
derived from wildtype mice in the presence of OVA or OVA-TG. Bar graphs show mean ± SEM
(n=3,***p< 0.001 using one-way ANOVA with Tukey’s post-test). (F) To assess the in vitro cross-
linking efficiency of VEGFC-TG into fibrin hydrogels, matrices with a total volume of 200μl containing
10mg/ml fibrinogen were polymerized in 96 well plates at 37°C for 45 minutes. Preformed gels were
then transferred into 24 well plates and rinsed with 500μl release buffer (PBS + 0.1% BSA) every 12h. 
VEGFC concentrations were quantified by ELISA. (G) To determine whether VEGFC-TG was
digested by enzymes used to digest fibrin hydrogels, VEGFC-TG (1μg/ml) was incubated with
Collagenase D (0.2 mg/ml) or plasmin (0.02 U/ml) in a total volume of 70μl buffer (20mm HEPES +
150mM NaCl, pH 7.5) at 37°C for 3h. VEGFC concentration in the supernatant was then determined
using ELISA. 
 
 
 74 
 
 
Figure 4.2 Fibrin hydrogels containing aprotinin-TG can be injected intradermally to
polymerize in situ and persist over extended periods of time in vivo. (A) Schematic of controlled
release of TG-proteins from fibrin hydrogels in vivo. (B-D) Two hydrogels with a total volume of 50μl
each containing unlabeled fibrinogen (10mg/ml), fibrinogen-AF-680 (0.1mg/ml), and aprotinin-TG
(20μM) were intradermally injected above the shoulders. (B) Representative images of fibrin hydrogel
spheres after intradermal injection in the front shoulder region. (C) Representative 3D reconstruction 
of fibrin hydrogels containing fluorescently labeled fibrinogen degrading over time. Images were taken
every day using fluorescence-mediated tomography (FMT). (D) Quantification of gel size over time as 
assessed by FMT. Data shown as mean ± SEM (n=4). (E) Fluorescent images of skin biopsies 15
days after hydrogel injection (10X, scale bar = 2mm). (F) H&E section of skin containing a fibrin 
hydrogel seven days after injection. 
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4.4.2 Fibrin hydrogels containing aprotinin-TG can be injected intradermally to polymerize in 
situ and persist over extended periods of time in vivo. 
Fibrin hydrogels have previously been used for the controlled release of bioactive factors, for example 
for the in vivo delivery of anti-tumor vaccines (Julier et al., 2015). However, in order to avoid 
inflammation caused by surgery, we wanted to establish a platform that allowed the injection and in 
situ polymerization of TG-factor loaded hydrogels (Figure 4.2A). To do so, fibrinogen was prepared 
separately at room temperature, while a mix containing TG-factors, Factor XIII, CaCl2 and thrombin 
was kept on ice until shortly before the injection. Once mixed, the gels were immediately injected 
intradermally where they polymerized within 10-20 seconds and formed solid spheres (Figure 4.2B). 
To assess the persistence of fibrin hydrogels in vivo, 1% of Alexa Fluor 647 (AF647) labeled 
fibrinogen was added to the hydrogels containing 20μM aprotinin-TG, and the fluorescence measured 
daily using fluorescence-mediated tomography (Figure 4.2C). Even though the hydrogel size 
decreased about 4-fold within one week (Figure 4.2D), skin biopsies taken 15 days after hydrogel 
injection still possessed detectable fluorescent signal, although the size had shrunk to approximatly 1-
1.5mm in diameter (Figure 4.2E), indicating that hydrogel remnants can be stable in the tissue over 
extended periods of time. H&E stained cryosections of tissue biopsies retrieved 7 days after injection 
confirmed that hydrogels were localized just below the epidermal layer (Figure 4.F). These results 
show that fibrin matrices containing aprotinin-TG can be injected intradermally to polymerize in situ, 
and that they persist more than a week in vivo. 
4.4.3 Empty fibrin hydrogels induce inflammation in the draining lymph node. 
Because we wanted to assess the effects of engineered lymphangiogenesis on local immune 
responses, we first had to determine whether fibrin hydrogels themselves might contribute to 
inflammation. To evaluate whether injection of fibrin hydrogels would change the local immune 
microenvironment, mice were injected intradermally with either empty or VEGFC-TG containing 
hydrogels. Mice that received intradermal injections of CpG or LPS adjuvant served as positive 
control groups for agents that induce inflammation in the draining lymph nodes. All groups were 
euthanized five days later, and the skin draining lymph nodes (brachial, axillary, inguinal) collected for 
flow cytometry analysis. We found that all treatment groups had increased numbers of CD45+ immune 
cells in their draining lymph nodes as compared to the naïve control group (Figure 4.3A). Similar to 
the CpG treated control group, both fibrin hydrogel groups showed increased fractions of B cells, and 
decreased fractions of CD4+ and CD8+ T cells, independently of the presence of VEGFC-TG (Figure 
4.3B). In terms of phenotype, there was an increase in the fraction of naïve CD8+ T cells in both fibrin 
hydrogels groups (Figure 4.3C), while VEGFC-TG containing fibrin hydrogels also increased the 
fraction of effector CD4+ T cells (Figure 4.3D). PD1 expression, a sign of T cell activation (Parry et al., 
2005), was upregulated on CD4+ and to a lesser extent on CD8+ T cells (Figure 4.3E). Finally, we 
assessed the number and maturation state of CD11c+ dendritic cells. Even though the number was 
constant across all groups, empty fibrin hydrogels induced upregulation of MHCII (Figure 4.3F), 
indicating enhanced maturation of DCs (Dalod et al., 2014). Taken together, these data indicate that 
empty fibrin hydrogels themselves induce changes in the draining lymph node similar to CpG-induced 
inflammation.  
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Figure 4.3 Empty fibrin hydrogels induce inflammation in the draining lymph node. (A-F) Two
hydrogels with a total volume of 50μl each containing fibrinogen (10mg/ml), aprotinin-TG (20μM), and
VEGFC-TG (5μg/ml) were intradermally injected in the anterior and posterior back skin of mice.
Control groups received CpG (60μg total) or LPS (100ng total) intradermally injected into all four
footpads. Five days later, the draining lymph nodes (brachial, axillary, inguinal) were collected, and 
single cell suspensions analyzed by flow cytometry. Quantification of (A) overall CD45+ immune cells
(gated on live cells), (B) B cells (B220+CD3-CD45+), CD4+ (CD4+CD3+CD45+), and CD8+
(CD8+CD3+CD45+) T cells. (C-D) Phenotype of CD4+ and CD8+ T cells with (C) showing naïve T cells
(CD62L+CD44-) and (D) showing effector T cells (CD62L+CD44+). (E) Status of programmed cell
death (PD1) expression on CD4+ and CD8+ T cells. (F) Quantification and MHCII+ status of CD11c+
dendritic cells. Data shown as box (showing median and 25th to 75th percentile) and whiskers
(showing min and max) (n=4, *p<0.05, **p<0.01, ***p<0.001 with Student’s t-test as compared to the
naïve group except indicated differently with a bar). 
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Figure 4.4 PEG gels induce inflammation at the injection site but not in the dLNs. (A)
Functionalized PEG polymers and TG-proteins are mixed and crosslinked in the presence of thrombin
and the clotting Factor XIII to create hydrogels. Inset photo showcases a hydrogel polymerized in vitro
(red arrowhead). In the presence of MMPs, the hydrogel matrix is degraded, releasing the free
protein.  (B-E) Mice were injected intradermally in the anterior back skin with 40μl hydrogels
containing sVEGFC (2μg)or VEGFC-TG (2μg). Mice injected with buffer only (naïve) or empty
hydrogels (empty) are shown as negative control. Mice were euthanized 9 or 22 days later, and the
gel site and draining lymph nodes (brachial) excised. Single cell suspensions of these tissues were
used for flow cytometry analysis. (B) Quantification of overall CD45+ immune cells in the draining 
lymph node on day 9 and 22. Data shown as box (showing median and 25th to 75th percentile) and
whiskers (showing min and max) (n=5-8, *p<0.05 with Student’s t-test). (C) Distribution of immune cell
subsets in the draining lymph node on day 9 and 22. (D) Overall immune cells at the gel site on day 
22 and (E) distribution of immune cells subsets at the gel site on day 9 and 22. B cells: B220+CD3-
CD45+, T cells: B220-CD3+CD45+, DCs: CD11c+B220-CD3+CD45+, myeloid cells: CD11b+B220-
CD3+CD45+, stromal cells: CD45-. 
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4.4.4 PEG gels induce inflammation at the injection site but not in the draining lymph nodes. 
Because we found that fibrin hydrogels induce baseline inflammation in the local microenvironment, 
we predicted that subtle changes to local immune cell homing or education induced by VEGFC-TG 
could be masked by the effects of the fibrin hydrogel system alone. We thus switched from using the 
natural polymer fibrin to the inert synthetic polymer polyethylene glycol (PEG) as the scaffold of our 
hydrogels. Fibrin-mimic PEG hydrogels have previously been developed, enabling the incorporation 
of TG-fusion proteins via Factor XIIIa (Ehrbar et al., 2007). Briefly, functionalized PEG polymers and 
TG-proteins are mixed in the presence of thrombin and the clotting Factor XIII and immediately 
 
Figure 4.5 The release rate of VEGFC from PEG hydrogels dictates the site of 
lymphangiogenesis. (A-B) Mice were injected intradermally in the anterior back skin with 40μl
hydrogels containing AF750-labeled VEGFC, either soluble (sVEGFC, 2μg) or cross-linkable
(VEGFC-TG, 2μg) format. Mice injected with buffer only (naïve) or empty hydrogels (empty) are
shown as negative control. (A) Intravital fluorescence imaging of the release of AF750-labeled
VEGFC from hydrogels over 20 days. (B) Quantification of sVEGFC and VEGFC-TG release profiles
over the study period. Data shown as mean ± SD (n=3). (C-E) Characterization of lymphangiogenesis 
at the gel site and at the draining lymph nodes 22 days after hydrogel injection. (C) Representative
image of a gel site from a VEGFC-TG releasing PEG hydrogel 22 days after injection. (D-E)
Quantification of LECs by flow cytometry (CD45-gp38+CD31+) at the gel site (D) and in the draining
brachial LNs (E). (Data points and error bars represent mean ± SD of n = 3-4 measurements. *p <
0.05 by Student’s t-test vs. all other groups; **p < 0.05 versus all other treatment groups by one-way
ANOVA with Tukey’s post-test. 
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injected intradermally where they polymerize to hydrogels within 10-15 minutes. TG-proteins are 
slowly released upon MMP mediated cleavage (Figure 4.4A). To assess whether PEG gels induce 
local inflammation that might obscure VEGFC induced changes, mice were injected intradermally with 
either empty or VEGFC containing hydrogels. As opposed to fibrin gels, empty PEG gels did not 
induce inflammation in the draining lymph node, neither on day 9 or 22 after injection (Figure 4.4B-C). 
Interestingly, addition of soluble VEGFC (sVEGFC) increased the numbers of CD45+ immune cells 
(Figure 4.4B), while the distribution of immune cell subsets stayed relatively constant (Figure 4.4C). At 
the gel site, the presence PEG hydrogels led to an increase of overall CD45+ immune cells including 
CD3+ T cells, myeloid cells and dendritic cells (Figure 4.4D-E), indicating some degree of local 
inflammation. Interestingly, the addition of VEGFC-TG led to a higher increase of CD45+ immune cell 
density as compared to empty or sVEGFC containing gels, suggesting that prolonged local presence 
of VEGFC can influence immune cell infiltration (Figure 4.4D). Altogether, these data suggest that 
PEG gels do not induce inflammation in the draining lymph node, but only at the injection site. 
Furthermore, it shows that release of soluble VEGFC mainly affects the immune composition in the 
draining lymph node, while release of VEGFC-TG induces changes at the injection site itself. 
4.4.5 The release rate of VEGFC from PEG hydrogels dictates the site of lymphangiogenesis. 
Having shown that PEG gels induce less bystander inflammation than fibrin hydrogels, we next 
assessed the potential of controlled release of VEGFC from PEG gels to induce local 
lymphangiogenesis. Mice were injected with PEG hydrogels containing fluorescently labeled sVEGFC 
or VEGFC-TG and their release measured over 20 days using intravital fluorescent imaging (Figure 
4.5A). Crosslinking of VEGFC to PEG hydrogels led to a slower in vivo release profile (Figure 4.5B). 
While sVEGFC levels dropped to 20% of administered amounts within 2 days post-injection, it took 3 
times longer (6 days) for VEGFC-TG to reach this level. When gel sites were excised at the end of the 
experiment, VEGFC-TG releasing gels could be recognized by having remodeled the local tissue 
(Figure 4.5C). Interestingly, while VEGFC-TG induced an increased number of LECs at the gel site 
(Figure 4.5D), soluble VEGFC did so in the draining lymph node (Figure 4.5E). These results suggest 
that the rate by which VEGFC is released from PEG hydrogels determines whether 
lymphangiogenesis is induced in the local tissue or in the draining lymph nodes. 
4.4.6 VEGFC-TG induced lymphangiogenesis increases local CCL21 expression. 
Lymphatic endothelial cells can express an array of cytokines (Card et al., 2014), including the 
lymphocyte homing chemokine CCL21 (Förster et al., 2008; Gunn et al., 1998; Kriehuber et al., 2001; 
Kuroshima et al., 2004; Shields et al., 2007), which we found to be upregulated in lymphangiogenic 
melanoma tumors (chapter 3). To evaluate whether lymphangiogenesis induces changes in the local 
cytokine milieu in the context of a steady-state environment, we screened protein concentrations of 
protein lysates from gel sites and draining lymph nodes excised on day 7, day 15 and day 22 after 
injection of PEG hydrogels. Protein concentration analysis using a multiplex assay revealed several 
clusters of cytokines that were differentially expressed across the different groups within the gel sites 
(Figure 4.6A-D). On day 7, most clusters differentiated naïve tissues from PEG hydrogel sites 
independent of the presence of VEGFC-TG, indicating a degree of baseline inflammation following  
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Figure 4.6 VEGFC-TG induced lymphangiogenesis increases local CCL21 expression. (A-F)
Mice were injected intradermally in the anterior back skin with 40μl hydrogels containing VEGFC-TG
(2μg). Mice injected with buffer only (naïve) or empty hydrogels (empty) are shown as negative 
control. (A-D) Protein lysates from gel sites retrieved on day 7 (A), 15 (B), and 22 (C) were analyzed
for the concentration of cytokines using Luminex or ELISA (CCL21, CCL19, CXCL3, IL-15) assays.
(A-C) Concentrations were normalized by subtracting the mean protein concentration determined 
across all mice from the protein concentration determined for an individual mouse, and dividing this by 
the SD protein concentration determined across all mice. Unsupervised hierarchical clustering of the 
protein data was performed based on Pearson correlations via GENE-E. (D) The same data from (A-
C) normalized to protein concentrations in naïve skin. (E-F) The tissue concentrations of selected 
immunologic markers assayed in (A-D) are plotted over time with (E) showing the gel site and (F) the
draining lymph nodes. Data shown as mean ± SD (n=4-6, *p<0.05 with Student’s t-test). 
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Figure 4.7 Lymphangiogenesis increases the local infiltration of CD4+ and CD8+ T cells. 
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(A-G) Mice were injected intradermally in the anterior back skin with 40μl hydrogels containing 
sVEGFC (2μg) or VEGFC-TG (2μg). Mice injected with buffer only (naïve) or empty hydrogels (empty) 
are shown as negative control. Mice were euthanized 9 or 22 days later, and the gel site and draining 
lymph nodes (brachial) excised. Single cell suspensions of these tissues were used for flow cytometry 
analysis. The gel site (A-D) and the draining lymph node (E-G) were analyzed. (A) Quantification of 
CD45+ immune cells, (B) CD4+ T cells (CD45+CD3e+CD11c-CD4+CD8-), CD8+ T cells 
(CD45+CD3e+CD11c-CD4-CD8+), and conventional DCs (CD45+CD3e-B220-CD11b+CD11c+) 
normalized to tissue weight at 22 days post injection. (C) Phenotype of infiltrated immune cells based 
on CD44 and CD62L expression. Percent of central memory T cells (Tcm, CD62L+CD44+), effector / 
effector-memory T cells (Teff/em, CD62L-CD44+), and naïve T cells (Tnaive, CD62L+CD44-) of CD4+ T 
cells or CD8+ T cells. (D) Quantification of CD4 and CD8 T cell phenotype as a percentage of total live 
cells. Data shown as box (showing median and 25th to 75th percentile) and whiskers (showing min and 
max) (n=7-8, *p<0.05 with Student’s t-test). (E) Quantification of CD4+ T cells, CD8+ T cells, and 
conventional DCs per brachial LN at 22 days post injection. (F-G) Analysis of CCR7 expression on 
CD4+ T cells, CD8+ T cells, and DCs in regional LNs at 22 days post injection. (F) At the selected 
implant site, the bLN and not the axillary LN (aLN) is typically the major draining lymph node. 
Histograms show CCR7 expression of the different immune cell subsets. (G) Quantification of CCR7 
expression on CD4+ T cells, CD8+ T cells, and conventional DCs at 22 days post injection normalized 
to weight. Bar graphs or dot plots shown as mean ± SD (n=3-10, pooled from up to 3 independent 
experiments. *p<0.05 by Student’s t-test. **p<0.05 by one-way ANOVA with Tukey’s post-test). 
injection (Figure 4.6A). However, on day 15 and day 22, we found clusters specific to the presence of 
VEGFC-TG (Figure 4.6B-C). Similar patterns were observed when the data was normalized to protein 
concentrations in naïve tissue (Figure 4.6D). The most notable difference within the gel sites was 
detected for CCL21, which steadily increased from day 15 (~5.6 fold increase) to day 22 (~6.8 fold 
increase) when gels were draining VEGFC-TG (Figure 4.6E). Others cytokines including CCL3, 
CXCL13, CCL5, and IL-33 showed differences. However, their expression was more variable or even 
decreasing over time, suggesting that their expression is induced due to inflammation in the presence 
of the hydrogel. In the draining lymph node, we did not find a cytokine that consistently changed over 
time except for CCL3 (Figure 4.6F), indicating that VEGFC-TG induced lymphangiogenesis leads to 
local changes in the cytokine environment. These data demonstrate that CCL21 might be one of the 
most differentially expressed cytokines induced by engineered lymphangiogenesis in peripheral 
tissues. 
4.4.7 Lymphangiogenesis increases local infiltration of CD4+ and CD8+ T cells.  
CCL21 is a ligand for CCR7, a CC-chemokine receptor mainly expressed by naïve, regulatory and 
central memory T cells as well as dendritic cells. Classically, CCL21 is expressed in the lymph node 
by stromal cells, high endothelial venules (HEVs) and LECs to guide CCR7+ immune cell subsets into 
the lymph node parenchyma, either from the blood stream (T cells) or from peripheral tissues (DCs) 
(Cyster, 1999; Förster et al., 2008). In addition, previous reports and the first chapter of this thesis 
have established the importance of CCL21 in recruiting immune cells into peripheral tissues, mostly in 
the context of tumors (Peske et al., 2015; Shields et al., 2010) and tertiary lymphoid organs induced 
during chronic inflammation (Ruddle, 2014). Given that engineered lymphangiogenesis induced 
changes to the peripheral tissue cytokine milieu, notably CCL21 expression, we asked the question of 
how this would affect local infiltration of immune cells. We found more CD45+ immune cells (Figure 
4.7A), including CD4+ T cells, CD8+ T cells and CD11c+ dendritic cells (Figure 4.7B) infiltrating the 
tissue sites of VEGFC-TG but not sVEGFC draining PEG gels. Using CD44 and CD62L staining, we 
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determined that the majority of infiltrating CD4+ T cells had an effector phenotype, while CD8+ T cells 
were mostly naïve both on day 9 and 22 after gel injection (Figure 4.7C). Interestingly, the presence 
of VEGFC-TG skewed the infiltrating CD4+ population towards an effector / effector-memory, and the 
CD8+ populations towards a central-memory phenotype (Figure 4.7D). In the draining lymph nodes, 
we found that soluble VEGFC but not VEGFC-TG increased the number of CD4+ and CD8+ T cells, 
but not of dendritic cells (Figure 4.7C). In line with our hypothesis that lymphangiogenesis associated 
immune infiltration might be at least partially CCL21 driven, immune cells in the draining but not in the 
non-draining (axillary) LN had increased CCR7 levels on their surface (Figure 4.7F). In the sVEGFC 
group, CCR7 expression was not only higher in terms of surface density, but also in terms of absolute 
numbers of immune cells expressing this receptor (Figure 4.7G). Intriguingly, there was a large 
fraction of CCR7+ immune cells that could not be further characterized by the available markers. 
Collectively, these data demonstrate that engineered lymphangiogenesis can induce the recruitment 
of T cells and dendritic cells into the local microenvironment, and that this mechanism might partially 
dependent on the CCL21/CCR7 axis. 
4.4.8 Engineered lymphangiogenic sites modulate local immune responses. 
We showed in the third chapter of this thesis that lymphangiogenic tumors have increased immune 
infiltrates as compared to non-lymphangiogenic ones, and that these infiltrates can contribute to anti-
tumor immunity when locally activated. Thus, we hypothesized that immune infiltrates attracted by 
 
Figure 4.8 Engineered lymphangiogenic sites modulate local immune responses. (A-C) Mice
were injected intradermally in the anterior back skin with four 40μl hydrogels containing VEGFC-TG
(2μg) and OVA-TG (10μg). Mice injected with OVA (10μg) or VEGFC (2μg) + OVA (10μg) served as
control. 27 days later, mice were re-challenged with an intradermal injection of OVA (10μg) into the
lymphangiogenic site. Mice were euthanized 5 days later, and the gel site and draining lymph nodes
(brachial), and spleens excised. (A) Experimental schedule. (B-C) ELISPOT assay showing the
number of IFNγ producing cells after antigen-specific restimulation (Figure 8B) or spontaneous
release (Figure 8C). Data show as mean ± SD (n=5, *p<0.05 by one-way ANOVA with Tukey’s post-
test). 
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engineered lymphangiogenesis can be exploited to regulate local immune responses. To assess 
whether local immunity could indeed be modulated by engineered lymphangiogenesis, mice received 
intradermal injections either of soluble OVA or OVA + VEGFC, or PEG hydrogels containing the same 
dose of crosslinked OVA-TG and VEGFC-TG (Figure 4.8A). To establish a local lymphangiogenic 
environment, we then waited 27 days. Next, mice were challenged with OVA by injecting a bolus of 
soluble antigen at the same site where they received the first injection. Interestingly, groups that 
received PEG gels including OVA-TG and VEGFC-TG had increased number of cells secreting IFNγ 
in the gel sites (Figure 4.8B). This was not the case for cells derived from the spleen or draining 
lymph node, suggesting that immunomodulation only happened locally at the engineered 
lymphangiogenic site. Interestingly, a similar but slightly decreased IFNγ release pattern was 
observed when single cell suspensions were restimulation with control media that did not contain 
OVA (Figure 4.8B), indicating that a fraction of IFNγ cells did not rely on antigen-specific restimulation. 
Taken together, these findings suggest that engineered lymphangiogenesis generates an 
environment which offers a point of intervention for the modulation of therapeutic immune responses. 
  
 85 
4.5 Discussion 
Here we show that engineered lymphangiogenesis can be achieved in mouse dermis by controlled 
release of VEGFC from PEG hydrogels. Furthermore, we found that these lymphangiogenic sites 
associated with increased concentrations of the chemokine CCL21, and with increased infiltration of 
CD4+ and CD8+ T cells, as compared to control PEG hydrogels. We thus propose that the 
orchestration of immune cell recruitment is a novel role of LEC-secreted chemokines in peripheral 
tissues. Finally, we observed that delivery of the model antigen ovalbumin into engineered 
lymphangiogenic sites led to increased numbers of IFNγ secreting effector cells in response to 
antigen re-challenge, suggesting opportunities for the regulation of therapeutic immune responses. 
In this study, we aimed at engineering of local tissue lymphangiogenesis to dissect 
mechanisms of LV-mediated peripheral immunoregulation without confounding effects such as tumor-
associated inflammation. Approaches to engineering lymphangiogenesis have so far mainly focused 
on the local delivery of soluble VEGFC, either via simple intradermal injection of recombinant protein 
(Kajiya et al., 2009; Szuba et al., 2002) or local overexpression using gene therapy (Karkkainen et al., 
2001; Saaristo et al., 2002; Tammela et al., 2007; Yoon et al., 2003). In the attempt to treat 
lymphedema, the accumulation of interstitial fluid due to lack of lymphatic drainage, several studies 
have even combined the local delivery of VEGFC with the transplantation of lymph nodes (Hartiala 
and Saaristo, 2010; Lähteenvuo et al., 2011). Even though some of these studies showed induction of 
functional lymphangiogenesis, these approaches have been facing several issues. For example, 
adenovirus-mediated VEGFC overexpression in the ear skin induces not only the formation of 
hyperplastic lymphatic vessels, but also of leaky blood vessel via VEGFR2 signaling (Saaristo et al., 
2002). Furthermore, it was shown that high levels of VEGFC may enhance LEC proliferation and 
cause lymphatic hyperplasia, however, these effects were only transient and did not lead to increased 
functionality of the lymphatic network (Goldman et al., 2005). The observation that sustained but low-
dose release of VEGFA from the extracellular matrix (ECM) induces more physiological blood vessel 
formation as compared to soluble growth factor (Ehrbar et al., 2004; Martino et al., 2014) led to our 
hypothesis that the same approach might be suitable for engineering lymphangiogenesis in peripheral 
tissues in vivo. In fact, our lab has previously established that there is a synergy between the 
controlled release of VEGFC and flow, establishing a morphogenic gradient that fosters lymphatic 
capillary formation in vitro (Helm et al., 2005). Here we show that the sustained release of VEGFC-TG 
from functionalized PEG hydrogels leads to increased density of LECs at the gel site (Figure 4.5). 
This study thus introduces a novel approach by which therapeutic lymphangiogenesis can be induced 
under minimally inflammatory conditions in vivo.  
 Lymphatic endothelial cells express an array of immunomodulatory cytokines that attract T 
cells, B cells, DCs as well as innate immune cells including monocytes, basophils, and neutrophils 
(Card et al., 2014). While it is well established that the secretion of CCL21 from LECs is crucial for the 
chemoattraction and transmigration of 1) tissue-resident DCs into afferent lymphatics during 
inflammation (Johnson and Jackson, 2010), and 2) circulating T cells into secondary lymphoid organs 
during steady-state and inflammation (Förster et al., 2008), it is less clear what the function of other 
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LEC secreted chemokines might be. We hypothesized that chemokines secreted by peripheral tissue 
LECs could potentially be involved in orchestrating extravasation of immune cells. This hypothesis is 
supported by recent observations that endothelial cells can translocate chemokines from the 
abluminal interstitium to their luminal surface, a process called transcytosis (Nibbs and Graham, 
2013). This process allows chemokines to be transported intact across cells, so that immune cell 
extravasation can be influenced by chemokine producing stromal cells adjacent to endothelial cells 
(Baekkevold et al., 2001; Carlsen et al., 2005; Lee et al., 2003). In line with this hypothesis, we found 
that lymphangiogenic sites had increased levels of CCL21 (Figure 4.6), and increased density of 
CD4+ and CD8+ T cells (Figure 7). Interestingly, these findings are very similar to the ones presented 
in the previous chapter, where we showed that lymphangiogenic melanoma tumors had high levels of 
CCL21 and increased infiltration of naïve T cells. Even though the phenotype of infiltrating T cells was 
different in this model based on CD44 and CD62L staining, we previously discussed that 
extravasation of different immune cell subsets depends not only on chemokine gradients, but also on 
the phenotype of the vasculature, which varies between different tissue contexts (Lanitis et al., 2015). 
Taken together, our studies around both engineered and tumor-associated lymphangiogenesis 
establish that peripheral lymphatics might be involved in the chemoattraction of immune cells, 
possibly by supplying the blood endothelium with chemokines such as CCL21. 
Inflammation and lymphangiogenesis in peripheral tissues often goes hand in hand, including 
during acute and chronic infections, autoimmune diseases such as Crohn’s disease and Rheumatoid 
Arthritis, wound healing, cancer, and transplant rejection (Alitalo, 2011). Classically, it is thought that 
inflammation precedes lymphangiogenesis, and that the latter represents a crucial feedback 
mechanism that ensures tissue clearance and resolution of the inflammatory process. For example, 
pro-inflammatory signaling increases the responsiveness of LECs towards VEGFC and VEGFD 
(Flister et al., 2010) while promoting the secretion of these growth factors from infiltrating and tissue-
resident cell types such as macrophages and DCs (Buckley et al., 2015). Furthermore, infiltrating 
lymphocytes secrete the lymphangiogenic factor lymphotoxin-alpha at the site of inflammation 
(Mounzer et al., 2010), further promoting local expansion of LECs. When an inflammation cannot be 
resolved and turns chronic, immune infiltrates and stromal are often restructured into well-defined 
lymphoid-like tissues, so called tertiary lymphoid organs (TLOs) (Aloisi and Pujol-Borrell, 2006). 
Interestingly, lymphatic vessels have been shown to be involved in the orchestration of immune 
infiltrates within TLOs. In the context of human kidney transplants, LVs within TLOs actively recruit 
lymphocytes via secretion of CCL21 in the absence of specialized HEVs, suggesting that the 
infiltrating lymphocytes were recruited locally and not from the circulation (Kerjaschki et al., 2004). In 
addition, together with the blood endothelium and other stroma cells, the lymphatic endothelium can 
influence chemokine gradients that lead to the accumulation of lymphocytes within the tissue during 
chronic inflammation (Burman et al., 2005). Taken together, it becomes clear that there is a close and 
complex interplay between lymphangiogenesis and the presence of immune cells in peripheral 
tissues. Even though we correlated engineered lymphangiogenesis with increased CCL21 levels and 
increased presence of CD4+ and CD8+ T cells, we were not able to demonstrate what the underlying 
mechanisms are. Further studies are needed to understand whether engineered lymphangiogenesis 
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leads to accumulation or recruitment of immune cells, and if it’s the latter, whether it is from the 
adjacent tissue or from the circulation. 
Co-delivery of antigen into lymphangiogenic sites led to enhanced effector immune responses 
upon antigen-restimulation as assessed by IFNγ secretion (Figure 8). This was rather surprising, 
because lymphatic endothelial cells are usually associated with immunological tolerance (Fletcher et 
al., 2011; Lund et al., 2012). Even though LECs can present endogenous and exogenous antigens to 
adaptive immune cells on MHCI and MHCII molecules, they do not express co-stimulatory molecules 
such as CD40, CD80, and CD86, which are needed to induce effective immune responses (Hirosue 
and Dubrot, 2015). However, recent data from our lab suggests that LEC-educated T cells might not 
be terminally tolerized, but rather take on an antigen-primed memory-phenotype, preparing them for 
reactivation. It is thought that this might be analogous to the non-terminally tolerized phenotype 
induced in antigen-specific T cells stromal cell type, liver sinusoidal endothelial cell (LSECs). During 
non-inflammatory conditions, LSECs induce antigen-experienced T cells with a central memory-like 
phenotype in secondary lymphoid organs (Böttcher et al., 2013). These cells are not terminally 
committed to their nonresponsive state, but generate effector T cells when their TCR is re-engaged 
under inflammatory conditions. Notably, we showed in this study that peripheral lymphangiogenesis 
associated immune infiltrates seem to have a effector/effector-memory (for CD4+ T cells) or central 
memory (for CD8+ T cells) phenotype (Figure 4.7D). Whether these cells were recruited with this 
phenotype, or whether they were recruited as naïve cells and then locally educated needs to be 
investigated.  
Our study has limitations. First of all, our goal was to understand immunoregulation 
mechanism of tumor-associated lymphatics by reducing the complexity of the tumor 
microenvironment into a sterile, engineered lymphangiogenic environment. One of the major 
drawbacks is that the amount of VEGFC released and the release profile from the two systems might 
be fundamentally different. In the B16 melanoma model studied in the previous chapter, the tumor 
cells overexpress VEGFC, presumably leading to an exponential increase of released growth factor 
as the tumor grows. When we tested the intratumoral concentration on day 9, it was roughly 0.5-
1.0μg/ml (Chapter 3, Figure 3.2A, re-calculated as the actual concentration within the tumors) at a 
tumor volume of about 100μl, resulting in a total amount of 50-100ng of VEGFC at this point in time 
alone. To counterbalance the different release profiles, we included a high dose of VEGFC-TG (2μg) 
in the hydrogels, which then exponentially decreased over time (Figure 4.5B). 40ng of remaining 
VEGFC-TG was reached at day 6 after implantation. However, thanks to the high initial dose and 
increased retention time of VEGFC-TG in the tissue, one can assume that we were in the same order 
of magnitude in terms of VEGFC that was available for VEGFR3 signaling. Secondly, even though we 
were able to abolish inflammation in the draining lymph node by switching from a fibrinogen to a PEG 
based hydrogel system (Figure 4.3 and 4.4), we still found baseline infiltration of lymphocytes and 
myeloid cells at the PEG gel injection site (Figure 4.4D). We cannot exclude that these infiltrates 
themselves participated in inducing lymphangiogenesis, cytokine secretion, and immune cell 
recruitment (Flister et al., 2010). Engineering approaches that induce completely non-inflammatory 
lymphangiogenesis are needed to further decipher the role of LECs in immunoregulation. A protein 
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domain from the placenta growth factors 2 was recently described to binding ECM with super-affinity 
(Martino et al., 2014). Tagging VEGFC with this domain might allow controlled release in vivo without 
having to crosslink the growth factor into hydrogels. Thirdly, VEGFC itself can act as a chemo 
attractant, mainly on VEGFR3+ macrophages (Kerjaschki, 2005). Interestingly, these cells can 
express VEGFC themselves, leading to a positive feedback loop that further drives 
lymphangiogenesis (Skobe et al., 2010). Absence of VEGFC-mediated chemoattraction of 
hematopoietic cells could potentially be achieved by bone marrow transplantation from tissue-specific 
VEFGR3 knockout into wildtype mice, because complete VEGFR3 knockout mice are embryonic 
lethality (Dumont et al., 1998). Fourthly, even though we correlated CCL21 and immune infiltration in 
engineered lymphangiogenic skin sites, we have not formally proven any mechanistic link as we did 
for lymphangiogenic B16 melanomas in the previous chapter. Further studies, including blocking of 
CCR7 signaling during engineered lymphangiogenesis will be needed to do so. Fifthly, we have not 
shown the functionality of engineered lymphangiogenesis in terms of drainage. Even though we 
observed increased LEC density following controlled release of VEGFC-TG (Figure 4.5D), we have 
not yet characterized whether these cells form functional vessels that connect to the existing 
lymphatic network. We assume that highly sensitive drainage assays need to be developed in order to 
tease out the potentially very small differences in drainage. Finally, there are technical difficulties 
inherent to studying lymphangiogenesis in peripheral tissue such as skin. Only very small numbers of 
cells (in the order of 100’000-500’000 per gel site) can be extracted as compared to several millions 
from lymph nodes and tumors. Thus, one can only do a limited number of meaningful analyses per 
extracted gel site, one of the reasons why we were not able to have the same readouts for all tissues. 
More sophisticated analysis methods such as multi-parametric CyTOF and single-cell omics might be 
needed to do further in depth characterization. 
We conclude that controlled released of VEGFC from an injectable scaffold offers a platform 
for engineering peripheral lymphangiogenesis. Furthermore, we establish that VEGFC-mediated 
induction of LECs under minimally inflammatory conditions leads to an altered cytokine and immune 
cell environment, including high levels of CCL21 and increased infiltrating lymphocytes. We thus add 
more evidence to the previously formulated hypothesis that LECs might have an underappreciated 
role in driving the formation of TLOs in peripheral tissues (Kerjaschki, 2005). Although we have shown 
that such an environment can be exploited for the regulation of therapeutic immune responses in vivo, 
further studies will need to establish whether this concept might have applications in clinical settings. 
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Chapter 5 
Intravital Immunofluorescence Imaging of the Dynamic
Tumor Microenvironment  
 
Manuel Fankhauser, Esra Güç, Witold W Kilarski, Amanda W Lund, and Melody A Swartz 
(adapted from Esra Güç* and Manuel Fankhauser* et al., JoVE, 2014) 
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5.1 Abstract 
Tumors not only consist of tumor cells, but also of a surrounding tumor microenvironment (TME). The 
TME includes the extracellular matrix (ECM) and non-malignant cells such as fibroblasts, blood and 
lymphatic endothelial cells, and immune cells. Besides offering a physical scaffold to maintain tissue 
morphology, the ECM is actively involved in regulating cell and tissue function. It does so by acting via 
biochemical, biomechanical, and biophysical signaling pathways, such as through the release of 
bioactive ECM protein fragments, regulating tissue tension, and providing pathways for cell migration.  
The ECM of the tumor microenvironment undergoes substantial remodeling during tumor initiation 
and progression, characterized by the degradation, deposition and organization of fibrillar and non-
fibrillar scaffolds. However, it is currently unclear how reorganization of ECM within the tumor 
microenvironment influences processes such as tumor cell migration towards blood and lymphatic 
vessels or the outcome of cancer immunotherapy. Dynamic imaging of these processes is currently 
limited to observation within the context of fibrillar collagens that can be detected by second harmonic 
generation using multi-photon microscopy, leaving the majority of matrix components largely invisible. 
Here we describe an adapted intravital microscopy method that allows simultaneous, high resolution 
and dynamic visualization of different components of the tumor microenvironment, including immune 
cells and fibrillar as well as mesh-like matrix proteins. The protocol includes procedures for tumor 
inoculation in the thin dorsal ear skin, immunolabeling of TME components, and intravital imaging of 
the exposed tissue in live mice using fluorescence stereomicroscopy or two-photon microscopy. We 
found that this intravital immunofluorescence protocol is suitable for imaging interactions between 
tumor cells and their microenvironment, without inducing noticeable immunotoxicity or 
photobleaching. For example, this allowed us to observe tumor cell migration along collagen IV 
structures, and T-cell mediated tumor cell killing over a period of 12 hours. Furthermore, we found 
that fibrillar matrix of the TME detected with second harmonic generation is spatially distinct from non-
fibrillar matrix components such as tenascin C. Taken together, this method allows the dynamic 
observation of tumor cells in a more holistic microenvironment, which may provide important insights 
into the mechanisms underlying tumor progression and ultimate success or resistance to cancer 
immunotherapy. 
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5.2 Introduction 
The tumor microenvironment surrounding tumors is defined as the extracellular matrix as well as non-
malignant cells including blood and lymphatic endothelial cells, fibroblasts, mesenchymal stem cells, 
and immune cells (Turley et al., 2015). The tumor microenvironment is actively involved in regulating 
tumor growth, metastatic spread, as well as access and responsiveness to therapeutics (Joyce and 
Pollard, 2009; Nakasone et al., 2012; Polyak et al., 2009). Understanding the interactions between 
tumor cells and the TME is thus crucial for the development of novel prognostic biomarkers and anti 
cancer therapies (Sund and Kalluri, 2009). The ECM undergoes substantial remodeling during tumor 
development, tissue inflammation and wound healing (Bonnans et al., 2014). The remodeling of 
tumor-associated ECM is characterized by the degradation, deposition and organization of fibrillar and 
non-fibrillar matrix proteins (Lu et al., 2012). One consequence of ECM remodeling is stromal 
stiffening, which promotes tumor growth and invasion due to stress-induced signaling mechanisms 
(Pickup et al., 2014) and causes reorganization of blood and lymphatic vessels (Kilarski et al., 2009). 
However, mechanistic insight into how the ECM contributes to tumor cell migration towards either 
lymphatic or blood vessels for metastatic dissemination is lacking (Mueller and Fusenig, 2004). In 
addition, if and how ECM remodeling influences tumor infiltration by lymphocytes such as after cancer 
immunotherapy is largely unknown (Boissonnas et al., 2007). This is partially due to the fact that 
intravital imaging of matrix proteins has classically been limited to large, heavily polymerized fibers or 
fibrillar collagens (I and II, III, V, VI) that can be detected by second harmonic generation using multi-
photon microscopy (Chen et al., 2012; Perentes et al., 2009). Therefore, the majority of matrix 
components including collagen type IV, tenascin C, fibronectin, hyaluronic acid, and perlecan have 
been largely invisible to intravital imaging approaches (Chen et al., 2012).  
Intravital imaging of processes associated with tumor initiation and progression, such as 
inflammation, metastasis, and matrix remodeling has added tremendously to our understanding on 
how these complex biologic phenomena unravel in the context of their native tissue (Ellenbroek and 
van Rheenen, 2014; Munn and Padera, 2014; Pittet and Weissleder, 2011). Intravital imaging is 
usually done using confocal or multi-photon scanning microscopy, because out-of-focus fluorescent 
signals detected by more conventional imaging modalities such as fluorescence stereomicroscopy 
reduce image quality and limit light penetration into the tissue (Halin et al., 2005). Using faster, less 
expensive epifluorescence stereomicroscopy is only possible with nearly two-dimensional tissues 
such as the chicken chorio-allantoic membrane or the mouse ear dermis (Kilarski et al., 2012; Kilarski 
et al., 2013). Most imaging systems take advantage of transgenic mice expressing various fluorescent 
proteins in a cell type-specific fashion (Martínez-Corral et al., 2012; Snippert et al., 2010). However, 
these approaches have several disadvantages. Firstly, even though these proteins offer weak 
phototoxicity, they can induce immune responses against the cells expressing them, thereby 
disturbing the native tissue context (Steinbauer et al., 2003). Secondly, it is difficult and time-
consuming to switch between the observation of specific cell subtypes or phenotypes, as this usually 
requires the engineering of a new genetic model. Thirdly, fluorescent protein expression is generally 
restricted to intracellular compartments, and it is thus usually not feasible to image extracellular 
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structures like basement membrane proteins or chemokine deposits in the tissue (Ohashi et al., 
1999). Instead, indirect labeling with antibodies targeting extracellular antigens offers flexibility for 
virtually any cell-type or matrix specific component (Egeblad et al., 2008; Tal et al., 2011). The major 
disadvantage of this labeling approach is associated with immunotoxicity mediated by antigen-
antibody immune complexes that can trigger complement system dependent cell toxicity and 
phagocytosis of cells and extracellular structures (Roos et al., 2005). Thus, despite substantial 
advances within the field of intravital imaging, simpler and more widely accessible methods are 
needed to image cell behaviors in the context of living tissue physiology. 
Our lab recently published a novel intravital imaging method that allows visualization of 
various extracellular matrix components of the normal skin using a fluorescence stereomicroscope 
(Kilarski et al., 2013). Intravital immunofluorescence (IF) is based on the innovative concept of using 
immunostaining for live cells and tissue matrix elements on surgically exposed mouse dermis with 
causing minimal immuno- and phototoxic side effects. Immunotoxicity of antibody stainings is avoided 
by saturating Fcγ receptors and complement with mouse polyclonal IgGs raised against and 
immunocomplexed with human IgGs, while photoxicity is avoided using a special ascorbate buffer. 
The surgical procedure itself is safe to the dermis vasculature as it relies only on the separation of two 
skin layers in the ear that are independently innervated, autonomously fed by blood and drained by 
separate lymphatic circulations. While established imaging techniques are generally limited to about 
30 minutes to 6 hours of imaging (Giampieri et al., 2009; Heymann et al., 2015; Lämmermann et al., 
2008; Padera et al., 2002; Pinner and Sahai, 2008; Sahai et al., 2005; Wyckoff et al., 2000), intravital 
IF allows continuous imaging of up to 12 hours.  Thus, this experimental setup enables long-term 
observation of a range of important physiological or pathophysiological events within their native 
tissue context, including leukocyte trafficking between blood and lymphatic vessels, wound healing 
processes, and tumor progression.  
Here we describe a modified intravital immunofluorescence method that besides allowing 
long term imaging of the tumor microenvironment using standard fluorescence stereomicroscopy, is 
also suitable for the visualization using two-photon microscopy. The protocol includes procedures for 
tumor inoculation in the thin dorsal ear skin, immunolabeling of different components of the tumor 
microenvironment, and intravital imaging of the exposed tissue in live mice using fluorescence 
stereomicroscopy and two-photon microscopy. We show that this protocol can be used for the long-
term visualization of interactions between tumor cells and their microenvironment, without inducing 
major side effects such as immunotoxicity or photobleaching. We show examples of dynamic 
processes such as tumor cell migration along collagen IV structures, and T-cell mediated tumor cell 
killing over a period of 12 hours. Furthermore, we demonstrate that fibrillar matrix components of the 
TME detected with second harmonic generation can be deposited in spatially distinct niches from the 
non-fibrillar matrix protein tenascin C. In conclusion, this method allows the simultaneous, dynamic 
imaging of tumor cells and several components of the TME that have previously been mostly invisible 
to observation.  
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5.3 Protocol 
All procedures performed on animals were in strict accordance with the Swiss Animal Protection Act, 
the ordinance on animal protection and the ordinance on animal experimentation. We confirm that our 
Institutional Animal Care and Use Committee (IACUC), named Commission de Surveillance de l'Etat 
de Vaud (Permit Number: 2687), approved this study. 
5.3.1 Tumor inoculation of the ear 
1. Culture B16F10-GFP melanoma cells in a 10cm petri dish using Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS). 
2. When the cells are 80-90% confluent, wash them with 1X phosphate buffered saline (PBS) 
and detach them by trypsinization. Spin down cells at 1,500g for 5min at 4°C, resuspend the 
pellet in 1ml Ringer's buffer and transfer it into a 1.5ml microcentrifuge tube. Spin again and 
remove all supernatant except a thin layer of medium that stays just above the pellet. 
Resuspend the cells to end up with a cell slurry. 
3. Anesthetize the mouse with a mixture of ketamine/dorbene (75mg/kg-1mg/kg) and confirm 
that the animal is sufficiently anesthetized by performing a gentle toe pinch. Keep mouse on a 
rectal thermistor controlled heating pad (37°C) during the whole procedure and protect its 
eyes with an appropriate ophthalmic ointment. 
4. Prepare a Hamilton syringe for the injection of the cells. Remove the tip cap with the needle 
and load 20μl of cell slurry on top of the tip chamber. Pull back the plunger until 5μl slurry is 
loaded inside the syringe. Remove the excess slurry from the tip chamber and close the tip 
cap. 
5. Using adhesive tape, fix the proximal edge of the ear on the tip of an index finger. In a 45° 
angle, slowly insert the Hamilton syringe needle between dorsal dermis and the cartilage. 
Once inside, penetrate the ear proximal to distal for about 2-3mm. Note: a trained and 
certified technician should do the cell injection procedure. In addition, this process must be 
performed slowly and in sequence: first, the needle should be placed horizontally to the ear 
skin and inserted slowly into the ear dermis. Once the needle is in the skin, press the plunger 
carefully to inoculate the cells between the two dermal layers of the ear (Figure 5.1A).  
6. Inject 3μl of cell slurry and slowly retract the needle from the ear. Let the tumor cells 
proliferate and form a solid tumor during the following 7-9 days. The tumor growth can be 
observed by fluorescence stereomicroscopy. 
5.3.2 Interactions of activated splenocytes with tumor cells in situ 
To visualize interactions between tumor-specific lymphocytes and tumor cells, this procedure can be 
performed prior to the immunofluorescence staining of the ear. 
1. Collect the spleen of tumor-bearing mouse seven days after intradermal inoculation of GFP-
B16F10 melanoma cells into the back skin. Isolate splenocytes with mechanical disruption of 
the spleen through a 70μm cell strainer. 
2. Label splenocytes for 8min at 37°C with 1μM CMTPX CellTracker in PBS. Then, wash the  
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Figure 5.1 Schematic of the intravital immunofluorescence imaging method. (A) GFP labeled
B16F10 melanoma cells are injected into the mouse ear dermis. (B) 7-9 days after injection, the
ventral and dermal ear skin layers are surgically separated from each other. (C) The dorsal dermis
containing the tumor mass is immunostained with primary and secondary antibodies against the
targets of interest. (D) Imaging setup for acquisition using a fluorescent stereomicroscope. (E)
Imaging setup for acquisition using a multiphoton microscope. 
 101 
cells 4 times in 15ml PBS at 4°C. Finally, inject the cells in 200μl serum free medium into the 
tail vein of mouse whose ears were inoculated with B16F10-GFP 7 days earlier. 
5.3.3 Ear surgery 
1. Three days before the experiment, shave the mouse head, and depilate the hairs around the 
head and ear (for example using hair depilation cream for 10-15 seconds) and thoroughly 
rinse the area with water. 
2. Anesthetize the mouse with a mixture of humidified oxygen and isoflurane (3-4% induction, 1-
2% maintenance) and confirm that the animal is sufficiently anesthetized by performing a 
gentle toe pinch. Increase the isoflurane concentration in steps of 0.1% in case movements 
are observed (e.g. withdrawal of the paw). Keep mouse on a rectal thermistor controlled 
heating pad (37°C) during the whole procedure and protect its eyes with an appropriate 
ophthalmic ointment. 
3. Build a platform made out of 8 glued glass histology slides. Turn the mouse on its back and 
gently place the tumor-bearing ear on the stack of glass slides. Use small stripes of adhesive 
tape to fixate the anterior and posterior edges of the ear to the stack. 
4. Cut the ventral skin of the ear along the antihelix of the mouse pinna using a scalpel. With the 
help of curved tweezers, gently peel off the ventral dermis and the cartilage from the dorsal 
dermis where the tumor was inoculated (Figure 5.1B). Pull off the ventral skin and cartilage 
with curved forceps, exposing the dorsal dermis. NOTE: If a major vessel of the ear is cut or 
the blood circulation does not return to normal flow within 15 minutes after surgery, the ear 
cannot be used for imaging. Always keep the opened ear skin wet by using Ringer's buffer 
and protect the humidity by using a coverslip. 
5. In case there is a persistent bleeding from a capillary, stop the bleeding by adding 100μl 
thrombin (5U/ml) in Ringer's buffer on top of the ear for 5 minutes. 
6. Wash the ear twice with approximately 5ml of Ringer's buffer and remove extra liquid with 
sterile wipes. Immediately proceed to the next step (do not let the open ear dry at any point!). 
5.3.4 Immunofluorescence staining 
Use Ringer's buffer supplemented with human serum (1:10), mouse polyclonal secondary antibody to 
human IgG (1:50), and 125IU/ml (2.5mg/ml) aprotinin (AP92; Elastin) (=blocking buffer) for all staining 
steps. Aprotinin inhibits plasmin, thereby promoting coagulation to limit initial bleeding that may occur 
after surgery. 
1. Fold the part of the ear with the open dermis into the eminentia conchae and dry the outer 
unopened ear dermis with sterile wipes. Immobilize the ear on the stack of glass slide by 
applying 0.5μl of surgical glue to the anterior and posterior dorsal edges. Then, gently flatten 
the dorsal ear dermis onto the glass. 
2. Apply primary antibodies targeting extracellular matrix molecules at a concentration of 
10μg/ml in a total volume of 100μl blocking buffer to the exposed ear (Figure 5.1C). Cover the 
ear with a cover slip in order to prevent the staining solution to dry on the ear edges. Incubate 
for 15min. Wash the ear twice with approximately 5ml of Ringer's buffer. 
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3. Apply appropriate secondary antibodies or streptavidin conjugates at a concentration of 
10μg/ml in a total volume of 100μl blocking buffer to the exposed ear. Cover the ear with a 
cover slip and incubate for 15min. Wash the ear twice with approximately 5ml of Ringer's 
buffer. 
5.3.5 Intravital imaging using fluorescence stereomicroscopy 
1. For short-term imaging (up to 2 hours), add freshly prepared sterile ascorbate-Ringer's buffer 
containing 140mM sodium ascorbate, 10mM HEPES, 4mM KCl and 5mM CaCl2, at a pH of 
7.5 (ascorbate-Ringer's buffer final osmolarity is 320mOsM) on top of the immobilized ear. 
Cover the ear with a coverslip (Figure 5.1D). 
2. For long-term imaging (more than 2 hours), place the outlet of a needle (connected to a 
reservoir containing ascorbate-Ringer's buffer) under the coverslip, about 0.5cm away from 
the ear. Use a peristaltic pump at a speed of 1μl/min to constantly deliver ascorbate-Ringer's 
buffer to the chamber under the coverslip. 
3. Change the 1X lens (Leica Microsystems CMS GmbH, working distance 6cm) to a 2X lens 
(Leica Microsystems CMS GmbH, working distance 2cm). Open the acquisition software 
(Leica LAS AF) and configure the settings of the fluorescent stereomicroscope. In the camera 
settings, choose 12bit as the image color depth and adjust the camera range of grey-scale 
values from 0% (minimum) to 5.1% (maximum) and set gamma correction to 2. Set 
acquisition gain to 1 (minimum), fluorescence intensity to 1,000 (maximum), magnification set 
to 280X-320X, and adjust the exposure time avoiding over- or under- exposure (should be 
less than 1sec). Depending on the number of imaging fields (usually 10 to 20), the time 
interval for the acquisition cycles should be set between 1 to 2min. Shorter times may cause 
photobleaching and -toxicity. 
4. Choose several fields that contain tumor cells as well as stained ECM proteins (such as in 
Figure 5.4). Using the motorized stage, acquire images of the appropriate fluorescent 
channels (such as GFP and AlexaFluor-647 in Figure 5.4) over time (e.g. every 2min). 
5. After the experiment, euthanize the mouse according to institutional animal guidelines. In our 
case, anesthetized mice were euthanized by cervical dislocation followed by exsanguination 
(intracardiac perfusion). 
5.3.6 Intravital imaging using two-photon microscopy 
1. Using silicon grease, build a circular wall of about 2cm diameter and 2-3mm height around 
the ear, starting at the base of the ear (Figure 5.1E). Make sure there are no leaking points. 
Fill the circle with ascorbate-Ringer's buffer. 
2. Place the mouse on a (motorized) microscope stage and connect the heating pad (37 °C). 
3. Open acquisition software (Leica LAS AF) and configure the settings of the multiphoton 
microscope (LEICA SP5, Leica Microsystems CMS GmbH). 
4. Choose several fields that contain tumor cells and stained ECM proteins (such as in Figure 
5.5). Acquire images of the appropriate fluorescent channels (such as GFP and AlexaFluor-
594 in Figure 5.5) and second harmonic generation over time, e.g. every 2min, with an 20X 
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immersion lens (HCX APO, 1.00 NA, 2mm working distance). 
5. After the experiment, euthanize the mouse according to institutional animal guidelines. In our 
case, anesthetized mice were euthanized by cervical dislocation followed by exsanguination 
(intracardiac perfusion). 
5.3.7 Reagents  
• Hamilton syringe (barrel: 84853; Hamilton, syringe: 7803-05; Hamilton) 
• Ringer’s buffer (445968; B. Braun Medical AG) 
• Aprotinin (AP92; Elastin) 
• Thrombin (T7326; Sigma-Aldrich) 
• Sodium ascorbate (11140; Sigma-Aldrich) 
• Mouse serum raised against human IgG (AB 34834; Abcam) 
• Rabbit anti-collagen IV (AB 6581; Abcam) 
• Rat anti-perlecan (AB79465; Abcam) 
• Goat anti-tenascin C (AF3358; RnD) 
• Goat anti-podoplanin (AF3244; RnD) 
• Rabbit anti-lyve1 (103-PA50; Reliatech) 
• Streptavidin Alexa Fluor 647 (S11222; Invitrogen) 
• Streptavidin Alexa Fluor 488 (S11223; Invitrogen) 
• Donkey anti-goat 594 (A21113; Invitrogen) 
• Donkey anti-rabbit 594 (A21207; Invitrogen) 
• Donkey anti-rat 594 (A21209; Invitrogen) 
• CMTPX CellTracker (C34552; Lifetechnologies) 
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5.4 Results 
5.4.1 Immersion of the exposed ear tissue in a large volume of ascorbate buffer inhibits 
photobleaching during image acquisition. 
Immunostaining is not typically done in live tissue, mainly because staining antibodies can form 
immune complexes that lead to a high staining background and immunotoxicity. Our lab previously 
published an intravital immunostaining protocol that circumvents these issues in large part (Kilarski et 
al., 2013). To avoid immunotoxicity, Fcγ receptors and complement were saturated with mouse 
polyclonal IgGs raised against and immunocomplexed with human IgGs, thus blinding phagocytes 
and the complement system to the subsequent immunostaining. Immersing the exposed ear tissue in 
anti-oxidant ascorbate-Ringer’s buffer ensured that photobleaching was inhibited. However, because 
we wanted to adapt intravital IF to high-energy two-photon microscopy, we wanted to further optimize 
the protection from photobleaching, ensuring that the fluorescent probes would be stable for long-term 
imaging. Thus, we changed two parameters about the use of ascorbate-Ringer’s: 1) We noticed that 
ascorbate-Ringer’s oxidized during storage, thereby loosing its anti-oxidant activity. We thus started to 
prepare fresh ascorbate-Ringer’s for each experiment. 2) Rather than using a small volume of buffer, 
we now immersed the tissues in a large volume of ascorbate-Ringer’s (100μl) within the chamber 
where the ears were immobilized, ensuring that the antioxidant capacity would not immediately 
exhaust. Indeed, we found that adapting the protocol led to increased resistance to photobleaching 
(Figure 5.2A-B). To assess bleaching of a fluorescent probe that binds abundantly to the ECM, we 
stained the basal membrane matrix protein collagen IV with AlexaFluor-647 and imaged it 
continuously for 300 seconds. Images taken at either t=0 or t=300s show that while the fluorescence 
decreases when the tissue is immersed in normal Ringer’s, the signal is stable when it is immersed in 
ascorbate-Ringer’s (Figure 5.2A). Note that 300 seconds of constant imaging time corresponds to 10 
hours of imaging when pictures are collected for 500ms every one minute (the average imaging 
settings). We further confirmed that adaptation of the ascorbate-Ringer’s protocol was an 
improvement from the initial description (Kilarski et al., 2013), as photobleaching could now be 
completely prevented during 17.5 minutes of continuous imaging (Figure 5.2B). This data suggests 
that long-term intravital imaging with a fluorescence stereomicroscope can be achieved without 
inducing photobleaching when a large volume of freshly prepared ascorbate-based buffer is used to 
protect the exposed tissue. 
5.4.2 Intravital immunofluorescence can be used to visualize ECM components such as 
perlecan and CCL21 in the normal mouse ear. 
We next asked whether our adapted intravital immunofluorescence method was suitable for the 
visualization of components of the tumor microenvironment, such as lymphatic vessels, ECM proteins 
and ECM-bound chemokines. To validate the protocol, we performed intravital IF for perlecan 
(basement membrane), Lyve-1 (lymphatics), podoplanin (lymphatics), and the chemokine CCL21 
(Figure 5.3A-D). Structures such as blood vessels and collecting lymphatics can be distinguished 
based on their morphology after immunostaining for perlecan (Figure 5.3A). Direct staining for specific  
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Figure 5.2 Placing the exposed ear tissue in a large volume of ascorbate buffer inhibits 
photobleaching during image acquisition. (A) Tissue was stained first with a biotinylated antibody
against collagen IV, a basement membrane matrix protein. The staining was detected with
streptavidin-AF647 (red), and then constantly imaged for 300 seconds in either normal Ringer's buffer 
(upper panel) or ascorbate-Ringer's (lower panel). The brightest 25% of pixel intensity values are
colored in green. (B) Quantification of immunofluorescence decay over 17.5m during continuous 
image acquisition (50% decay in Ringer's vs. 0% in ascorbate-Ringer's). Values were normalized to
the initial fluorescence. Image acquisition was done using an immunofluorescence stereomicroscope.
Scale bar in (A): 100μm. 
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Figure 5.3 Intravital immunofluorescence can be used to visualize ECM components such as
perlecan and CCL21 in the normal mouse ear. (A) Staining for perlecan, a basement membrane
component, depicts all blood and lymphatic vessels, nerves, muscle fibers and adipocytes. (B) Lyve1
staining marks the initial lymphatic capillary network. (C) Co-staining for Lyve1 (green) and
podoplanin (red), a pan-lymphatic marker, depicts networks of initial (Lyve1+podoplaninlow) and
collecting lymphatics (Lyve1-podoplaninhigh). The dorsal ear dermis can be imaged using classic
fluorescence stereomicroscopy (without optical sectioning) as the ear dermis has low number of 
adipocytes that would otherwise cover the imaging field. (D) CCL21 staining (green) on lymphatic
basement membrane stained for perlecan (red). Images collected with an immunofluorescence
stereomicroscope. Scale bars in (A) and (B): 1mm; in (C): 100μm; and in (D): 50μm. 
cell surface markers such as Lyve1 (Figure 5.3B) and podoplanin (Figure 5.3C) further allows 
distinguishing initial, capillary lymphatics (Lyve1+podoplaninlow) from lymphatic collectors (Lyve1-
podoplaninhigh). Staining for matrix-bound CCL21 revealed chemokine deposits on the basement 
membrane of lymphatic collectors identified with the staining for perlecan (Figure 5.3D). Taken 
together, this data shows that intravital immunofluorescence is suitable for the visualization of 
components of the ECM that are often part of the tumor microenvironment. 
5.4.3 Intravital immunofluorescence is suitable for the long-term visualization of interactions 
between tumor cells and their microenvironment including anti-tumor immune 
responses. 
Having demonstrated that intravital IF can be used to visualize components of the extracellular 
environment over prolonged periods of time in the normal mouse ear, we next explored whether this 
approach would be suitable for imaging of an actual tumor microenvironment. We first assessed 
whether B16F10-GFP melanoma cells would be viable and interacting with the microenvironment 
when placed directly on the exposed and immunostained ear dermis. We thus freshly isolated 
B16F10-GFP tumor cells and added 100’000 cells directly on the exposed ear dermis that was 
already immunostained for collagen IV (Figure 5.4A). We observed that after adhering to the tissue, 
some groups of cells started to migrate along the basement membrane of blood vessels and 
adipocytes (Figure 5.4A, white arrows), indicating that even though they were simply placed on the 
exposed naïve tissue, tumor cells were viable and could start interacting with the local 
microenvironment. To mimic a more natural situation, we next assessed how tumor cells interact with 
the microenvironment after they established themselves within the tissue. To do so, mice ears were 
inoculated with B16F10-GFP cells, and the cells given time to organize in situ for a few days before 
imaging. As we were specifically interested in visualizing anti-tumor immune responses, we adoptively 
transferred tumor-educated splenocytes into these mice seven days after inoculation of the ear 
tumors. Five hours later, enough time for the adoptively transferred cells to reach the tumor site, the 
dorsal ear dermis was exposed and immunostained for collagen IV. Because imaging of entire tumor  
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Figure 5.4 Intravital immunofluorescence is suitable for the long-term visualization of
interactions between tumor cells and their microenvironment including anti-tumor immune
responses. (A) The exposed ear dermis of a non-tumor bearing mouse was immunostained for
collagen IV, and freshly isolated B16F10-GFP tumor cells were directly added (100’000 cells in 50μl
Ringer’s buffer) on top of the exposed ear. Images were then collected every 1.5 minutes with an 
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immunofluorescence stereomicroscope over 5 hours. Migration of tumor cells along the basement 
membrane of blood vessels and adipocytes was observed (white arrows). (B) Seven days after
inoculation, a B16F10-GFP tumor-bearing mouse received adoptive transfer of tumor-educated
CMPTX-labeled splenocytes. Five hours later, the tumor microenvironment in the dorsal ear dermis 
was exposed and immunostained for collagen IV. Images were then collected over 8 hours every 47 
seconds with an immunofluorescence stereomicroscope. Rare interactions (white arrow) of
splenocytes (red) with tumor cells (cyan) within the context of the collagen IV matrix (green) could be
observed, even if they did not seem to result in tumor cell killing. (C-D) One day after inoculation, a
B16F10-OVA-GFP tumor-bearing mouse received an OVA-specific vaccination (40μg OVA + 20μg
CpG) to raise an endogenous anti-tumor immune response. Eight days later, the tumor
microenvironment in the dorsal ear dermis was exposed and immunostained for CD69, a marker of T 
cell activation. Images were then collected over 12 hours every 2 minutes with an
immunofluorescence stereomicroscope. In two different imaging fields, (C) and (D). Abundant
interactions of activated immune cells (red) with tumor cells (green) could be observed, most of which 
resulted in tumor cell killing within the observed time. Scale bar in all images: 50μm. 
masses generally caused out-of-focus images, we chose to image fields that only showed single 
tumor cells dispersed within the tissue (Figure 5.4B). We found that a splenocytes arrived from the 
circulation (Figure 5.4B, left panel, white arrow) and interacted with a tumor cell for almost 8 hours 
(Figure 5.4B, center and right panel) before leaving again (Figure 5.4B, right panel). Interestingly, the 
interaction between the tumor cell and the splenocyte did not seem to induce tumor cell killing in this 
case, indicating that it might have been a non-antigen specific interaction. Finally, to induce a potent 
endogenous anti-tumor immune response, a B16F10-OVA-GFP tumor-bearing mouse received an 
OVA-specific vaccination (40μg OVA + 20μg CpG) one day after tumor inoculation into the ear. Eight 
days later, the tumor microenvironment in the dorsal ear dermis was exposed and immunostained for 
CD69, a marker of T cell activation. Images were then collected over 12 hours every 2 minutes with 
an immunofluorescence stereomicroscope (Figure 5.4C and D). Strikingly, we were able to visualize 
two different fields with extensive infiltration of activated immune cells that were swarming around 
tumor cells. These interactions induced tumor cell death, as most of the tumor cells underwent 
apoptosis and disappeared within the 12 hours of imaging. This was not an artifact due to 
photobleaching or out-of-focus imaging, as residual tumor cells and activated immune cells were still 
clearly visible at the end of the experiment (Figure 5.4C and D, right panels). These results 
demonstrate that intravital immunofluorescence is suitable for the observation of tumor cell behavior 
in their complex microenvironment over prolonged periods of time, allowing one to study processes 
such as tumor cell migration along ECM and interactions between tumor cells and anti-tumor 
immunity. 
5.4.4 Intravital two-photon microscopy can be used to visualize B16F10 melanoma cells in 
the context of fibrillar and non-fibrillar extracellular matrix proteins. 
Because we found that intravital IF was suitable for long-term imaging using fluorescent 
stereomicroscopy, we next asked whether the same staining technique is suitable for intravital 
imaging using high-energy two-photon microscopy. Amongst other applications, combining second 
harmonic generation and fluorescence would allow us to simultaneously visualize fibrillar and non-
fibrillar ECM networks, which to our knowledge has not previously been achieved in vivo (Brown et 
al., 2003). The B16-F10 tumor stroma of an exposed dorsal mouse ear was exposed 9 days after  
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Figure 5.5 Intravital two-photon microscopy can be used to visualize B16F10 melanoma cells 
in the context of fibrillar and non-fibrillar extracellular matrix proteins. The B16-F10 tumor
stroma of an exposed dorsal mouse ear was imaged 9 days after inoculation. The fluorescent signal
was protected by application of ascorbate-Ringer's buffer onto the tissue, and images collected with a 
two-photon microscope. (A) Fluorescence of the tenascin C (red) network (left panel) and second 
harmonic generation (SHG, green) (center panel) of fibrillar collagens were detected. These two
networks are superimposed with B16F10-GFP tumor cells (cyan) (right panel). Non-fibrillar ECM
represented by tenascin C does not seem to overlap with fibrillar collagens detected with SHG.
Images were acquired over 44, 4x averaged z-sections with z-step 1.0μm. The maximum intensity
projection is shown. Scale bar: 100μm. (B) Field of the tumor microenvironment showing tenascin C 
(red), fibrillar collagens (green) and B16F10-GFP tumor cells (cyan). Images were acquired over 11,
4x averaged z-sections with z-step 1.9μm. Images were taken every minute over 10 minutes. The
maximum intensity projection at a given time point is shown. Scale bar: 50μm. 
inoculation, and an immunostaining for tenascin C performed. Next, GFP labeled tumor cells and 
tenascin C were imaged in vivo using fluorescence stereomicroscopy, and fibrillar ECM using SHG 
capabilities of a two-photon microscope. Interestingly, we found that tenascin C, a matrix protein that 
is expressed during tumorigenesis, wound healing and inflammation (Midwood and Orend, 2009) is 
deposited in different locations of the tumor microenvironment than fibrillar collagens (Figure 4A). 
Using two-photon microscopy with immunostaining is problematic the high photon flux used in these 
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experiments can quickly bleach fluorescent dyes that are not protected from oxidation (Patterson and 
Piston, 2000). To assess whether our adapted protocol using ascorbate-Ringer’s might protect the 
immunostaining, we performed a time-lapse experiment where we imaged the same field containing 
tenascin C, fibrillar collagens, and tumor cells every minute over 10 minutes (Figure 5.5B). Indeed, 
the signal of immuno-labeled tenascin C did not noticeably decrease over the course of the 
experiment (Figure 5.5B, left vs. right panel). Collectively, these data show that our intravital 
immunofluorescence protocol allows the dynamic observation of tumor cells in the context of fibrillar 
and non-fibrillar extracellular matrix proteins using intravital two-photon microscopy. 
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5.5 Discussion 
Here we present a novel intravital microscopy method that allows simultaneous, high resolution and 
dynamic visualization of different components of the tumor microenvironment, including immune cells 
and fibrillar as well as mesh-like matrix proteins. This method addresses several shortcomings of 
current intravital imaging techniques: (i) Even though intravital immunostaining offers a high variety of 
potential target stainings, existing protocols are not able to achieve homogenous distribution of 
primary and secondary antibodies in the tissue except in the rare cases where the targets are within 
the blood or lymphatic network (Egawa et al., 2013; Kilarski et al., 2013; Woodruff et al., 2014). (ii) 
Concerns about immunotoxicity and photobleaching have limited the applications for intravital 
immunofluorescence, especially in the context of high energy two-photon microscopy (Patterson and 
Piston, 2000; Roos et al., 2005). (ii) The use of genetically modified reporter mice allows for specific 
cell types to be imaged, but requires their availability (or substantial effort to create new ones) and 
limits the number of interacting cell types that can be studied. (iii) Extracellular matrix can be imaged 
in vivo using second harmonic generation, but this technique can only detect fibrillar collagens, 
leaving a large number of important extracellular components such as basement membranes, 
fibronectins, tenascins, growth factors, chemokines and tissue glycosaminoglycans out of reach for 
current research. Our method overcomes some of these limitations. By performing intravital IF in a 
controlled environment in the exposed ear dermis, we show that multiple cell types, tissue structures, 
deposits of heparin sulfate binding growth factors (e.g. VEGF(Jakobsson et al., 2006)) and 
chemokines (e.g. CCL21 (Kilarski et al., 2013; Weber et al., 2013) and Figure 5.3D), or extracellular 
matrix proteins can be visualized over prolonged periods of time without inducing major side effects. 
Thus, this method allows one to look at live processes within the tissue microenvironment in a more 
holistic manner while simultaneously tracking blood and/or lymphatic flows. Applications of intravital IF 
include but are not limited to the investigation of skin immunity during inflammation, mechanisms of 
transplant rejection, blood and lymphatic vessel growth during tumorigenesis, and of anti-tumor 
immune responses. To this end, we were able to observe lymphocyte mediated tumor killing in real 
time using standard fluorescence stereomicroscopy (Figure 5.3C-D), achieving similar results as other 
studies that used more elaborate imaging approaches (Boissonnas et al., 2007; Breart et al., 2008; 
Deguine et al., 2010). Interestingly, our preliminary observation that B16F10 tumor cells are killed 
approximately within 6-12 hours is in line with a study by Breart et al. that showed that killing of one 
target tumor cell occupied an individual cytotoxic T cell (CTL) for an average of 6 hours (Breart et al., 
2008). The ability to stain and observe the lymphocyte activation marker CD69 indicates that intravital 
IF could be used to detect dynamic phenotype changes of tumor infiltrating immune cells, thereby 
shedding light on processes such as T cell exhaustion within the tumor microenvironment (Baitsch et 
al., 2011; Jiang et al., 2015). 
Because we found that intravital IF is suitable for visualization using two-photon microscopy, 
we were able to image non-fibrillar components of the tumor microenvironment in combination with 
SHG-detected fibrillar and matured collagens (Figure 5.5). Tenascin C is heterogeneously expressed 
in tumors, and often accumulates at the invasive front (Lowy and Oskarsson, 2015). In line with this, 
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we found that tenascin C occupies different areas in the TME as compared to fibrillar collagens. 
Future work will have to establish whether matrix heterogeneity is relevant for tumor cell migration 
towards lymphatic and blood vessels. Apart from the ability to do SHG, another advantage of using 
two-photon microscopy over standard fluorescence stereomicroscopy is the possibility to do z-stacks. 
This enables one to observe spatial co-localization of events occurring within the extracellular matrix, 
such as tumor cell intravasation into lymphatic or blood vessel. In the case of standard fluorescence 
stereomicroscopy, conclusions can be only inferred from morphological changes of the invading cell, 
as it is impossible to determine whether a cell is above, inside, or behind a vessel.  
Our method has several limitations. First, fluorescence stereomicroscopy based imaging of 
intravital IF is limited to thin skin flaps that are deprived of thick hypodermis (adipose tissue). To 
extend the use of intravital IF to other body areas, one could consider using this approach in the 
context of an in vivo observation chamber. Different models such as the dorsal skin fold chamber 
(DSFC) (Koehl et al., 2009) or the chronic lymph node window (CLNW) (Jeong et al., 2015) have 
been established to study primary tumor growth or lymph node metastasis, respectively, over several 
days to weeks. We propose that intravital IF could especially be interesting in settings where the 
removal of the chamber’s cover slip directly exposes the tissue to be stained. Second, rapid antibody 
staining (in the order of 15 minutes) in intravital IF is only achieved thanks to functional lymphatic 
drainage and interstitial fluid flow. Therefore, no staining can be observed if lymphatic vessels are 
occluded (Kilarski et al., 2014). In line with that, lymphatic vessels stain stronger than leaky blood 
vasculature (injured vessels, arterioles) (Kilarski et al., 2013). Third, even though the separation of the 
dorsal and ventral ear skin flaps is a mild surgical procedure, it still causes injury to some capillaries 
and cell death to various tissue cells. This might be a problem when one needs to investigate 
completely intact tissue, for example to assess effects of drugs on cell survival. Fourth, the need for 
ascorbate-Ringer’s for the protection from phototoxicity and photobleaching excludes certain 
metabolic studies, such as on oxidative stress or nitric oxide biology, from the use of this protocol. In 
order to study such phenomena, ascorbate has to be replaced with other tissue compatible media that 
does not interfere with the experimental output. Finally, saturating tissue resident phagocytes and the 
complement system with immune complexes might modulate both innate and adaptive immunity, and 
thus influence the study of local tissue immune responses (Kolev et al., 2014; Nimmerjahn and 
Ravetch, 2008). Using secondary antibodies with cleaved Fc fragments (F(ab)2 antibody fragments) 
or the use of biotinylated antibodies and fluorescent streptavidin as detection reagents could reduce 
this effect. In either case, local immunity will most likely be modulated to a certain extent, and 
interpretation of the interactions such as between tumor cells and anti-tumor immunity thus needs to 
be done with caution. 
In summary, we present an adapted intravital IF protocol that bridges real-time, local 
measurements of physiological function with molecular imaging of complex cellular events in the 
context of the native microenvironment. With its flexibility and high-throughput potential, we propose 
that this intravital technique could be specifically interesting to elucidate mechanisms of anti-tumor 
immune responses, such as in the context of cancer immunotherapy.  
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6.1 LEC-mediated chemokine secretion as a driving force of immune cell 
trafficking into peripheral tissues 
Lymphatic endothelial cells are passive and active modulators of adaptive immune responses (Card 
et al., 2014; Hirosue and Dubrot, 2015). In this context, three main modes of actions have been 
ascribed to LECs: 1) Acting as an information highway by offering a physical connection between the 
periphery and the draining lymph nodes. 2) Influencing immune cell trafficking by secretion of 
chemokines, most notably CCL21. 3) Influencing immune cell education by mediating cell-cell 
interactions through molecules such as MHCI and MCHII, or secreting immunomodulatory molecules 
such as IDO and TGFβ. Even though a considerable amount of work has been done towards 
understanding the role of LECs in active immunomodulation, one question has been very difficult to 
address experimentally: where in terms of anatomical location do these mechanisms take place in a 
complex human body? Because the lymphatic network is spread throughout the entire organism, 
ranging from the very periphery, to the lymph nodes, back into the blood circulation, it is very difficult if 
not impossible to conclude physiological function from pure in vitro systems. For example, even 
though it has been well established that LECs can present exogenous and endogenous antigens on 
MHC class I and class I molecules, it is still unclear where this happens in the physiological context. 
Do initial lymphatics present antigen to influence immunity in peripheral organs? Do pre-collecting or 
collecting lymphatics do it to re-educate effector cells egressing through lymphatics from peripheral 
tissues? Does it only happen in the lymph node, and if yes, in which particular zone? Or is it needed 
to fine-tune immune responses when activated T cells egress from the lymph node into the 
circulation?  
We specifically aimed at better understanding the role of the second mode of action, LEC-
mediated immunomodulation by secretion of chemokines, in peripheral tissues. CCL21 has been the 
most widely studied LEC-secreted chemokine (Gunn et al., 1998; Kriehuber et al., 2001; Vigl et al., 
2011). In peripheral tissues, initial lymphatics produce CCL21 to generate a chemokine gradient that 
attracts activated, antigen-loaded CCR7+ DCs (Teijeira et al., 2014). DCs then transmigrate into 
lymphatic capillaries from where they first actively crawl along the luminal vessel wall, before they are 
passively transported through collecting vessels to reach the draining lymph node (Tal et al., 2011). In 
the lymph node, CCL21 gradients established by lymph node stromal cells including LECs orchestrate 
the encounter antigen-loaded DCs from the periphery with naïve CCR7+ T cells arriving from the 
blood circulation via high endothelial venules (HEVs) (Andrian and Mempel, 2003). Interestingly, 
HEVs can translocate perivascular chemokine to their luminal surface by a process called 
transcytosis, suggesting that extravasation can be influenced by chemokine producing stromal cells 
adjacent to HEVs (Baekkevold et al., 2001; Carlsen et al., 2005). Thus, chemokine secretion by LECs 
has so far shown to be crucial for immune cell trafficking from peripheral tissue or the blood circulation 
to secondary lymphoid organs (SLOs), within SLOs themselves, as well as for the egress from SLOs 
back into blood circulation. However, it has not yet been explored whether initial lymphatics might 
employ similar mechanisms to regulate trafficking of immune cells from the circulation into peripheral 
tissues. Because our lab has previously shown that tumor-derived CCL21 attracts immune cells that  
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Figure 6.1 Lymphangiogenic potentiation of antigen-specific cancer immunotherapy. (A)
VEGFC low tumors show low lymphatic density, and baseline immune infiltrations including effector T 
cells (Tem) and regulatory T cells (Treg) that keep each other in check. Tem cells are classically
infiltrated via the blood vasculature, which is decorated with effector chemokines such as CXCL9/10. 
(B) VEGFC high tumors have high levels of CCL21 (blue). We hypothesize that CCL21 is
transcytosed on the luminal side of HEVs, leading to the chemoattraction and extravasation of CCR7+
immune cells, including naïve (Tnaive), central memory (Tcm) and more regulatory T cells. Overall, 
the microenvironment in these tumors shows hallmarks of immunosuppression, and no spontaneous
regression induced by an endogenous effector anti-tumor immune response is observed. (C)
However, in the context of antigen-specific cancer immunotherapy, massive cell death is induced,
releasing antigen and danger signal from the dying cancer cells. These signals are most likely
activating local antigen presenting cells, which in turn activate the tissue resident naïve T cells. This
broadens the endogenous anti-tumor immune response to novel antigens, and immunological
memory protects the host from tumor re-challenge. 
establish a lymphoid-like structure in primary melanoma tumors (Shields et al., 2010), we 
hypothesized that LEC-derived CCL21 might have a similar role in local immunoregulation, especially 
in the context of lymphangiogenic melanoma tumors.  
Throughout this thesis research, we used three different approaches to address questions 
relevant to our overall hypothesis: first, we used melanoma mouse models to study the effect of 
tumor-associated lymphangiogenesis on the local immune environment. Second, we used an 
engineering approach with the goal to induce and study lymphangiogenesis in mouse dermis, 
representing a more controlled environment as compared to the tumor microenvironment. Third, we 
developed a novel intravital imaging modality that allows observation of immune responses in the 
context of the dynamic tumor microenvironment. Our findings suggest a relatively simple mechanism 
of peripheral LEC-mediated immunoregulation, which seems to be common amongst both the tumor 
and the steady-state peripheral tissue microenvironment: VEGFC induced lymphangiogenesis 
upregulates the local secretion of CCL21, which in turn leads to the infiltration of CCR7+ immune cells 
(Figure 6.1, step 1 to 3). We found that different CCR7+ immune cell subsets were attracted in 
different settings, indicating that the specificity most likely depends on multiple factors, such as the 
presence of other cytokines or adhesion molecules on the tissue vasculature. Because we found 
similar mechanisms occurring both in lymphangiogenic melanoma and the engineered 
lymphangiogenic dermis, we propose that chemoattraction by LECs might happen as a bystander 
effect: the more LECs there are, the more CCL21 is constitutively secreted into the microenvironment. 
This might certainly be further exaggerated in settings of enhanced flow and presence of inflammatory 
cytokines, as both of these stimuli can further upregulate CCL21 expression by LECs (Martín-
Fontecha et al., 2003; Miteva et al., 2010). An important question remains: once CCL21 is deposited 
in the interstitium by LECs, how exactly does it influence immune cell trafficking into the tissue? Does 
it reach the luminal sides of high endothelial venules by transcytosis to influence immune cell 
extravasation? Or does it simply attract cells from the adjacent tissue by creating chemokine 
gradients? Considering that we observed the infiltration of naïve T cells into lymphangiogenic tumors, 
and that these cells are usually in the circulation rather than in the periphery, a model where CCL21 is 
transcytosed to influence immune cell extravasation seems more plausible. However, these novel 
hypotheses are based on our observations and will need further experimental validation. 
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6.2 Exploiting lymphangiogenic sites to induce tolerance or immunity: a 
question of context? 
An increasing body of literature has been describing the immunosuppressive capacity of lymphatic 
endothelial cells (Lund et al., 2016). The general concept has been that even though LECs can 
present antigen on MHC class I and II molecules to T cells, they lack costimulatory molecules 
necessary to induce effector immune responses. Surprisingly, this thesis research suggests that even 
though LEC-secreted chemokines establish a local immune microenvironment that shows hallmarks 
of immunosuppression, including regulatory T cells, this environment can be exploited to generate 
highly potent effector responses. This was especially striking in our experiments where we performed 
antigen-specific immunotherapy in lymphangiogenic melanoma tumors. We found that the release of 
danger signal and antigen following immunotherapy-induced cancer cell death was able to activate 
naïve T cells that previously infiltrated the tumor in a CCL21-dependent manner (Figure 6.1, step 4). 
Not only led this to a broader anti-tumor response by antigen-spreading, it also conferred 
immunological memory and thus protected mice from tumor re-challenge. Interestingly, similar 
mechanisms might be relevant in non-inflamed lymphangiogenic sites as we found that delivering the 
model antigen ovalbumin to lymphangiogenic tissue sites increased the effectors response upon 
antigen re-challenge. Our data suggest that the role of lymphangiogenic sites in immunoregulation 
might not be as black and white as previously assumed, and that they might be useful for therapeutic 
exploitation in settings of both tolerance and immunity. 
6.3 Implications for the translation into clinics 
This thesis research has generated novel concepts that - after further pre-clinical validation - could be 
applicable for the translation into clinics: 
 
1) Intratumoral lymphatic density, VEGFC and/or CCL21 expression as biomarkers to stratify 
cancer patients eligible for cancer immunotherapy. 
 
2) Engineering lymphangiogenesis in non T-cell inflamed tumors could to render tumors more 
sensitive to cancer immunotherapy. One major concern of such an approach would be that 
increasing lymphangiogenesis in the primary tumor could increase the metastatic potential. 
However, as patients eligible for immunotherapy are usually already metastatic, this might not 
be of concern for this specific patient population. 
 
3) Engineering lymphangiogenic skin sites could potentially be used to guide therapeutic 
immune responses. Our data suggested that using this approach might be suitable to 
increase the efficacy of vaccinations as we found increased effector responses upon antigen 
re-challenge.  
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6.4 Future directions 
In this thesis, we introduced novel concepts and tools relevant to the field of lymphatic biology, cancer 
immunology, and bioengineering. Yet, by answering one scientific question, multiple follow up 
questions are generated. The ones I think are most interesting and pressing are summarized below. 
6.4.1 The role of lymphangiogenesis in cancer immunotherapy 
- What cells ultimately secret CCL21 within lymphangiogenic tumors? Is it indeed LECs or does 
it come from other sources?  
- Does VEGFC increase CCL21 production simply by increasing the number of cells that 
produce chemokine, or does VEGFR3 signaling itself upregulate CCL21 expression per cell? 
- How does CCL21 finally attract immune cells into the tissue? Is it transcytosed to the luminal 
side of HEVs? Or could it be that CCL21 in the tissue signals to other molecular pathways 
that ultimately induce extravasation?   
- What other cytokines and chemokines could be relevant to the observed effects?  
- Are intratumoral lymphatics indeed non-functional in terms of drainage? We often observed 
vessels with a wide-open lumen, suggesting that they might still be able to transport cells and 
interstitial fluid. 
- What cells are presenting tumor antigen in lymphangiogenic tumors in response to cancer 
immunotherapy? Is it dendritic cells, macrophages, or stromal cells? Are these cells also 
attracted by lymphangiogenesis, or are they already present within the tumor 
microenvironment? 
- What are the growth factors driving lymphangiogenesis in the iBIP2 model of melanoma apart 
from VEGFR3 ligands? VEGFR3 blocking only reduced, but not completely abrogated the 
development of LVs. 
- Is “lymphangiogenic potentiation of cancer immunotherapy” a generally applicable 
mechanism for any kind of lymphangiogenic tumor, or does it depend on other factors such 
as from what tissue the tumor arises? 
- Could activation of naïve T cells within inflamed tissues be a more broadly relevant 
mechanism, taking place in a different set of diseases?  
- Is there evidence for tertiary lymphoid organ formation specifically within lymphangiogenic 
tumors?  
- Could it potentially be more efficient to generate “a local lymph node” / tertiary lymphoid organ 
because the immune response is directly generated at the place where it needs to act?  
- Does this mechanism only work when cancer immunotherapy is targeting a neoantigen, or 
could it be equally efficient when targeting a cancer-testis, differentiation, or overexpressed 
antigen? 
- Could other therapeutic interventions that lead to immunogenic cell death be used instead of 
cancer immunotherapy? Radiation? 
- Do B16 melanoma cells overexpressing CCL21 react in the same way to immunotherapy as 
the VEGFC ones? 
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- Can non T cell-inflamed tumors be turned into inflamed ones by intratumoral injections of 
VEGFC? If yes, will they respond better to immunotherapy? 
- Do VEGFC or CCL21 serum levels of patients undergoing cancer immunotherapy correlate 
with outcome?  
6.4.2 Engineering lymphangiogenic sites for therapeutic immunomodulation 
- Are engineered lymphangiogenic sites functional in terms of drainage? If yes, could the same 
system be used to re-connect the lymphatic network after damage that induces lymphedema? 
- How can engineered lymphangiogenic sites be therapeutically exploited? Can they be used 
for therapeutic tolerance, or rather for increasing vaccine responses? 
- Do LECs in lymphangiogenic sites contribute to immunoregulation only be chemokine 
secretion only, or also via immune cell education by actively engaging in cell-cell interactions? 
If both, what is the relevance of each of those as compared to the other mechanism? 
- What is the functional consequence of inducing lymphangiogenesis in the downstream lymph 
node instead of in the periphery? 
- Could other growth factors, or a combination of growth factors, be more efficient in inducing 
local lymphangiogenesis? 
- Could the hydrogel system be avoided by designing growth factors that stick to the 
extracellular matrix?  
6.4.3 Intravital immunofluorescence to observe anti-tumor immune responses 
- Can intravital IF be used in other settings, such as in combination with intravital imaging 
windows to reach other organs than the ear dermis? 
- Can intravital IF be used to quantify interactions between tumor cells and immune cells? How 
many cells can be killed by one immune cells and how long does it take? 
- What are the actual mechanisms of tumor invasion and rejection by T cells?  
- What is the relative contribution of direct tumor cell killing by cytotoxic T cells compared with 
killing by other effectors of innate immunity?  
- How do the dynamics of anti-tumor immunity differ from a non-lymphaniogenic to a 
lymphangiogenic tumor microenvironment? 
- Do tumor cells actively crawl along matrix proteins, and if so, which ones? Can we observe 
extravasation of tumor cells into lymphatic or blood vessels? 
- Do interactions take place between LECs and infiltrating immune cells, indicating that LECs 
might be re-educating these cells? 
- What is the phenotype of tumor killing cells, and does it change during tumor rejection? 
- What are the dynamics of adaptive resistance mechanisms to cancer immunotherapy? E.g. 
can upregulation of PD-L1 during an ongoing anti-tumor immune response be observed? 
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